Organic electroluminescent materials and devices

ABSTRACT

Imidazophenanthridine ligands and metal complexes are provided. The compounds exhibit improved stability through a linking substitution that links a nitrogen bonded carbon of an imidizole ring to a carbon on the adjacent fused aryl ring. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is (1) a continuation-in-part of U.S. application Ser.No. 14/933,684, filed Nov. 5, 2015, which is a continuation-in-part ofPCT application Serial No. PCT/US15/29269, filed on May 5, 2015, whichclaims priority to U.S. Provisional Application Serial No. 61/990,239,filed on May 8, 2014, and to U.S. Provisional Application Serial No.62/082,970, filed on Nov. 21, 2014, (2) a continuation-in-part of U.S.application Ser. No. 15/291,381, filed Oct. 12, 2016, (3) acontinuation-in-part of U.S. application Ser. No. 15/399,724, filed Jan.5, 2017, which claims priority to U.S. Provisional Application No.62/251,447, filed Nov. 5, 2015, (4) a continuation-in-part of U.S.application Ser. No. 15/825,798, filed Nov. 29, 2017, (5) acontinuation-in-part of U.S. application Ser. No. 15/948,031, filed Apr.9, 2018, which claims priority to U.S. Provisional Application No.62/488,107, filed Apr. 21, 2017, and U.S. Provisional Application No.62/488,406, filed Apr. 21, 2017, the entire contents of which areincorporated herein by reference.

FIELD OF THE INVENTION

The present invention generally relates to novel compounds, compositionscomprising the same, and applications of the compounds and compositions,including organic electroluminescent devices comprising the compoundsand/or compositions.

JOINT RESEARCH AGREEMENT

The claimed inventions were made by, on behalf of, and/or in connectionwith one or more of the following parties to a joint universitycorporation research agreement: University of Southern California, andthe Universal Display Corporation. The agreement was in effect on andbefore the date the claimed inventions were made, and the claimedinventions were made as a result of activities undertaken within thescope of the agreement.

BACKGROUND OF THE INVENTION

Generally, an OLED comprises at least one organic layer disposed betweenand electrically connected to an anode and a cathode. When a current isapplied, the anode injects holes and the cathode injects electrons intothe organic layer(s). The injected holes and electrons each migratetoward the oppositely charged electrode. When an electron and holelocalize on the same molecule, an “exciton,” which is a localizedelectron-hole pair having an excited energy state, is formed. Light isemitted when the exciton relaxes via a photoemissive mechanism. In somecases, the exciton may be localized on an excimer or an exciplex.Non-radiative mechanisms, such as thermal relaxation, may also occur,but are generally considered undesirable.

The initial OLEDs used emissive molecules that emitted light from theirsinglet states (“fluorescence”) as disclosed, for example, in U.S. Pat.No. 4,769,292, which is incorporated by reference in its entirety.Fluorescent emission generally occurs in a time frame of less than 10nanoseconds.

More recently, OLEDs having emissive materials that emit light fromtriplet states (“phosphorescence”) have been demonstrated. Baldo et al.,“Highly Efficient Phosphorescent Emission from OrganicElectroluminescent Devices,” Nature, vol. 395, 151-154, 1998;(“Baldo-I”) and Baldo et al., “Very high-efficiency green organiclight-emitting devices based on electrophosphorescence,” Appl. Phys.Lett., vol. 75, No. 3, 4-6 (1999) (“Baldo-II”), which are incorporatedby reference in their entireties. Phosphorescence may be referred to asa “forbidden” transition because the transition requires a change inspin states, and quantum mechanics indicates that such a transition isnot favored. As a result, phosphorescence generally occurs in a timeframe exceeding at least 10 nanoseconds, and typically greater than 100nanoseconds. If the natural radiative lifetime of phosphorescence is toolong, triplets may decay by a non-radiative mechanism, such that nolight is emitted. Organic phosphorescence is also often observed inmolecules containing heteroatoms with unshared pairs of electrons atvery low temperatures. 2,2′-bipyridine is such a molecule. Non-radiativedecay mechanisms are typically temperature dependent, such that anorganic material that exhibits phosphorescence at liquid nitrogentemperatures typically does not exhibit phosphorescence at roomtemperature. But, as demonstrated by Baldo, this problem may beaddressed by selecting phosphorescent compounds that do phosphoresce atroom temperature. Representative emissive layers include doped orun-doped phosphorescent organometallic materials such as disclosed inU.S. Pat. Nos. 6,303,238; 6,310,360; 6,830,828 and 6,835,469; U.S.Patent Application Publication No. 2002-0182441; and WO 2002/074015.

Phosphorescence may be preceded by a transition from a triplet excitedstate to an intermediate non-triplet state from which the emissive decayoccurs. For example, organic molecules coordinated to lanthanideelements often phosphoresce from excited states localized on thelanthanide metal. However, such materials do not phosphoresce directlyfrom a triplet excited state but instead emit from an atomic excitedstate centered on the lanthanide metal ion. The europium diketonatecomplexes illustrate one group of these types of species.

Phosphorescence from triplets can be enhanced over fluorescence byconfining, preferably through bonding, the organic molecule in closeproximity to an atom of high atomic number. This phenomenon, called theheavy atom effect, is created by a mechanism known as spin-orbitcoupling. Such a phosphorescent transition may be observed from anexcited metal-to-ligand charge transfer (MLCT) state of anorganometallic molecule such as tris(2-phenylpyridine)iridium(III).

Opto-electronic devices that make use of organic materials are becomingincreasingly desirable for a number of reasons. Many of the materialsused to make such devices are relatively inexpensive, so organicopto-electronic devices have the potential for cost advantages overinorganic devices. In addition, the inherent properties of organicmaterials, such as their flexibility, may make them well suited forparticular applications such as fabrication on a flexible substrate.Examples of organic opto-electronic devices include organic lightemitting devices (OLEDs), organic phototransistors, organic photovoltaiccells, and organic photodetectors. For OLEDs, the organic materials mayhave performance advantages over conventional materials. For example,the wavelength at which an organic emissive layer emits light maygenerally be readily tuned with appropriate dopants.

OLEDs make use of thin organic films that emit light when voltage isapplied across the device. OLEDs are becoming an increasinglyinteresting technology for use in applications such as flat paneldisplays, illumination, and backlighting. Several OLED materials andconfigurations are described in U.S. Pat. Nos. 5,844,363, 6,303,238, and5,707,745, which are incorporated herein by reference in their entirety.

One application for phosphorescent emissive molecules is a full colordisplay. Industry standards for such a display call for pixels adaptedto emit particular colors, referred to as “saturated” colors. Inparticular, these standards call for saturated red, green, and bluepixels. Alternatively, the OLED can be designed to emit white light. Inconventional liquid crystal displays, emission from a white backlight isfiltered using absorption filters to produce red, green and blueemission. The same technique can also be used with OLEDs. The white OLEDcan be either a single EML device or a stacked structure. Color may bemeasured using CIE coordinates, which are well known to the art.

One example of a green emissive molecule is tris(2-phenylpyridine)iridium, denoted Ir(ppy)₃, which has the following structure:

In this, and later figures herein, we depict the dative bond fromnitrogen to metal (here, Ir) as a straight line.

As used herein, the term “organic” includes polymeric materials as wellas small molecule organic materials that may be used to fabricateorganic opto-electronic devices. “Small molecule” refers to any organicmaterial that is not a polymer, and “small molecules” may actually bequite large. Small molecules may include repeat units in somecircumstances. For example, using a long chain alkyl group as asubstituent does not remove a molecule from the “small molecule” class.Small molecules may also be incorporated into polymers, for example as apendent group on a polymer backbone or as a part of the backbone. Smallmolecules may also serve as the core moiety of a dendrimer, whichconsists of a series of chemical shells built on the core moiety. Thecore moiety of a dendrimer may be a fluorescent or phosphorescent smallmolecule emitter. A dendrimer may be a “small molecule,” and it isbelieved that all dendrimers currently used in the field of OLEDs aresmall molecules.

As used herein, “top” means furthest away from the substrate, while“bottom” means closest to the substrate. Where a first layer isdescribed as “disposed over” a second layer, the first layer is disposedfurther away from substrate. There may be other layers between the firstand second layer, unless it is specified that the first layer is “incontact with” the second layer. For example, a cathode may be describedas “disposed over” an anode, even though there are various organiclayers in between.

As used herein, “solution processible” means capable of being dissolved,dispersed, or transported in and/or deposited from a liquid medium,either in solution or suspension form.

A ligand may be referred to as “photoactive” when it is believed thatthe ligand directly contributes to the photoactive properties of anemissive material. A ligand may be referred to as “ancillary” when it isbelieved that the ligand does not contribute to the photoactiveproperties of an emissive material, although an ancillary ligand mayalter the properties of a photoactive ligand.

As used herein, and as would be generally understood by one skilled inthe art, a first “Highest Occupied Molecular Orbital” (HOMO) or “LowestUnoccupied Molecular Orbital” (LUMO) energy level is “greater than” or“higher than” a second HOMO or LUMO energy level if the first energylevel is closer to the vacuum energy level. Since ionization potentials(IP) are measured as a negative energy relative to a vacuum level, ahigher HOMO energy level corresponds to an IP having a smaller absolutevalue (an IP that is less negative). Similarly, a higher LUMO energylevel corresponds to an electron affinity (EA) having a smaller absolutevalue (an EA that is less negative). On a conventional energy leveldiagram, with the vacuum level at the top, the LUMO energy level of amaterial is higher than the HOMO energy level of the same material. A“higher” HOMO or LUMO energy level appears closer to the top of such adiagram than a “lower” HOMO or LUMO energy level.

As used herein, and as would be generally understood by one skilled inthe art, a first work function is “greater than” or “higher than” asecond work function if the first work function has a higher absolutevalue. Because work functions are generally measured as negative numbersrelative to vacuum level, this means that a “higher” work function ismore negative. On a conventional energy level diagram, with the vacuumlevel at the top, a “higher” work function is illustrated as furtheraway from the vacuum level in the downward direction. Thus, thedefinitions of HOMO and LUMO energy levels follow a different conventionthan work functions.

More details on OLEDs, and the definitions described above, can be foundin U.S. Pat. No. 7,279,704, which is incorporated herein by reference inits entirety.

SUMMARY OF THE INVENTION

According to an aspect of the present disclosure, a compound having astructure (L_(A))_(n)ML_(m) according to the following Formula 1 isdisclosed:

In Formula 1, M is a metal having an atomic weight greater than 40, nhas a value of at least 1 and m+n is the maxiumn number of ligands thatmay be attached to the metal M;

-   wherein A is a linking group having two to three linking atoms,    wherein the linking atoms are each independently selected from the    group consisting of C, Si, O, S, N, B or combinations thereof;-   wherein the linking atoms form at least one single bond between two    linking atoms; wherein R^(1a)-R^(1g) are each independently selected    from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl,    heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,    heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂,    NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclic    group, and combinations thereof;-   wherein each R is independently selected from the group consisting    of hydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl,    alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,    alkynyl, aralkyl, aryl, heteroaryl, and combinations thereof;-   wherein any one of the ring atoms to which R^(1b) to R^(1g) are    attached may be replaced with a nitrogen atom,-   wherein when the ring atom is replaced with a nitrogen atom the    corresponding R group is not present; and wherein L is a substituted    or unsubstituted cyclometallated ligand.

According to another aspect of the present disclosure, an organic lightemitting device is disclosed. The OLED comprises an anode; a cathode;and an organic layer disposed between the anode and the cathode, whereinthe organic layer comprises the compound having the structure accordingto Formula 1.

According to another aspect of the present disclosure, a formulationcomprising the compound having the structure according to Formula 1 isalso disclosed.

According to another aspect of the present disclosure, a compound havinga structure according to Formula (1a) shown below is disclosed.

In Formula (1a), A is a linking group having two to three linking atoms,wherein the linking atoms are each independently selected from the groupconsisting of C, Si, O, S, N, B or combinations thereof;

-   wherein R^(ab), R^(ga), and R^(1b) to R^(1f) are each independently    selected from the group consisting of hydrogen, deuterium, alkyl,    cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl,    cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R,    C(O)NR₂, NR₂, NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a    heterocyclic group, and combinations thereof;-   wherein each R is independently selected from the group consisting    of hydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl,    alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,    alkynyl, aralkyl, aryl, heteroaryl, and combinations thereof; and-   wherein any one of the ring atoms to which R^(ab), R^(ga), and    R^(1b) to R^(1f) are attached may be replaced with a nitrogen atom,    wherein when the ring atom is replaced with a nitrogen atom the    corresponding R group is not present.

According to another aspect of the present disclosure, the compound ofFormula (1a) can be a compound having a structure represented bystructural formulas, Formula (2a) and Formula (2b) tethered together asdefined below:

-   wherein A¹ and A² are each a first linking group having two to three    linking atoms, wherein the linking atoms are each independently    selected from the group consisting of C, Si, O, S, N, B and    combinations thereof, and-   wherein R^(ac), R^(gb), and R^(2b) to R^(2f) are each independently    selected from the group consisting of hydrogen, deuterium, alkyl,    cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl,    cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R,    C(O)NR₂, NR₂, NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a    heterocyclic group, and combinations thereof;-   wherein the compound is tethered together via at least one second    linking group formed between R^(ab) and R^(ac) and/or R^(ga) and    R^(gb), wherein at least one second linking group has one to three    linking atoms and each linking atom is independently selected from    the group consisting of B, N, P, O, S, Se, C, Si, Ge and    combinations thereof; and any one of the ring atoms to which R^(1b)    to R^(1f) and R^(2b) to R^(2f) are attached may be replaced with a    nitrogen atom, wherein when the ring atom is replaced with a    nitrogen atom the corresponding R group is not present.

According to another aspect of the present disclosure, the compound ofFormula (1a) can be a compound having a structure represented by Formula(3a) shown below:

-   wherein L² and L³ are each independently selected from the group    consisting of a single bond, BR¹, NR¹, PR¹, O, S, Se, C═O, S═O, SO₂,    CR¹R², SiR¹R², and GeR¹R²;-   wherein R^(3a) to R^(3f), are each independently selected from the    group consisting of hydrogen, deuterium, alkyl, cycloalkyl,    heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,    heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂,    NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclic    group, and combinations thereof;-   wherein each R¹ and R² is independently selected from the group    consisting of hydrogen, deuterium, halo, alkyl, cycloalkyl,    heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,    heteroalkenyl, alkynyl, aralkyl, aryl, heteroaryl, and combinations    thereof;-   wherein any two adjacent R^(1f), R^(3a), R^(3c), R^(3d), R¹ and R²    are optionally joined to form a ring; wherein L² and R^(1f), L² and    R^(3a), or L² and both R^(1f) and R^(3a) are optionally joined to    form one or more rings; and wherein L³ and R^(3c), L³ and R^(3d), or    L³ and both R^(3c) and R^(3d) are optionally joined to form one or    more rings.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description ofexemplary embodiments of the compounds, compositions and devices inaccordance with the present invention, will be better understood whenread in conjunction with the appended drawings of exemplary embodiments.It should be understood, however, that the invention is not limited tothe precise arrangements and instrumentalities shown.

In the drawings:

FIG. 1 shows an exemplary organic light emitting device 100; and

FIG. 2 illustrates an exemplary organic light emitting device 200according to the present disclosure.

FIGS. 3a and 3b illustrate a computational model of minimizedbond-broken geometry (top) and minimized non-bond broken geometry(bottom) for comparative example 1.

FIG. 4 illustrates a MALDI negative mode mass spectrum for comparativecompound 4. The highest intensity peak corresponds to fragmentation ofthe imidazole ring.

FIG. 5 illustrates the x-ray crystal structure of3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine.

FIG. 6 illustrates the x-ray crystal structure of3,3-dimethyl-3,4-dihydro-1,2a1-diaza-3-silabenzo[fg]aceanthrylene.

FIG. 7 depicts Emission spectrum of Compound 49 in 77 K and roomtemperature 2-methyl THF solvent and solid state PMMA matrix.

DETAILED DESCRIPTION

Generally, an OLED comprises at least one organic layer disposed betweenand electrically connected to an anode and a cathode. When a current isapplied, the anode injects holes and the cathode injects electrons intothe organic layer(s). The injected holes and electrons each migratetoward the oppositely charged electrode. When an electron and holelocalize on the same molecule, an “exciton,” which is a localizedelectron-hole pair having an excited energy state, is formed. Light isemitted when the exciton relaxes via a photoemissive mechanism. In somecases, the exciton may be localized on an excimer or an exciplex.Non-radiative mechanisms, such as thermal relaxation, may also occur,but are generally considered undesirable.

The initial OLEDs used emissive molecules that emitted light from theirsinglet states (“fluorescence”) as disclosed, for example, in U.S. Pat.No. 4,769,292, which is incorporated by reference in its entirety.Fluorescent emission generally occurs in a time frame of less than 10nanoseconds.

More recently, OLEDs having emissive materials that emit light fromtriplet states (“phosphorescence”) have been demonstrated. Baldo et al.,“Highly Efficient Phosphorescent Emission from OrganicElectroluminescent Devices,” Nature, vol. 395, 151-154, 1998;(“Baldo-I”) and Baldo et al., “Very high-efficiency green organiclight-emitting devices based on electrophosphorescence,” Appl. Phys.Lett., vol. 75, No. 3, 4-6 (1999) (“Baldo-II”), which are incorporatedby reference in their entireties. Phosphorescence is described in moredetail in U.S. Pat. No. 7,279,704 at cols. 5-6, which are incorporatedby reference.

Imidazophenanthridines are useful ligands that can provide 460 nmemission when ligated to both platinum and iridium metals.Phosphorescent imidazophenanthridine complexes can provide deep blueemission with tunable photoluminescent quantum yield ranging from nearlyzero to unity. Unfortunately, the device lifetime is limited for bothiridium and platinum based blue-emitting complexes. We provide astrategy herein to improve the stability of the imidazophenanthridineligand by addressing a bond on the ligand that is shown by computationaltheory, mass spec fragmentation analysis, and photooxidative studies tobe a weak bond due to polycyclic ring strain and electronic structure.

FIG. 1 shows an organic light emitting device 100. The figures are notnecessarily drawn to scale. Device 100 may include a substrate 110, ananode 115, a hole injection layer 120, a hole transport layer 125, anelectron blocking layer 130, an emissive layer 135, a hole blockinglayer 140, an electron transport layer 145, an electron injection layer150, a protective layer 155, a cathode 160, and a barrier layer 170.Cathode 160 is a compound cathode having a first conductive layer 162and a second conductive layer 164. Device 100 may be fabricated bydepositing the layers described, in order. The properties and functionsof these various layers, as well as example materials, are described inmore detail in U.S. Pat. No. 7,279,704 at cols. 6-10, which areincorporated by reference.

More examples for each of these layers are available. For example, aflexible and transparent substrate-anode combination is disclosed inU.S. Pat. No. 5,844,363, which is incorporated by reference in itsentirety. An example of a p-doped hole transport layer is m-MTDATA dopedwith F₄-TCNQ at a molar ratio of 50:1, as disclosed in U.S. PatentApplication Publication No. 2003/0230980, which is incorporated byreference in its entirety. Examples of emissive and host materials aredisclosed in U.S. Pat. No. 6,303,238 to Thompson et al., which isincorporated by reference in its entirety. An example of an n-dopedelectron transport layer is BPhen doped with Li at a molar ratio of 1:1,as disclosed in U.S. Patent Application Publication No. 2003/0230980,which is incorporated by reference in its entirety. U.S. Pat. Nos.5,703,436 and 5,707,745, which are incorporated by reference in theirentireties, disclose examples of cathodes including compound cathodeshaving a thin layer of metal such as Mg:Ag with an overlyingtransparent, electrically-conductive, sputter-deposited ITO layer. Thetheory and use of blocking layers is described in more detail in U.S.Pat. No. 6,097,147 and U.S. Patent Application Publication No.2003/0230980, which are incorporated by reference in their entireties.Examples of injection layers are provided in U.S. Patent ApplicationPublication No. 2004/0174116, which is incorporated by reference in itsentirety. A description of protective layers may be found in U.S. PatentApplication Publication No. 2004/0174116, which is incorporated byreference in its entirety.

FIG. 2 shows an inverted OLED 200. The device includes a substrate 210,a cathode 215, an emissive layer 220, a hole transport layer 225, and ananode 230. Device 200 may be fabricated by depositing the layersdescribed, in order. Because the most common OLED configuration has acathode disposed over the anode, and device 200 has cathode 215 disposedunder anode 230, device 200 may be referred to as an “inverted” OLED.Materials similar to those described with respect to device 100 may beused in the corresponding layers of device 200. FIG. 2 provides oneexample of how some layers may be omitted from the structure of device100.

The simple layered structure illustrated in FIGS. 1 and 2 is provided byway of non-limiting example, and it is understood that embodiments ofthe invention may be used in connection with a wide variety of otherstructures. The specific materials and structures described areexemplary in nature, and other materials and structures may be used.Functional OLEDs may be achieved by combining the various layersdescribed in different ways, or layers may be omitted entirely, based ondesign, performance, and cost factors. Other layers not specificallydescribed may also be included. Materials other than those specificallydescribed may be used. Although many of the examples provided hereindescribe various layers as comprising a single material, it isunderstood that combinations of materials, such as a mixture of host anddopant, or more generally a mixture, may be used. Also, the layers mayhave various sublayers. The names given to the various layers herein arenot intended to be strictly limiting. For example, in device 200, holetransport layer 225 transports holes and injects holes into emissivelayer 220, and may be described as a hole transport layer or a holeinjection layer. In one embodiment, an OLED may be described as havingan “organic layer” disposed between a cathode and an anode. This organiclayer may comprise a single layer, or may further comprise multiplelayers of different organic materials as described, for example, withrespect to FIGS. 1 and 2.

Structures and materials not specifically described may also be used,such as OLEDs comprised of polymeric materials (PLEDs) such as disclosedin U.S. Pat. No. 5,247,190 to Friend et al., which is incorporated byreference in its entirety. By way of further example, OLEDs having asingle organic layer may be used. OLEDs may be stacked, for example asdescribed in U.S. Pat. No. 5,707,745 to Forrest et al, which isincorporated by reference in its entirety. The OLED structure maydeviate from the simple layered structure illustrated in FIGS. 1 and 2.For example, the substrate may include an angled reflective surface toimprove out-coupling, such as a mesa structure as described in U.S. Pat.No. 6,091,195 to Forrest et al., and/or a pit structure as described inU.S. Pat. No. 5,834,893 to Bulovic et al., which are incorporated byreference in their entireties.

Unless otherwise specified, any of the layers of the various embodimentsmay be deposited by any suitable method. For the organic layers,preferred methods include thermal evaporation, ink-jet, such asdescribed in U.S. Pat. Nos. 6,013,982 and 6,087,196, which areincorporated by reference in their entireties, organic vapor phasedeposition (OVPD), such as described in U.S. Pat. No. 6,337,102 toForrest et al., which is incorporated by reference in its entirety, anddeposition by organic vapor jet printing (OVJP), such as described inU.S. Pat. No. 7,431,968, which is incorporated by reference in itsentirety. Other suitable deposition methods include spin coating andother solution based processes. Solution based processes are preferablycarried out in nitrogen or an inert atmosphere. For the other layers,preferred methods include thermal evaporation. Preferred patterningmethods include deposition through a mask, cold welding such asdescribed in U.S. Pat. Nos. 6,294,398 and 6,468,819, which areincorporated by reference in their entireties, and patterning associatedwith some of the deposition methods such as ink-jet and OVJD. Othermethods may also be used. The materials to be deposited may be modifiedto make them compatible with a particular deposition method. Forexample, substituents such as alkyl and aryl groups, branched orunbranched, and preferably containing at least 3 carbons, may be used insmall molecules to enhance their ability to undergo solution processing.Substituents having 20 carbons or more may be used, and 3-20 carbons isa preferred range. Materials with asymmetric structures may have bettersolution processibility than those having symmetric structures, becauseasymmetric materials may have a lower tendency to recrystallize.Dendrimer substituents may be used to enhance the ability of smallmolecules to undergo solution processing.

Devices fabricated in accordance with embodiments of the presentinvention may further optionally comprise a barrier layer. One purposeof the barrier layer is to protect the electrodes and organic layersfrom damaging exposure to harmful species in the environment includingmoisture, vapor and/or gases, etc. The barrier layer may be depositedover, under or next to a substrate, an electrode, or over any otherparts of a device including an edge. The barrier layer may comprise asingle layer, or multiple layers. The barrier layer may be formed byvarious known chemical vapor deposition techniques and may includecompositions having a single phase as well as compositions havingmultiple phases. Any suitable material or combination of materials maybe used for the barrier layer. The barrier layer may incorporate aninorganic or an organic compound or both. The preferred barrier layercomprises a mixture of a polymeric material and a non-polymeric materialas described in U.S. Pat. No. 7,968,146, PCT Pat. Application Nos.PCT/US2007/023098 and PCT/US2009/042829, which are herein incorporatedby reference in their entireties. To be considered a “mixture”, theaforesaid polymeric and non-polymeric materials comprising the barrierlayer should be deposited under the same reaction conditions and/or atthe same time. The weight ratio of polymeric to non-polymeric materialmay be in the range of 95:5 to 5:95. The polymeric material and thenon-polymeric material may be created from the same precursor material.In one example, the mixture of a polymeric material and a non-polymericmaterial consists essentially of polymeric silicon and inorganicsilicon.

Devices fabricated in accordance with embodiments of the invention canbe incorporated into a wide variety of electronic component modules (orunits) that can be incorporated into a variety of electronic products orintermediate components. Examples of such electronic products orintermediate components include display screens, lighting devices suchas discrete light source devices or lighting panels, etc. that can beutilized by the end-user product manufacturers. Such electroniccomponent modules can optionally include the driving electronics and/orpower source(s). Devices fabricated in accordance with embodiments ofthe invention can be incorporated into a wide variety of consumerproducts that have one or more of the electronic component modules (orunits) incorporated therein. Such consumer products would include anykind of products that include one or more light source(s) and/or one ormore of some type of visual displays. Some examples of such consumerproducts include flat panel displays, computer monitors, medicalmonitors, televisions, billboards, lights for interior or exteriorillumination and/or signaling, heads-up displays, fully or partiallytransparent displays, flexible displays, laser printers, telephones,cell phones, tablets, phablets, personal digital assistants (PDAs),wearable devices, laptop computers, digital cameras, camcorders,viewfinders, micro-displays, 3-D displays, vehicles, a large area wall,theater or stadium screen, or a sign. Various control mechanisms may beused to control devices fabricated in accordance with the presentinvention, including passive matrix and active matrix. Many of thedevices are intended for use in a temperature range comfortable tohumans, such as 18 degrees C. to 30 degrees C., and more preferably atroom temperature (20-25 degrees C.), but could be used outside thistemperature range, for example, from −40 degree C. to +80 degree C.

The materials and structures described herein may have applications indevices other than OLEDs. For example, other optoelectronic devices suchas organic solar cells and organic photodetectors may employ thematerials and structures. More generally, organic devices, such asorganic transistors, may employ the materials and structures.

The term “halo,” “halogen,” or “halide” as used herein includesfluorine, chlorine, bromine, and iodine.

The term “alkyl” as used herein means a straight or branched chainsaturated acyclic hydrocarbon radical, which may optionally besubstituted with any suitable substituent. Accordingly, an alkyl radicalin accordance with the present invention can comprise any combination ofprimary, secondary, tertiary and quaternary carbon atoms. Exemplaryalkyl radicals include, but are not limited to, C₁-C₂₀-alkyl,C₁-C₁₈-alkyl, C₁-C₁₆-alkyl, C₁-C₁₄-alkyl, C₁-C₁₂-alkyl, C₁-C₁₀-alkyl,C₁-C₈-alkyl, C₁-C₆-alkyl, C₁-C₄-alkyl, C₁-C₃-alkyl, and C₂-alkyl.Specific examples include methyl, ethyl, 1-propyl, 2-propyl,2-methyl-1-propyl, 1-butyl, 2-butyl, t-butyl, n-octyl, n-decyl, andn-hexadecyl.

As used herein, the term “heteroalkyl” refers to an alkyl group asdescribed herein in which one or more carbon atoms is replaced by aheteroatom. Suitable heteroatoms include oxygen, sulfur, nitrogen,phosphorus, and the like. Examples of heteroalkyl groups include, butare not limited to, alkoxy, amino, thioester, poly(ethylene glycol), andalkyl-substituted amino.

The term “cycloalkyl” as used herein contemplates cyclic alkyl radicals.Preferred cycloalkyl groups are those containing 3 to 7 carbon atoms andincludes cyclopropyl, cyclopentyl, cyclohexyl, and the like.Additionally, the cycloalkyl group may be optionally substituted.

As used herein, the term “alkenyl” means acyclic branched or unbranchedhydrocarbon radical having one or more carbon-carbon double bonds.Exemplary alkenyl radicals include, but are not limited to,C₁-C₂₀-alkenyl radical, C₂-C₁₈-alkenyl radical, C₂-C₁₆-alkenyl radical,C₂-C₁₄-alkenyl radical, C₂-C₁₂-alkenyl radical, C₂-C₁₀-alkenyl radical,C₂-C₈-alkenyl radical, C₂-C₆-alkenyl radical, C₂-C₄-alkenyl radical,C₂-C₃-alkenyl radical, and C₂-alkenyl radical. Specific examplesinclude, but are not limited to, ethylenyl, propylenyl, 1-butenyl,2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl,2-methyl-2-butenyl, and 2,3-dimethyl-2-butenyl.

As used herein, the term “alkylene” means an optionally substitutedsaturated straight or branched chain hydrocarbon radical. Exemplaryalkylene radicals include, but are not limited to, C₁-C₂₀-alkylene,C₂-C₁₈-alkylene, C₂-C₁₆-alkylene, C₂-C₁₄-alkylene, C₂-C₁₂-alkylene,C₂-C₁₀-alkylene, C₂-C₈-alkylene, C₂-C₆-alkylene, C₂-C₄-alkylene,C₂-C₃-alkylene, and C₂-alkylene. Specific examples of alkylene include,but are not limited to, methylene, dimethylene, and trimethylene.

As used herein, the term “alkynyl” means an acyclic branched orunbranched hydrocarbon having at least one carbon-carbon triple bond.Exemplary alkylene radicals include, but are not limited to,C₁-C₂₀-alkynyl radical, C₂-C₁₈-alkynyl radical, C₂-C₁₆-alkynyl radical,C₂-C₁₄-alkynyl radical, C₂-C₁₂-alkynyl radical, C₂-C₁₀-alkynyl radical,C₂-C₈-alkynyl radical, C₂-C₆-alkynyl radical, C₂-C₄-alkynyl radical,C₂-C₃-alkynyl radical, and C₂-alkynyl radical. Specific examples ofalkynyl include, but are not limited to, propargyl, and 3-pentynyl,acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, and3-methyl-1-butynyl.

As used herein, the term “aralkyl” means one or more aryl radicals asdefined herein attached through an alkyl bridge (e.g.,-alkyl-(aryl)_(j), wherein j is 1, 2 or 3). Specific examples of aralkylinclude, but are not limited to, benzyl (—CH₂-phenyl, i.e., Bn),diphenyl methyl (—CH -(phenyl)₂) and trityl (—C-(phenyl)₃).Additionally, the aralkyl group may be optionally substituted.

Unless stated otherwise, as used herein, the term “heterocycle” andvariants of the term, including “heterocyclic group” and “heterocyclyl,”means an optionally substituted monocyclic or polycyclic ring systemhaving as ring members atoms of at least two different elements andwherein the monocyclic or polycyclic ring system is either saturated,unsaturated or aromatic. In some embodiments, heterocyle comprisescarbon atoms and at least one heteroatom. In some embodiments,heterocyle comprises carbon atoms and at least one heteroatom selectedfrom nitrogen, oxygen, silicon, selenium, and sulfur, and wherein thenitrogen, oxygen, silicon, selenium, and sulfur heteroatoms may beoptionally oxidized, and the nitrogen heteroatom may be optionallyquaternized. Examples of heterocycle include, but are not limited to,furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl,isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl,isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl,thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl,pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl. Thus,in addition to the aromatic heteroaryls listed above, heterocycles alsoinclude (but are not limited to) morpholinyl, pyrrolidinonyl,pyrrolidinyl, piperizinyl, piperidinyl, hydantoinyl, valerolactamyl,oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl,tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl,tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, andtetrahydrothiopyranyl.

As used herein, the term “aryl” means an optionally substitued monoyclicor polycyclic aromatic hydrocarbon. Specific examples of aryl include,but are not limited to, phenyl, phenyl, 4-methylphenyl,2,6-dimethylphenyl, naphthyl,anthracenyl, and phenanthrenyl. The term“aryl” or “aromatic group” as used herein contemplates single-ringgroups and polycyclic ring systems. The polycyclic rings may have two ormore rings in which two carbons are common to two adjoining rings (therings are “fused”) wherein at least one of the rings is aromatic, e.g.,the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles,and/or heteroaryls. Additionally, the aryl group may be optionallysubstituted.

As used herein, the term “heteroaryl” means an optionally substitutedmonoyclic or polycyclic aromatic hydrocarbon having at least oneheteroatom and at least one carbon atom. In some embodiments, the atleast one heteroatom is selected from nitrogen, oxygen, silicon,selenium, and sulfur. Specific examples of heteroaryl include, but arenot limited to, furyl, benzofuranyl, thiophenyl, benzothiophenyl,pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl,isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl,imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl,pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl,phthalazinyl, and quinazolinyl.

The alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heterocyclic group,aryl, and heteroaryl may be optionally substituted with one or moresubstituents selected from the group consisting of hydrogen, deuterium,halogen, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy,amino, cyclic amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ether,ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, andcombinations thereof.

The terms “substituted” and “substitution” refer to a substituent otherthan H that is bonded to the relevant position, e.g., a carbon ornitrogen. For example, when R¹ represents mono-substitution, then one R¹must be other than H (i.e., a substitution). Similarly, when R¹represents di-substitution, then two of R¹ must be other than H.Similarly, when R¹ represents no substitution, R¹, for example, can be ahydrogen for available valencies of ring atoms, as in carbon atoms forbenzene and the nitrogen atom in pyrrole, or simply represents nothingfor ring atoms with fully filled valencies, e.g., the nitrogen atom inpyridine. The maximum number of substitutions possible in a ringstructure will depend on the total number of available valencies in thering atoms. As used herein, “combinations thereof” indicates that one ormore members of the applicable list are combined to form a known orchemically stable arrangement that one of ordinary skill in the art canenvision from the applicable list. For example, an alkyl and deuteriumcan be combined to form a partial or fully deuterated alkyl group; ahalogen and alkyl can be combined to form a halogenated alkylsubstituent; and a halogen, alkyl, and aryl can be combined to form ahalogenated arylalkyl. In one instance, the term substitution includes acombination of two to four of the listed groups. In another instance,the term substitution includes a combination of two to three groups. Inyet another instance, the term substitution includes a combination oftwo groups. Preferred combinations of substituent groups are those thatcontain up to fifty atoms that are not hydrogen or deuterium, or thosewhich include up to forty atoms that are not hydrogen or deuterium, orthose that include up to thirty atoms that are not hydrogen ordeuterium. In many instances, a preferred combination of substituentgroups will include up to twenty atoms that are not hydrogen ordeuterium.

The “aza” designation in the fragments described herein, i.e.aza-dibenzofuran, aza-dibenzothiophene, etc. means that one or more ofthe C—H groups in the respective aromatic ring can be replaced by anitrogen atom, for example, and without any limitation, azatriphenyleneencompasses both dibenzo[fh]quinoxaline and dibenzo[f,h]quinoline. Oneof ordinary skill in the art can readily envision other nitrogen analogsof the aza-derivatives described above, and all such analogs areintended to be encompassed by the terms as set forth herein.

It is to be understood that when a molecular fragment is described asbeing a substituent or otherwise attached to another moiety, its namemay be written as if it were a fragment (e.g. phenyl, phenylene,naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g.benzene, naphthalene, dibenzofuran). As used herein, these differentways of designating a substituent or attached fragment are considered tobe equivalent.

As used herein, and as would be generally understood by one skilled inthe art, a first “Highest Occupied Molecular Orbital” (HOMO) or “LowestUnoccupied Molecular Orbital” (LUMO) energy level is “greater than” or“higher than” a second HOMO or LUMO energy level if the first energylevel is closer to the vacuum energy level. Since ionization potentials(IP) are measured as a negative energy relative to a vacuum level, ahigher HOMO energy level corresponds to an IP having a smaller absolutevalue (an IP that is less negative). Similarly, a higher LUMO energylevel corresponds to an electron affinity (EA) having a smaller absolutevalue (an EA that is less negative). On a conventional energy leveldiagram, with the vacuum level at the top, the LUMO energy level of amaterial is higher than the HOMO energy level of the same material. A“higher” HOMO or LUMO energy level appears closer to the top of such adiagram than a “lower” HOMO or LUMO energy level.

As used herein, the term “triplet energy” refers to an energycorresponding to the highest energy feature discernable in thephosphorescence spectrum of a given material. The highest energy featureis not necessarily the peak having the greatest intensity in thephosphorescence spectrum, and could, for example, be a local maximum ofa clear shoulder on the high energy side of such a peak.

According to an aspect of the present disclosure, a compound having astructure (L_(A))_(n)ML_(m) according to Formula 1 shown below isdisclosed.

In Formula 1, M is a metal having an atomic weight greater than 40, nhas a value of at least 1 and m+n is the maxiumn number of ligands thatmay be attached to the metal;

wherein A is a linking group having two to three linking atoms, whereinthe linking atoms are each independently selected from the groupconsisting of C, Si, O, S, N, B or combinations thereof;

wherein the linking atoms form at least one single bond between twolinking atoms;

wherein R^(1a) to R^(1g) are each independently selected from the groupconsisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl,alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂, NO₂, OR, SR, SO₂,SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclic group, andcombinations thereof;

wherein each R is independently selected from the group consisting ofhydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aralkyl, aryl, heteroaryl, and combinations thereof;

wherein any one of the ring atoms to which R^(1b) to R^(1g) are attachedmay be replaced with a nitrogen atom, wherein when the ring atom isreplaced with a nitrogen atom the corresponding R group is not present;and

wherein L is a substituted or unsubstituted cyclometallated ligand.

In some embodiments of the compound of Formula 1, one of the ring atomsto which R^(1b) to R^(1g) are attached is a nitrogen atom. In someembodiments, the ring atom to which R^(1e) is attached a nitrogen atom.

In one embodiment, the compound has a triplet excited state and whereinthe linking group A stabilizes the bond between N² and C^(1b) fromcleavage when the compound is in the triplet excited state.

In one embodiment, the compound has a peak emissive wavelength less than500 nm. In another embodiment, the compound has a peak emissivewavelength less than 480 nm. In yet another embodiment, the compound hasa peak emissive wavelength ranging from 400 nm to 500 nm.

In some embodiments of the compound of Formula 1, the linking group A isa saturated group.

In one embodiment of the compound of Formula 1, the linking group A isindependently selected from the group consisting of —CR¹R²—CR³R⁴—,—CR¹R²—CR³R⁴—CR⁵R⁶—, —CR¹R²—NR³—, —CR¹═CR²—CR³R⁴—, —O—SiR¹R²—,—CR¹R²—S—, —CR¹R²—O—, and —C—SiR¹R²—, wherein the substituents R¹ to R⁶can be same or different, and are independently selected from the groupconsisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl,and combinations thereof; wherein any adjacent R¹ to R⁶ are optionallyconnected to form a saturated five membered ring or a saturated sixmembered ring. Any adjacent substituents refers to any two ofsubstituents that are possible to form the ring. The two adjacentsubstituents can be on the same atom, or on different atoms. The linkinggroup A can be selected from the group consisting of:

In some embodiments, the linking group A can be selected from the groupconsisting of

In some embodiments where the linking group A is independently selectedfrom the group consisting of —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—,—CR¹R²—NR³—, —CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—, and—C—SiR¹R²—, wherein the substituents R¹ to R⁶ can be same or different,and are independently selected from the group consisting of hydrogen,deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinationsthereof; at least one adjacent R¹ to R⁶ are connected to form asaturated five membered ring or a saturated six membered ring. In someembodiments, at least two adjacent R¹ to R⁶, if present, are connectedto form a saturated five membered ring or a saturated six membered ring.In some embodiments, each R¹ to R⁶ are independently selected from thegroup consisting of alkyl, cycloalkyl, aryl, heteroaryl, partially orfully deuterated variants thereof, and combinations thereof wherein anyadjacent R¹ to R⁶ are optionally connected to form a saturated fivemembered ring or a saturated six membered ring.

In some embodiments where the linking group A is independently selectedfrom the group consisting of —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—,—CR¹R²—NR³—, —CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—, and—C—SiR¹R²—, wherein the substituents R¹ to R⁶ can be same or different,and are independently selected from the group consisting of hydrogen,deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinationsthereof; each R¹ to R⁶ are independently selected from the groupconsisting of methyl, ethyl, propyl, 1-methylethyl, butyl,1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl,3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl,2,2-dimethylpropyl, cyclopentyl, cyclohexyl, phenyl, 2,6-dimethylphenyl,2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, partially or fullydeuterated variants thereof and combinations thereof. In someembodiments, each R¹ to R⁶ are independently selected from the groupconsisting of alkyl, partially or fully deuterated variants thereof, andcombinations thereof wherein any adjacent R¹ to R⁶ are optionallyconnected to form a saturated five membered ring or a saturated sixmembered ring.

In some embodiments of the compound of Formula 1, at least one of R^(1a)to R^(1g) is selected from the group consisting of alkyl, cycloalkyl,aryl, heteroaryl, partially or fully deuterated variants thereof, andcombinations thereof. In other embodiments, at least one of R^(1b),R^(1d) and R^(1e) is selected from the group consisting of alkyl,cycloalkyl, aryl, heteroaryl, partially or fully deuterated variantsthereof, and combinations thereof. In other embodiments, R^(1d) isselected from the group consisting of alkyl, cycloalkyl, aryl,heteroaryl, partially or fully deuterated variants thereof, andcombinations thereof. In other embodiments, R^(1a) is selected from thegroup consisting of alkyl, cycloalkyl, aryl, heteroaryl, partially orfully deuterated variants thereof, and combinations thereof.

In some embodiments, R^(1a) is selected from the group consisting ofnon-deuterated aryl, partially deuterated aryl, and fully deuteratedaryl. In some embodiments, R^(1a) is selected from the group consistingof non-deuterated phenyl, partially deuterated phenyl, and fullydeuterated phenyl. In some embodiments, R^(1d) is selected from thegroup consisting of methyl, deuterated methyl, and isopropyl. In someembodiments, R^(1f) is selected from the group consisting of methyl,deuterated methyl, and isopropyl.

In some embodiments of the compound of Formula 1, the metal M isselected from the group consisting of Re, Ru, Os, Rh, Ir, Pd, Pt, andAu. In some embodiments, the metal M is selected from the groupconsisting of Ir and Pt.

In some embodiments of the compound of Formula 1, the ligand LA isselected from the group consisting of:

L_(A) Linker A R^(1a) R^(1b) R^(1c) R^(1d) R^(1e) R^(1f) R^(1g) L_(A)1L_(A)2 L_(A)3 L_(A)4 L_(A)5

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)6 H H H H Me H H L_(A)7 CD₃ H H H H H H L_(A)8 H CD₃ H H H H HL_(A)9 H H CD₃ H H H H L_(A)10 H H H CD₃ H H H L_(A)11 H H H H CD₃ H HL_(A)12 ^(i)Pr H H H H H H L_(A)13 H ^(i)Pr H H H H H L_(A)14 H H ^(i)PrH H H H L_(A)15 H H H ^(i)Pr H H H L_(A)16 H H H H ^(i)Pr H H L_(A)17 PhH H H H H H L_(A)18 H Ph H H H H H L_(A)19 H H Ph H H H H L_(A)20 H H HPh H H H L_(A)21 H H H H Ph H H L_(A)22 Me Me H H H H H L_(A)23 Me H MeH H H H L_(A)24 Me H H Me H H H L_(A)25 Me H H H Me H H L_(A)26 Me CD₃ HH H H H L_(A)27 Me H CD₃ H H H H L_(A)28 Me H H CD₃ H H H L_(A)29 Me H HH CD₃ H H L_(A)30 Me ^(i)Pr H H H H H L_(A)31 Me H ^(i)Pr H H H HL_(A)32 Me H H ^(i)Pr H H H L_(A)33 Me H H H ^(i)Pr H H L_(A)34 Me Ph HH H H H L_(A)35 Me H Ph H H H H L_(A)36 Me H H Ph H H H L_(A)37 Me H H HPh H H L_(A)38 CD₃ Me H H H H H L_(A)39 CD₃ H Me H H H H L_(A)40 CD₃ H HMe H H H L_(A)41 CD₃ H H H Me H H L_(A)42 CD₃ CD₃ H H H H H L_(A)43 CD₃H CD₃ H H H H L_(A)44 CD₃ H H CD₃ H H H L_(A)45 CD₃ H H H CD₃ H HL_(A)46 CD₃ ^(i)Pr H H H H H L_(A)47 CD₃ H ^(i)Pr H H H H L_(A)48 CD₃ HH ^(i)Pr H H H L_(A)49 CD₃ H H H ^(i)Pr H H L_(A)50 CD₃ Ph H H H H HL_(A)51 CD₃ H Ph H H H H L_(A)52 L_(A)53 L_(A)54 L_(A)55

CD₃ CD₃ ^(i)Pr ^(i)Pr H H Me H H H H Me Ph H H H H Ph H H H H H H H H HH L_(A)56 ^(i)Pr H H Me H H H L_(A)57 ^(i)Pr H H H Me H H L_(A)58 ^(i)PrCD₃ H H H H H L_(A)59 ^(i)Pr H CD₃ H H H H L_(A)60 ^(i)Pr H H CD₃ H H HL_(A)61 ^(i)Pr H H H CD₃ H H L_(A)62 ^(i)Pr ^(i)Pr H H H H H L_(A)63^(i)Pr H ^(i)Pr H H H H L_(A)64 ^(i)Pr H H ^(i)Pr H H H L_(A)65 ^(i)Pr HH H ^(i)Pr H H L_(A)66 ^(i)Pr Ph H H H H H L_(A)67 ^(i)Pr H Ph H H H HL_(A)68 ^(i)Pr H H Ph H H H L_(A)69 ^(i)Pr H H H Ph H H L_(A)70 Ph Me HH H H H L_(A)71 Ph H Me H H H H L_(A)72 Ph H H Me H H H L_(A)73 Ph H H HMe H H L_(A)74 Ph CD₃ H H H H H L_(A)75 Ph H CD₃ H H H H L_(A)76 Ph H HCD₃ H H H L_(A)77 Ph H H H CD₃ H H L_(A)78 Ph ^(i)Pr H H H H H L_(A)79Ph H ^(i)Pr H H H H L_(A)80 Ph H H ^(i)Pr H H H L_(A)81 Ph H H H ^(i)PrH H L_(A)82 Ph Ph H H H H H L_(A)83 Ph H Ph H H H H L_(A)84 Ph H H Ph HH H L_(A)85 Ph H H H Ph H H L_(A)86 H Me Me H H H H L_(A)87 H Me H Me HH H L_(A)88 H Me H H Me H H L_(A)89 H Me CD₃ H H H H L_(A)90 H Me H CD₃H H H L_(A)91 H Me H H CD₃ H H L_(A)92 H Me ^(i)Pr H H H H L_(A)93 H MeH ^(i)Pr H H H L_(A)94 H Me H H ^(i)Pr H H L_(A)95 H Me Ph H H H HL_(A)96 H Me H Ph H H H L_(A)97 H Me H H Ph H H L_(A)98 H CD₃ Me H H H HL_(A)99 H CD₃ H Me H H H L_(A)100 H CD₃ H H Me H H L_(A)101 H CD₃ CD₃ HH H H L_(A)102 H CD₃ H CD₃ H H H L_(A)103 L_(A)104 L_(A)105 L_(A)106L_(A)107

H H H H H CD₃ CD₃ CD₃ CD₃ CD₃ H ^(i)Pr H H Ph H H ^(i)Pr H H CD₃ H H^(i)Pr H H H H H H H H H H H L_(A)108 H CD₃ H Pr H H H L_(A)109 H CD₃ HH Ph H H L_(A)110 H ^(i)Pr Me H H H H L_(A)111 H ^(i)Pr H Me H H HL_(A)112 H ^(i)Pr H H Me H H L_(A)113 H ^(i)Pr CD₃ H H H H L_(A)114 H^(i)Pr H CD₃ H H H L_(A)115 H ^(i)Pr H H CD₃ H H L_(A)116 H ^(i)Pr^(i)Pr H H H H L_(A)117 H ^(i)Pr H ^(i)Pr H H H L_(A)118 H ^(i)Pr H H^(i)Pr H H L_(A)119 H ^(i)Pr Ph H H H H L_(A)120 H ^(i)Pr H Pr H H HL_(A)121 H ^(i)Pr H H Ph H H L_(A)122 H Ph Me H H H H L_(A)123 H Ph H MeH H H L_(A)124 H Ph H H Me H H L_(A)125 H Ph CD₃ H H H H L_(A)126 H Ph HCD₃ H H H L_(A)127 H Ph H H CD₃ H H L_(A)128 H Ph ^(i)Pr H H H HL_(A)129 H Ph H ^(i)Pr H H H L_(A)130 H Ph H H ^(i)Pr H H L_(A)131 H PhPh H H H H L_(A)132 H Ph H Pr H H H L_(A)133 H Ph H H Ph H H L_(A)134 HH Me Me H H H L_(A)135 H H CD₃ Me H H H L_(A)136 H H ^(i)Pr Me H H HL_(A)137 H H Ph Me H H H L_(A)138 H H Me CD₃ H H H L_(A)139 H H CD₃ CD₃H H H L_(A)140 H H ^(i)Pr CD₃ H H H L_(A)141 H H Ph CD₃ H H H L_(A)142 HH Me ^(i)Pr H H H L_(A)143 H H CD₃ ^(i)Pr H H H L_(A)144 H H ^(i)Pr^(i)Pr H H H L_(A)145 H H Ph ^(i)Pr H H H L_(A)146 H H Me Ph H H HL_(A)147 H H CD₃ Ph H H H L_(A)148 H H ^(i)Pr Ph H H H L_(A)149 H H PhPh H H H L_(A)150 H H Me H Me H H L_(A)151 H H CD₃ H Me H H L_(A)152 H H^(i)Pr H Me H H L_(A)153 H H Ph H Me H H L_(A)154 H H Me H CD₃ H HL_(A)155 H H CD₃ H CD₃ H H L_(A)156 H H ^(i)Pr H CD₃ H H L_(A)157 H H PhH CD₃ H H L_(A)158 L_(A)159 L_(A)160 L_(A)161 L_(A)162

H H H H H H H H H H Me CD₃ ^(i)Pr Ph Me H H H H H ^(i)Pr ^(i)Pr ^(i)Pr^(i)Pr Ph H H H H H H H H H H L_(A)163 H H CD₃ H Ph H H L_(A)164 H H^(i)Pr H Ph H H L_(A)165 H H Ph H Ph H H L_(A)166 Me Me H Me H H HL_(A)167 H Me Me Me H H H L_(A)168 CD₃ Me H Me H H H L_(A)169 H Me CD₃Me H H H L_(A)170 ^(i)Pr Me H Me H H H L_(A)171 H Me ^(i)Pr Me H H HL_(A)172 Ph Me H Me H H H L_(A)173 H Me Ph Me H H H L_(A)174 Me CD₃ HCD₃ H H H L_(A)175 H CD₃ Me CD₃ H H H L_(A)176 CD₃ CD₃ H CD₃ H H HL_(A)177 H CD₃ CD₃ CD₃ H H H L_(A)178 ^(i)Pr CD₃ H CD₃ H H H L_(A)179 HCD₃ ^(i)Pr CD₃ H H H L_(A)180 Ph CD₃ H CD₃ H H H L_(A)181 H CD₃ Ph CD₃ HH H L_(A)182 Me ^(i)Pr H ^(i)Pr H H H L_(A)183 H ^(i)Pr Me ^(i)Pr H H HL_(A)184 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)185 H ^(i)Pr CD₃ ^(i)Pr H H HL_(A)186 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)187 H ^(i)Pr ^(i)Pr ^(i)Pr HH H L_(A)188 Ph ^(i)Pr H ^(i)Pr H H H L_(A)189 H ^(i)Pr Ph ^(i)Pr H H HL_(A)190 Me Ph H Ph H H H L_(A)191 H Ph Me Ph H H H L_(A)192 CD₃ Ph H PhH H H L_(A)193 H Ph CD₃ Ph H H H L_(A)194 ^(i)Pr Ph H Ph H H H L_(A)195H Ph ^(i)Pr Ph H H H L_(A)196 Ph Ph H Ph H H H L_(A)197 H Ph Ph Ph H H HL_(A)198 L_(A)199 L_(A)200 L_(A)201 L_(A)202

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)203 H H H H Me H H L_(A)204 CD₃ H H H H H H L_(A)205 H CD₃ H H HH H L_(A)206 H H CD₃ H H H H L_(A)207 H H H CD₃ H H H L_(A)208 H H H HCD₃ H H L_(A)209 ^(i)Pr H H H H H H L_(A)210 H ^(i)Pr H H H H H L_(A)211H H ^(i)Pr H H H H L_(A)212 H H H ^(i)Pr H H H L_(A)213 L_(A)214L_(A)215 L_(A)216 L_(A)217

H Ph H H H H H Ph H H H H H Ph H H H H H Ph ^(i)Pr H H H H H H H H H H HH H H L_(A)218 H H H H Ph H H L_(A)219 Me Me H H H H H L_(A)220 Me H MeH H H H L_(A)221 Me H H Me H H H L_(A)222 Me H H H Me H H L_(A)223 MeCD₃ H H H H H L_(A)224 Me H CD₃ H H H H L_(A)225 Me H H CD₃ H H HL_(A)226 Me H H H CD₃ H H L_(A)227 Me ^(i)Pr H H H H H L_(A)228 Me H^(i)Pr H H H H L_(A)229 Me H H ^(i)Pr H H H L_(A)230 Me H H H ^(i)Pr H HL_(A)231 Me Ph H H H H H L_(A)232 Me H Ph H H H H L_(A)233 Me H H Ph H HH L_(A)234 Me H H H Ph H H L_(A)235 CD₃ Me H H H H H L_(A)236 CD₃ H Me HH H H L_(A)237 CD₃ H H Me H H H L_(A)238 CD₃ H H H Me H H L_(A)239 CD₃CD₃ H H H H H L_(A)240 CD₃ H CD₃ H H H H L_(A)241 CD₃ H H CD₃ H H HL_(A)242 CD₃ H H H CD₃ H H L_(A)243 CD₃ ^(i)Pr H H H H H L_(A)244 CD₃ H^(i)Pr H H H H L_(A)245 CD₃ H H ^(i)Pr H H H L_(A)246 CD₃ H H H ^(i)Pr HH L_(A)247 CD₃ Ph H H H H H L_(A)248 CD₃ H Ph H H H H L_(A)249 CD₃ H HPh H H H L_(A)250 CD₃ H H H Ph H H L_(A)251 ^(i)Pr Me H H H H H L_(A)252^(i)Pr H Me H H H H L_(A)253 ^(i)Pr H H Me H H H L_(A)254 ^(i)Pr H H HMe H H L_(A)255 ^(i)Pr CD₃ H H H H H L_(A)256 ^(i)Pr H CD₃ H H H HL_(A)257 ^(i)Pr H H CD₃ H H H L_(A)258 ^(i)Pr H H H CD₃ H H L_(A)259^(i)Pr ^(i)Pr H H H H H L_(A)260 ^(i)Pr H ^(i)Pr H H H H L_(A)261 ^(i)PrH H ^(i)Pr H H H L_(A)262 ^(i)Pr H H H ^(i)Pr H H L_(A)263 ^(i)Pr Ph H HH H H L_(A)264 ^(i)Pr H Ph H H H H L_(A)265 ^(i)Pr H H Ph H H H L_(A)266^(i)Pr H H H Ph H H L_(A)267 Ph Me H H H H H L_(A)268 L_(A)269 L_(A)270L_(A)271 L_(A)272

Ph Ph Ph Ph Ph H H H CD₃ H Me H H H CD₃ H Me H H H H H Me H H H H H H HH H H H H L_(A)273 Ph H H CD₃ H H H L_(A)274 Ph H H H CD₃ H H L_(A)275Ph ^(i)Pr H H H H H L_(A)276 Ph H ^(i)Pr H H H H L_(A)277 Ph H H ^(i)PrH H H L_(A)278 Ph H H H ^(i)Pr H H L_(A)279 Ph Ph H H H H H L_(A)280 PhH Ph H H H H L_(A)281 Ph H H Ph H H H L_(A)282 Ph H H H Ph H H L_(A)283H Me Me H H H H L_(A)284 H Me H Me H H H L_(A)285 H Me H H Me H HL_(A)286 H Me CD₃ H H H H L_(A)287 H Me H CD₃ H H H L_(A)288 H Me H HCD₃ H H L_(A)289 H Me ^(i)Pr H H H H L_(A)290 H Me H ^(i)Pr H H HL_(A)291 H Me H H ^(i)Pr H H L_(A)292 H Me Ph H H H H L_(A)293 H Me H PhH H H L_(A)294 H Me H H Ph H H L_(A)295 H CD₃ Me H H H H L_(A)296 H CD₃H Me H H H L_(A)297 H CD₃ H H Me H H L_(A)298 H CD₃ CD₃ H H H H L_(A)299H CD₃ H CD₃ H H H L_(A)300 H CD₃ H H CD₃ H H L_(A)301 H CD₃ ^(i)Pr H H HH L_(A)302 H CD₃ H ^(i)Pr H H H L_(A)303 H CD₃ H H ^(i)Pr H H L_(A)304 HCD₃ Ph H H H H L_(A)305 H CD₃ H Ph H H H L_(A)306 H CD₃ H H Ph H HL_(A)307 H ^(i)Pr Me H H H H L_(A)308 H ^(i)Pr H Me H H H L_(A)309 H^(i)Pr H H Me H H L_(A)310 H ^(i)Pr CD₃ H H H H L_(A)311 H ^(i)Pr H CD₃H H H L_(A)312 H ^(i)Pr H H CD₃ H H L_(A)313 H ^(i)Pr ^(i)Pr H H H HL_(A)314 H ^(i)Pr H ^(i)Pr H H H L_(A)315 H ^(i)Pr H H ^(i)Pr H HL_(A)316 H ^(i)Pr Ph H H H H L_(A)317 H ^(i)Pr H Ph H H H L_(A)318 H^(i)Pr H H Ph H H L_(A)319 H Ph Me H H H H L_(A)320 H Ph H Me H H HL_(A)321 H Ph H H Me H H L_(A)322 H Ph CD₃ H H H H L_(A)323 L_(A)324L_(A)325 L_(A)326 L_(A)327

H H H H H Ph Ph Ph Ph P H H ^(i)Pr H H CD₃ H H ^(i)Pr H H CD₃ H H ^(i)PrH H H H H H H H H H L_(A)328 H Ph Ph H H H H L_(A)329 H Ph H Ph H H HL_(A)330 H Ph H H Ph H H L_(A)331 H H Me Me H H H L_(A)332 H H CD₃ Me HH H L_(A)333 H H ^(i)Pr Me H H H L_(A)334 H H Ph Me H H H L_(A)335 H HMe CD₃ H H H L_(A)336 H H CD₃ CD₃ H H H L_(A)337 H H ^(i)Pr CD₃ H H HL_(A)338 H H Ph CD₃ H H H L_(A)339 H H Me ^(i)Pr H H H L_(A)340 H H CD₃^(i)Pr H H H L_(A)341 H H ^(i)Pr ^(i)Pr H H H L_(A)342 H H Ph ^(i)Pr H HH L_(A)343 H H Me Ph H H H L_(A)344 H H CD₃ Ph H H H L_(A)345 H H ^(i)PrPh H H H L_(A)346 H H Ph Ph H H H L_(A)347 H H Me H Me H H L_(A)348 H HCD₃ H Me H H L_(A)349 H H ^(i)Pr H Me H H L_(A)350 H H Ph H Me H HL_(A)351 H H Me H CD₃ H H L_(A)352 H H CD₃ H CD₃ H H L_(A)353 H H ^(i)PrH CD₃ H H L_(A)354 H H Ph H CD₃ H H L_(A)355 H H Me H ^(i)Pr H HL_(A)356 H H CD₃ H ^(i)Pr H H L_(A)357 H H ^(i)Pr H ^(i)Pr H H L_(A)358H H Ph H ^(i)Pr H H L_(A)359 H H Me H Ph H H L_(A)360 H H CD₃ H Ph H HL_(A)361 H H ^(i)Pr H Ph H H L_(A)362 H H Ph H Ph H H L_(A)363 Me Me HMe H H H L_(A)364 H Me Me Me H H H L_(A)365 CD₃ Me H Me H H H L_(A)366 HMe CD₃ Me H H H L_(A)367 ^(i)Pr Me H Me H H H L_(A)368 H Me ^(i)Pr Me HH H L_(A)369 Ph Me H Me H H H L_(A)370 H Me Ph Me H H H L_(A)371 Me CD₃H CD₃ H H H L_(A)372 H CD₃ Me CD₃ H H H L_(A)373 CD₃ CD₃ H CD₃ H H HL_(A)374 H CD₃ CD₃ CD₃ H H H L_(A)375 ^(i)Pr CD₃ H CD₃ H H H L_(A)376 HCD₃ ^(i)Pr CD₃ H H H L_(A)377 Ph CD₃ H CD₃ H H H L_(A)378 L_(A)379L_(A)380 L_(A)381 L_(A)382

H Me H CD₃ H CD₃ ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr Ph H Me H CD₃ CD₃ ^(i)Pr^(i)Pr ^(i)Pr ^(i)Pr H H H H H H H H H H H H H H H L_(A)383 ^(i)Pr^(i)Pr H ^(i)Pr H H H L_(A)384 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)385 Ph^(i)Pr H ^(i)Pr H H H L_(A)386 H ^(i)Pr Ph ^(i)Pr H H H L_(A)387 Me Ph HPh H H H L_(A)388 H Ph Me Ph H H H L_(A)389 CD₃ Ph H Ph H H H L_(A)390 HPh CD₃ Ph H H H L_(A)391 ^(i)Pr Ph H Ph H H H L_(A)392 H Ph ^(i)Pr Ph HH H L_(A)393 Ph Ph H Ph H H H L_(A)394 H Ph Ph Ph H H H L_(A)395L_(A)396 L_(A)397 L_(A)398 L_(A)399 L_(A)400

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)401 CD₃ H H H H H H L_(A)402 H CD₃ H H H H HL_(A)403 H H CD₃ H H H H L_(A)404 H H H CD₃ H H H L_(A)405 H H H H CD₃ HH L_(A)406 ^(i)Pr H H H H H H L_(A)407 H ^(i)Pr H H H H H L_(A)408 H H^(i)Pr H H H H L_(A)409 H H H ^(i)Pr H H H L_(A)410 H H H H ^(i)Pr H HL_(A)411 Ph H H H H H H L_(A)412 H Ph H H H H H L_(A)413 H H Ph H H H HL_(A)414 H H H Ph H H H L_(A)415 H H H H Ph H H L_(A)416 Me Me H H H H HL_(A)417 Me H Me H H H H L_(A)418 Me H H Me H H H L_(A)419 Me H H H Me HH L_(A)420 Me CD₃ H H H H H L_(A)421 Me H CD₃ H H H H L_(A)422 Me H HCD₃ H H H L_(A)423 Me H H H CD₃ H H L_(A)424 Me ^(i)Pr H H H H HL_(A)425 Me H ^(i)Pr H H H H L_(A)426 Me H H ^(i)Pr H H H L_(A)427 Me HH H ^(i)Pr H H L_(A)428 Me Ph H H H H H L_(A)429 Me H Ph H H H HL_(A)430 Me H H Ph H H H L_(A)431 Me H H H Ph H H L_(A)432 CD₃ Me H H HH H L_(A)433 L_(A)434 L_(A)435 L_(A)436 L_(A)437 L_(A)438

CD₃ CD₃ CD₃ CD₃ CD₃ CD₃ H H H CD₃ H H Me H H H CD₃ H H Me H H H CD₃ H HMe H H H H H H H H H H H H H H H L_(A)439 CD₃ H H H CD₃ H H L_(A)440 CD₃^(i)Pr H H H H H L_(A)441 CD₃ H ^(i)Pr H H H H L_(A)442 CD₃ H H ^(i)Pr HH H L_(A)443 CD₃ H H H ^(i)Pr H H L_(A)444 CD₃ Ph H H H H H L_(A)445 CD₃H Ph H H H H L_(A)446 CD₃ H H Ph H H H L_(A)447 CD₃ H H H Ph H HL_(A)448 ^(i)Pr Me H H H H H L_(A)449 ^(i)Pr H Me H H H H L_(A)450^(i)Pr H H Me H H H L_(A)451 ^(i)Pr H H H Me H H L_(A)452 ^(i)Pr CD₃ H HH H H L_(A)453 ^(i)Pr H CD₃ H H H H L_(A)454 ^(i)Pr H H CD₃ H H HL_(A)455 ^(i)Pr H H H CD₃ H H L_(A)456 ^(i)Pr ^(i)Pr H H H H H L_(A)457^(i)Pr H ^(i)Pr H H H H L_(A)458 ^(i)Pr H H ^(i)Pr H H H L_(A)459 ^(i)PrH H H ^(i)Pr H H L_(A)460 ^(i)Pr Ph H H H H H L_(A)461 ^(i)Pr H Ph H H HH L_(A)462 ^(i)Pr H H Ph H H H L_(A)463 ^(i)Pr H H H Ph H H L_(A)464 PhMe H H H H H L_(A)465 Ph H Me H H H H L_(A)466 Ph H H Me H H H L_(A)467Ph H H H Me H H L_(A)468 Ph CD₃ H H H H H L_(A)469 Ph H CD₃ H H H HL_(A)470 Ph H H CD₃ H H H L_(A)471 Ph H H H CD₃ H H L_(A)472 Ph ^(i)Pr HH H H H L_(A)473 Ph H ^(i)Pr H H H H L_(A)474 Ph H H ^(i)Pr H H HL_(A)475 Ph H H H ^(i)Pr H H L_(A)476 Ph Ph H H H H H L_(A)477 Ph H Ph HH H H L_(A)478 Ph H H Ph H H H L_(A)479 Ph H H H Ph H H L_(A)480 H Me MeH H H H L_(A)481 H Me H Me H H H L_(A)482 H Me H H Me H H L_(A)483 H MeCD₃ H H H H L_(A)484 H Me H CD₃ H H H L_(A)485 H Me H H CD₃ H H L_(A)486H Me ^(i)Pr H H H H L_(A)487 H Me H ^(i)Pr H H H L_(A)488 L_(A)489L_(A)490 L_(A)491 L_(A)492 L_(A)493

H H H H H H Me Me Me Me CD₃ CD₃ H Ph H H Me H H H Ph H H Me ^(i)Pr H HPr H H H H H H H H H H H H H H L_(A)494 H CD₃ H H Me H H L_(A)495 H CD₃CD₃ H H H H L_(A)496 H CD₃ H CD₃ H H H L_(A)497 H CD₃ H H CD₃ H HL_(A)498 H CD₃ ^(i)Pr H H H H L_(A)499 H CD₃ H ^(i)Pr H H H L_(A)500 HCD₃ H H ^(i)Pr H H L_(A)501 H CD₃ Ph H H H H L_(A)502 H CD₃ H Ph H H HL_(A)503 H CD₃ H H Ph H H L_(A)504 H ^(i)Pr Me H H H H L_(A)505 H ^(i)PrH Me H H H L_(A)506 H ^(i)Pr H H Me H H L_(A)507 H ^(i)Pr CD₃ H H H HL_(A)508 H ^(i)Pr H CD₃ H H H L_(A)509 H ^(i)Pr H H CD₃ H H L_(A)510 H^(i)Pr ^(i)Pr H H H H L_(A)511 H ^(i)Pr H ^(i)Pr H H H L_(A)512 H ^(i)PrH H ^(i)Pr H H L_(A)513 H ^(i)Pr Ph H H H H L_(A)514 H ^(i)Pr H Ph H H HL_(A)515 H ^(i)Pr H H Ph H H L_(A)516 H Ph Me H H H H L_(A)517 H Ph H MeH H H L_(A)518 H Ph H H Me H H L_(A)519 H Ph CD₃ H H H H L_(A)520 H Ph HCD₃ H H H L_(A)521 H Ph H H CD₃ H H L_(A)522 H Ph ^(i)Pr H H H HL_(A)523 H Ph H ^(i)Pr H H H L_(A)524 H Ph H H ^(i)Pr H H L_(A)525 H PhPh H H H H L_(A)526 H Ph H Ph H H H L_(A)527 H Ph H H Ph H H L_(A)528 HH Me Me H H H L_(A)529 H H CD₃ Me H H H L_(A)530 H H ^(i)Pr Me H H HL_(A)531 H H Ph Me H H H L_(A)532 H H Me CD₃ H H H L_(A)533 H H CD₃ CD₃H H H L_(A)534 H H ^(i)Pr CD₃ H H H L_(A)535 H H Ph CD₃ H H H L_(A)536 HH Me ^(i)Pr H H H L_(A)537 H H CD₃ ^(i)Pr H H H L_(A)538 H H ^(i)Pr^(i)Pr H H H L_(A)539 H H Ph ^(i)Pr H H H L_(A)540 H H Me Ph H H HL_(A)541 H H CD₃ Ph H H H L_(A)542 H H ^(i)Pr Ph H H H L_(A)543 L_(A)544L_(A)545 L_(A)546 L_(A)547 L_(A)548

H H H H H H H H H H H H Ph Me CD₃ ^(i)Pr Ph Me Ph H H H H H H Me Me MeMe CD₃ H H H H H H H H H H H H L_(A)549 H H CD₃ H CD₃ H H L_(A)550 H H^(i)Pr H CD₃ H H L_(A)551 H H Ph H CD₃ H H L_(A)552 H H Me H ^(i)Pr H HL_(A)553 H H CD₃ H ^(i)Pr H H L_(A)554 H H ^(i)Pr H ^(i)Pr H H L_(A)555H H Ph H ^(i)Pr H H L_(A)556 H H Me H Ph H H L_(A)557 H H CD₃ H Ph H HL_(A)558 H H ^(i)Pr H Ph H H L_(A)559 H H Ph H Ph H H L_(A)560 Me Me HMe H H H L_(A)561 H Me Me Me H H H L_(A)562 CD₃ Me H Me H H H L_(A)563 HMe CD₃ Me H H H L_(A)564 ^(i)Pr Me H Me H H H L_(A)565 H Me ^(i)Pr Me HH H L_(A)566 Ph Me H Me H H H L_(A)567 H Me Ph Me H H H L_(A)568 Me CD₃H CD₃ H H H L_(A)569 H CD₃ Me CD₃ H H H L_(A)570 CD₃ CD₃ H CD₃ H H HL_(A)571 H CD₃ CD₃ CD₃ H H H L_(A)572 ^(i)Pr CD₃ H CD₃ H H H L_(A)573 HCD₃ ^(i)Pr CD₃ H H H L_(A)574 Ph CD₃ H CD₃ H H H L_(A)575 H CD₃ Ph CD₃ HH H L_(A)576 Me ^(i)Pr H ^(i)Pr H H H L_(A)577 H ^(i)Pr Me ^(i)Pr H H HL_(A)578 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)579 H ^(i)Pr CD₃ ^(i)Pr H H HL_(A)580 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)581 H ^(i)Pr ^(i)Pr ^(i)Pr HH H L_(A)582 Ph ^(i)Pr H ^(i)Pr H H H L_(A)583 H ^(i)Pr Ph ^(i)Pr H H HL_(A)584 Me Ph H Ph H H H L_(A)585 H Ph Me Ph H H H L_(A)586 CD₃ Ph H PhH H H L_(A)587 H Ph CD₃ Ph H H H L_(A)588 ^(i)Pr Ph H Ph H H H L_(A)589H Ph ^(i)Pr Ph H H H L_(A)590 Ph Ph H Ph H H H L_(A)591 H Ph Ph Ph H H HL_(A)592 L_(A)593 L_(A)594 L_(A)595 L_(A)596 L_(A)597

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)598 L_(A)599 L_(A)600 L_(A)601 L_(A)602

CD₃ H H H H H CD₃ H H H H H CD₃ H H H H H CD₃ H H H H H CD₃ H H H H H HH H H H L_(A)603 ^(i)Pr H H H H H H L_(A)604 H ^(i)Pr H H H H H L_(A)605H H ^(i)Pr H H H H L_(A)606 H H H ^(i)Pr H H H L_(A)607 H H H H ^(i)Pr HH L_(A)608 Ph H H H H H H L_(A)609 H Ph H H H H H L_(A)610 H H Ph H H HH L_(A)611 H H H Ph H H H L_(A)612 H H H H Ph H H L_(A)613 Me Me H H H HH L_(A)614 Me H Me H H H H L_(A)615 Me H H Me H H H L_(A)616 Me H H H MeH H L_(A)617 Me CD₃ H H H H H L_(A)618 Me H CD₃ H H H H L_(A)619 Me H HCD₃ H H H L_(A)620 Me H H H CD₃ H H L_(A)621 Me ^(i)Pr H H H H HL_(A)622 Me H ^(i)Pr H H H H L_(A)623 Me H H ^(i)Pr H H H L_(A)624 Me HH H ^(i)Pr H H L_(A)625 Me Ph H H H H H L_(A)626 Me H Ph H H H HL_(A)627 Me H H Ph H H H L_(A)628 Me H H H Ph H H L_(A)629 CD₃ Me H H HH H L_(A)630 CD₃ H Me H H H H L_(A)631 CD₃ H H Me H H H L_(A)632 CD₃ H HH Me H H L_(A)633 CD₃ CD₃ H H H H H L_(A)634 CD₃ H CD₃ H H H H L_(A)635CD₃ H H CD₃ H H H L_(A)636 CD₃ H H H CD₃ H H L_(A)637 CD₃ ^(i)Pr H H H HH L_(A)638 CD₃ H ^(i)Pr H H H H L_(A)639 CD₃ H H ^(i)Pr H H H L_(A)640CD₃ H H H ^(i)Pr H H L_(A)641 CD₃ Ph H H H H H L_(A)642 CD₃ H Ph H H H HL_(A)643 CD₃ H H Ph H H H L_(A)644 CD₃ H H H Ph H H L_(A)645 ^(i)Pr Me HH H H H L_(A)646 ^(i)Pr H Me H H H H L_(A)647 ^(i)Pr H H Me H H HL_(A)648 ^(i)Pr H H H Me H H L_(A)649 ^(i)Pr CD₃ H H H H H L_(A)650^(i)Pr H CD₃ H H H H L_(A)651 ^(i)Pr H H CD₃ H H H L_(A)652 ^(i)Pr H H HCD₃ H H L_(A)653 L_(A)654 L_(A)655 L_(A)656 L_(A)657

^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr H H H Ph H ^(i)Pr H H H H H^(i)Pr H H H H H ^(i)Pr H H H H H H H H H H H L_(A)658 ^(i)Pr H Ph H H HH L_(A)659 ^(i)Pr H H Ph H H H L_(A)660 ^(i)Pr H H H Ph H H L_(A)661 PhMe H H H H H L_(A)662 Ph H Me H H H H L_(A)663 Ph H H Me H H H L_(A)664Ph H H H Me H H L_(A)665 Ph CD₃ H H H H H L_(A)666 Ph H CD₃ H H H HL_(A)667 Ph H H CD₃ H H H L_(A)668 Ph H H H CD₃ H H L_(A)669 Ph ^(i)Pr HH H H H L_(A)670 Ph H ^(i)Pr H H H H L_(A)671 Ph H H ^(i)Pr H H HL_(A)672 Ph H H H ^(i)Pr H H L_(A)673 Ph Ph H H H H H L_(A)674 Ph H Ph HH H H L_(A)675 Ph H H Ph H H H L_(A)676 Ph H H H Ph H H L_(A)677 H Me MeH H H H L_(A)678 H Me H Me H H H L_(A)679 H Me H H Me H H L_(A)680 H MeCD₃ H H H H L_(A)681 H Me H CD₃ H H H L_(A)682 H Me H H CD₃ H H L_(A)683H Me ^(i)Pr H H H H L_(A)684 H Me H ^(i)Pr H H H L_(A)685 H Me H H^(i)Pr H H L_(A)686 H Me Ph H H H H L_(A)687 H Me H Ph H H H L_(A)688 HMe H H Ph H H L_(A)689 H CD₃ Me H H H H L_(A)690 H CD₃ H Me H H HL_(A)691 H CD₃ H H Me H H L_(A)692 H CD₃ CD₃ H H H H L_(A)693 H CD₃ HCD₃ H H H L_(A)694 H CD₃ H H CD₃ H H L_(A)695 H CD₃ ^(i)Pr H H H HL_(A)696 H CD₃ H ^(i)Pr H H H L_(A)697 H CD₃ H H ^(i)Pr H H L_(A)698 HCD₃ Ph H H H H L_(A)699 H CD₃ H Ph H H H L_(A)700 H CD₃ H H Ph H HL_(A)701 H ^(i)Pr Me H H H H L_(A)702 H ^(i)Pr H Me H H H L_(A)703 H^(i)Pr H H Me H H L_(A)704 H ^(i)Pr CD₃ H H H H L_(A)705 H ^(i)Pr H CD₃H H H L_(A)706 H ^(i)Pr H H CD₃ H H L_(A)707 H ^(i)Pr ^(i)Pr H H H HL_(A)708 L_(A)709 L_(A)710 L_(A)711 L_(A)712

H H H H H ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr H H Ph H H ^(i)Pr H H Ph HH ^(i)Pr H H Ph H H H H H H H H H H L_(A)713 H Ph Me H H H H L_(A)714 HPh H Me H H H L_(A)715 H Ph H H Me H H L_(A)716 H Ph CD₃ H H H HL_(A)717 H Ph H CD₃ H H H L_(A)718 H Ph H H CD₃ H H L_(A)719 H Ph ^(i)PrH H H H L_(A)720 H Ph H ^(i)Pr H H H L_(A)721 H Ph H H ^(i)Pr H HL_(A)722 H Ph Ph H H H H L_(A)723 H Ph H Ph H H H L_(A)724 H Ph H H Ph HH L_(A)725 H H Me Me H H H L_(A)726 H H CD₃ Me H H H L_(A)727 H H ^(i)PrMe H H H L_(A)728 H H Ph Me H H H L_(A)729 H H Me CD₃ H H H L_(A)730 H HCD₃ CD₃ H H H L_(A)731 H H ^(i)Pr CD₃ H H H L_(A)732 H H Ph CD₃ H H HL_(A)733 H H Me ^(i)Pr H H H L_(A)734 H H CD₃ ^(i)Pr H H H L_(A)735 H H^(i)Pr ^(i)Pr H H H L_(A)736 H H Ph ^(i)Pr H H H L_(A)737 H H Me Ph H HH L_(A)738 H H CD₃ Ph H H H L_(A)739 H H ^(i)Pr Ph H H H L_(A)740 H H PhPh H H H L_(A)741 H H Me H Me H H L_(A)742 H H CD₃ H Me H H L_(A)743 H H^(i)Pr H Me H H L_(A)744 H H Ph H Me H H L_(A)745 H H Me H CD₃ H HL_(A)746 H H CD₃ H CD₃ H H L_(A)747 H H ^(i)Pr H CD₃ H H L_(A)748 H H PhH CD₃ H H L_(A)749 H H Me H ^(i)Pr H H L_(A)750 H H CD₃ H ^(i)Pr H HL_(A)751 H H ^(i)Pr H ^(i)Pr H H L_(A)752 H H Ph H ^(i)Pr H H L_(A)753 HH Me H Ph H H L_(A)754 H H CD₃ H Ph H H L_(A)755 H H ^(i)Pr H Ph H HL_(A)756 H H Ph H Ph H H L_(A)757 Me Me H Me Ph H H L_(A)758 H Me Me MeH H H L_(A)759 CD₃ Me H Me H H H L_(A)760 H Me CD₃ Me H H H L_(A)761^(i)Pr Me H Me H H H L_(A)762 H Me ^(i)Pr Me H H H L_(A)763 L_(A)764L_(A)765 L_(A)766 L_(A)767

Ph H Me H CD₃ Me Me CD₃ CD₃ CD₃ H Ph H Me H Me Me CD₃ CD₃ CD₃ H H H H HH H H H H H H H H H L_(A)768 H CD₃ CD₃ CD₃ H H H L_(A)769 ^(i)Pr CD₃ HCD₃ H H H L_(A)770 H CD₃ ^(i)Pr CD₃ H H H L_(A)771 Ph CD₃ H CD₃ H H HL_(A)772 H CD₃ Ph CD₃ H H H L_(A)773 Me ^(i)Pr H ^(i)Pr H H H L_(A)774 H^(i)Pr Me ^(i)Pr H H H L_(A)775 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)776 H^(i)Pr CD₃ ^(i)Pr H H H L_(A)777 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)778 H^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)779 Ph ^(i)Pr H ^(i)Pr H H H L_(A)780 H^(i)Pr Ph ^(i)Pr H H H L_(A)781 Me Ph H Ph H H H L_(A)782 H Ph Me Ph H HH L_(A)783 CD₃ Ph H Ph H H H L_(A)784 H Ph CD₃ Ph H H H L_(A)785 ^(i)PrPh H Ph H H H L_(A)786 H Ph ^(i)Pr Ph H H H L_(A)787 Ph Ph H Ph H H HL_(A)788 H Ph Ph Ph H H H L_(A)789 L_(A)790 L_(A)791 L_(A)792 L_(A)793

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)794 H H H H Me H H L_(A)795 CD₃ H H H H H H L_(A)796 H CD₃ H H HH H L_(A)797 H H CD₃ H H H H L_(A)798 H H H CD₃ H H H L_(A)799 H H H HCD₃ H H L_(A)800 ^(i)Pr H H H H H H L_(A)801 H ^(i)Pr H H H H H L_(A)802H H ^(i)Pr H H H H L_(A)803 H H H ^(i)Pr H H H L_(A)804 H H H H ^(i)Pr HH L_(A)805 Ph H H H H H H L_(A)806 H Ph H H H H H L_(A)807 H H Ph H H HH L_(A)808 H H H Ph H H H L_(A)809 H H H H Ph H H L_(A)810 Me Me H H H HH L_(A)811 Me H Me H H H H L_(A)812 Me H H Me H H H L_(A)813 Me H H H MeH H L_(A)814 Me CD₃ H H H H H L_(A)815 Me H CD₃ H H H H L_(A)816 Me H HCD₃ H H H L_(A)817 Me H H H CD₃ H H L_(A)818 L_(A)819 L_(A)820 L_(A)821L_(A)822

Me Me Me Me Me ^(i)Pr H H H Ph H ^(i)Pr H H H H H ^(i)Pr H H H H H^(i)Pr H H H H H H H H H H H L_(A)823 Me H Ph H H H H L_(A)824 Me H H PhH H H L_(A)825 Me H H H Ph H H L_(A)826 CD₃ Me H H H H H L_(A)827 CD₃ HMe H H H H L_(A)828 CD₃ H H Me H H H L_(A)829 CD₃ H H H Me H H L_(A)830CD₃ CD₃ H H H H H L_(A)831 CD₃ H CD₃ H H H H L_(A)832 CD₃ H H CD₃ H H HL_(A)833 CD₃ H H H CD₃ H H L_(A)834 CD₃ ^(i)Pr H H H H H L_(A)835 CD₃ H^(i)Pr H H H H L_(A)836 CD₃ H H ^(i)Pr H H H L_(A)837 CD₃ H H H ^(i)Pr HH L_(A)838 CD₃ Ph H H H H H L_(A)839 CD₃ H Ph H H H H L_(A)840 CD₃ H HPh H H H L_(A)841 CD₃ H H H Ph H H L_(A)842 ^(i)Pr Me H H H H H L_(A)843^(i)Pr H Me H H H H L_(A)844 ^(i)Pr H H Me H H H L_(A)845 ^(i)Pr H H HMe H H L_(A)846 ^(i)Pr CD₃ H H H H H L_(A)847 ^(i)Pr H CD₃ H H H HL_(A)848 ^(i)Pr H H CD₃ H H H L_(A)849 ^(i)Pr H H H CD₃ H H L_(A)850^(i)Pr ^(i)Pr H H H H H L_(A)851 ^(i)Pr H ^(i)Pr H H H H L_(A)852 ^(i)PrH H ^(i)Pr H H H L_(A)853 ^(i)Pr H H H ^(i)Pr H H L_(A)854 ^(i)Pr Ph H HH H H L_(A)855 ^(i)Pr H Ph H H H H L_(A)856 ^(i)Pr H H Ph H H H L_(A)857^(i)Pr H H H Ph H H L_(A)858 Ph Me H H H H H L_(A)859 Ph H Me H H H HL_(A)860 Ph H H Me H H H L_(A)861 Ph H H H Me H H L_(A)862 Ph CD₃ H H HH H L_(A)863 Ph H CD₃ H H H H L_(A)864 Ph H H CD₃ H H H L_(A)865 Ph H HH CD₃ H H L_(A)866 Ph ^(i)Pr H H H H H L_(A)867 Ph H ^(i)Pr H H H HL_(A)868 Ph H H ^(i)Pr H H H L_(A)869 Ph H H H ^(i)Pr H H L_(A)870 Ph PhH H H H H L_(A)871 Ph H Ph H H H H L_(A)872 Ph H H Ph H H H L_(A)873L_(A)874 L_(A)875 L_(A)876 L_(A)877

Ph H H H H H Me Me Me Me H Me H H CD₃ H H Me H H Ph H H Me H H H H H H HH H H H L_(A)878 H Me H CD₃ H H H L_(A)879 H Me H H CD₃ H H L_(A)880 HMe ^(i)Pr H H H H L_(A)881 H Me H ^(i)Pr H H H L_(A)882 H Me H H ^(i)PrH H L_(A)883 H Me Ph H H H H L_(A)884 H Me H Ph H H H L_(A)885 H Me H HPh H H L_(A)886 H CD₃ Me H H H H L_(A)887 H CD₃ H Me H H H L_(A)888 HCD₃ H H Me H H L_(A)889 H CD₃ CD₃ H H H H L_(A)890 H CD₃ H CD₃ H H HL_(A)891 H CD₃ H H CD₃ H H L_(A)892 H CD₃ ^(i)Pr H H H H L_(A)893 H CD₃H ^(i)Pr H H H L_(A)894 H CD₃ H H ^(i)Pr H H L_(A)895 H CD₃ Ph H H H HL_(A)896 H CD₃ H Ph H H H L_(A)897 H CD₃ H H Ph H H L_(A)898 H ^(i)Pr MeH H H H L_(A)899 H ^(i)Pr H Me H H H L_(A)900 H ^(i)Pr H H Me H HL_(A)901 H ^(i)Pr CD₃ H H H H L_(A)902 H ^(i)Pr H CD₃ H H H L_(A)903 H^(i)Pr H H CD₃ H H L_(A)904 H ^(i)Pr ^(i)Pr H H H H L_(A)905 H ^(i)Pr H^(i)Pr H H H L_(A)906 H ^(i)Pr H H ^(i)Pr H H L_(A)907 H ^(i)Pr Ph H H HH L_(A)908 H ^(i)Pr H Ph H H H L_(A)909 H ^(i)Pr H H Ph H H L_(A)910 HPh Me H H H H L_(A)911 H Ph H Me H H H L_(A)912 H Ph H H Me H H L_(A)913H Ph CD₃ H H H H L_(A)914 H Ph H CD₃ H H H L_(A)915 H Ph H H CD₃ H HL_(A)916 H Ph ^(i)Pr H H H H L_(A)917 H Ph H ^(i)Pr H H H L_(A)918 H PhH H ^(i)Pr H H L_(A)919 H Ph Ph H H H H L_(A)920 H Ph H Ph H H HL_(A)921 H Ph H H Ph H H L_(A)922 H H Me Me H H H L_(A)923 H H CD₃ Me HH H L_(A)924 H H ^(i)Pr Me H H H L_(A)925 H H Ph Me H H H L_(A)926 H HMe CD₃ H H H L_(A)927 H H CD₃ CD₃ H H H L_(A)928 L_(A)929 L_(A)930L_(A)931 L_(A)932

H H H H H H H H H H ^(i)Pr Ph Me CD₃ ^(i)Pr CD₃ CD₃ ^(i)Pr ^(i)Pr ^(i)PrH H H H H H H H H H H H H H H L_(A)933 H H Ph ^(i)Pr H H H L_(A)934 H HMe Ph H H H L_(A)935 H H CD₃ Ph H H H L_(A)936 H H ^(i)Pr Ph H H HL_(A)937 H H Ph Ph H H H L_(A)938 H H Me H Me H H L_(A)939 H H CD₃ H MeH H L_(A)940 H H ^(i)Pr H Me H H L_(A)941 H H Ph H Me H H L_(A)942 H HMe H CD₃ H H L_(A)943 H H CD₃ H CD₃ H H L_(A)944 H H ^(i)Pr H CD₃ H HL_(A)945 H H Ph H CD₃ H H L_(A)946 H H Me H ^(i)Pr H H L_(A)947 H H CD₃H ^(i)Pr H H L_(A)948 H H ^(i)Pr H ^(i)Pr H H L_(A)949 H H Ph H ^(i)Pr HH L_(A)950 H H Me H Ph H H L_(A)951 H H CD₃ H Ph H H L_(A)952 H H ^(i)PrH Ph H H L_(A)953 H H Ph H Ph H H L_(A)954 Me Me H Me H H H L_(A)955 HMe Me Me H H H L_(A)956 CD₃ Me H Me H H H L_(A)957 H Me CD₃ Me H H HL_(A)958 ^(i)Pr Me H Me H H H L_(A)959 H Me ^(i)Pr Me H H H L_(A)960 PhMe H Me H H H L_(A)961 H Me Ph Me H H H L_(A)962 Me CD₃ H CD₃ H H HL_(A)963 H CD₃ Me CD₃ H H H L_(A)964 CD₃ CD₃ H CD₃ H H H L_(A)965 H CD₃CD₃ CD₃ H H H L_(A)966 ^(i)Pr CD₃ H CD₃ H H H L_(A)967 H CD₃ ^(i)Pr CD₃H H H L_(A)968 Ph CD₃ H CD₃ H H H L_(A)969 H CD₃ Ph CD₃ H H H L_(A)970Me ^(i)Pr H ^(i)Pr H H H L_(A)971 H ^(i)Pr Me ^(i)Pr H H H L_(A)972 CD₃^(i)Pr H ^(i)Pr H H H L_(A)973 H ^(i)Pr CD₃ ^(i)Pr H H H L_(A)974 ^(i)Pr^(i)Pr H ^(i)Pr H H H L_(A)975 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)976 Ph^(i)Pr H ^(i)Pr H H H L_(A)977 H ^(i)Pr Ph ^(i)Pr H H H L_(A)978 Me Ph HPh H H H L_(A)979 H Ph Me Ph H H H L_(A)980 CD₃ Ph H Ph H H H L_(A)981 HPh CD₃ Ph H H H L_(A)982 ^(i)Pr Ph H Ph H H H L_(A)983 L_(A)984 L_(A)985

H Ph H Ph Ph Ph ^(i)Pr H Ph Ph Ph Ph H H H H H H H H H L_(A)986 L_(A)987L_(A)988 L_(A)989 L_(A)990

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)991 H H H H Me H H L_(A)992 CD₃ H H H H H H L_(A)993 H CD₃ H H HH H L_(A)994 H H CD₃ H H H H L_(A)995 H H H CD₃ H H H L_(A)996 H H H HCD₃ H H L_(A)997 ^(i)Pr H H H H H H L_(A)998 H ^(i)Pr H H H H H L_(A)999H H ^(i)Pr H H H H L_(A)1000 H H H ^(i)Pr H H H L_(A)1001 H H H H ^(i)PrH H L_(A)1002 Ph H H H H H H L_(A)1003 H Ph H H H H H L_(A)1004 H H Ph HH H H L_(A)1005 H H H Ph H H H L_(A)1006 H H H H Ph H H L_(A)1007 Me MeH H H H H L_(A)1008 Me H Me H H H H L_(A)1009 Me H H Me H H H L_(A)1010Me H H H Me H H L_(A)1011 Me CD₃ H H H H H L_(A)1012 Me H CD₃ H H H HL_(A)1013 Me H H CD₃ H H H L_(A)1014 Me H H H CD₃ H H L_(A)1015 Me^(i)Pr H H H H H L_(A)1016 Me H ^(i)Pr H H H H L_(A)1017 Me H H ^(i)Pr HH H L_(A)1018 Me H H H ^(i)Pr H H L_(A)1019 Me Ph H H H H H L_(A)1020 MeH Ph H H H H L_(A)1021 Me H H Ph H H H L_(A)1022 Me H H H Ph H HL_(A)1023 CD₃ Me H H H H H L_(A)1024 CD₃ H Me H H H H L_(A)1025 CD₃ H HMe H H H L_(A)1026 CD₃ H H H Me H H L_(A)1027 CD₃ CD₃ H H H H HL_(A)1028 CD₃ H CD₃ H H H H L_(A)1029 CD₃ H H CD₃ H H H L_(A)1030 CD₃ HH H CD₃ H H L_(A)1031 CD₃ ^(i)Pr H H H H H L_(A)1032 CD₃ H ^(i)Pr H H HH L_(A)1033 CD₃ H H ^(i)Pr H H H L_(A)1034 CD₃ H H H ^(i)Pr H HL_(A)1035 CD₃ Ph H H H H H L_(A)1036 CD₃ H Ph H H H H L_(A)1037 CD₃ H HPh H H H L_(A)1038 L_(A)1039 L_(A)1040 L_(A)1041 L_(A)1042

CD₃ ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr H Me H H H H H Me H H H H H Me H Ph H HH Me H H H H H H H H H H L_(A)1043 ^(i)Pr CD₃ H H H H H L_(A)1044 ^(i)PrH CD₃ H H H H L_(A)1045 ^(i)Pr H H CD₃ H H H L_(A)1046 ^(i)Pr H H H CD₃H H L_(A)1047 ^(i)Pr ^(i)Pr H H H H H L_(A)1048 ^(i)Pr H ^(i)Pr H H H HL_(A)1049 ^(i)Pr H H ^(i)Pr H H H L_(A)1050 ^(i)Pr H H H ^(i)Pr H HL_(A)1051 ^(i)Pr Ph H H H H H L_(A)1052 ^(i)Pr H ^(i)Pr H H H HL_(A)1053 ^(i)Pr H H Ph H H H L_(A)1054 ^(i)Pr H H H Ph H H L_(A)1055 PhMe H H H H H L_(A)1056 Ph H Me H H H H L_(A)1057 Ph H H Me H H HL_(A)1058 Ph H H H Me H H L_(A)1059 Ph CD₃ H H H H H L_(A)1060 Ph H CD₃H H H H L_(A)1061 Ph H H CD₃ H H H L_(A)1062 Ph H H H CD₃ H H L_(A)1063Ph ^(i)Pr H H H H H L_(A)1064 Ph H ^(i)Pr H H H H L_(A)1065 Ph H H^(i)Pr H H H L_(A)1066 Ph H H H ^(i)Pr H H L_(A)1067 Ph Ph H H H H HL_(A)1068 Ph H Ph H H H H L_(A)1069 Ph H H Ph H H H L_(A)1070 Ph H H HPh H H L_(A)1071 H Me Me H H H H L_(A)1072 H Me H Me H H H L_(A)1073 HMe H H Me H H L_(A)1074 H Me CD₃ H H H H L_(A)1075 H Me H CD₃ H H HL_(A)1076 H Me H H CD₃ H H L_(A)1077 H Me ^(i)Pr H H H H L_(A)1078 H MeH ^(i)Pr H H H L_(A)1079 H Me H H ^(i)Pr H H L_(A)1080 H Me Ph H H H HL_(A)1081 H Me H Ph H H H L_(A)1082 H Me H H Ph H H L_(A)1083 H CD₃ Me HH H H L_(A)1084 H CD₃ H Me H H H L_(A)1085 H CD₃ H H Me H H L_(A)1086 HCD₃ CD₃ H H H H L_(A)1087 H CD₃ H CD₃ H H H L_(A)1088 H CD₃ H H CD₃ H HL_(A)1089 H CD₃ ^(i)Pr H H H H L_(A)1090 H CD₃ H ^(i)Pr H H H L_(A)1091H CD₃ H H ^(i)Pr H H L_(A)1092 H CD₃ Ph H H H H L_(A)1093 L_(A)1094L_(A)1095 L_(A)1096 L_(A)1097

H H H H H CD₃ CD₃ ^(i)Pr ^(i)Pr ^(i)Pr H H Me H H Ph H H Me H H Ph H HMe H H H H H H H H H H L_(A)1098 H ^(i)Pr CD₃ H H H H L_(A)1099 H ^(i)PrH CD₃ H H H L_(A)1100 H ^(i)Pr H H CD₃ H H L_(A)1101 H ^(i)Pr ^(i)Pr H HH H L_(A)1102 H ^(i)Pr H ^(i)Pr H H H L_(A)1103 H ^(i)Pr H H ^(i)Pr H HL_(A)1104 H ^(i)Pr Ph H H H H L_(A)1105 H ^(i)Pr H Ph H H H L_(A)1106 H^(i)Pr H H Ph H H L_(A)1107 H Ph Me H H H H L_(A)1108 H Ph H Me H H HL_(A)1109 H Ph H H Me H H L_(A)1110 H Ph CD₃ H H H H L_(A)1111 H Ph HCD₃ H H H L_(A)1112 H Ph H H CD₃ H H L_(A)1113 H Ph ^(i)Pr H H H HL_(A)1114 H Ph H ^(i)Pr H H H L_(A)1115 H Ph H H ^(i)Pr H H L_(A)1116 HPh Ph H H H H L_(A)1117 H Ph H Ph H H H L_(A)1118 H Ph H H Ph H HL_(A)1119 H H Me Me H H H L_(A)1120 H H CD₃ Me H H H L_(A)1121 H H^(i)Pr Me H H H L_(A)1122 H H Ph Me H H H L_(A)1123 H H Me CD₃ H H HL_(A)1124 H H CD₃ CD₃ H H H L_(A)1125 H H ^(i)Pr CD₃ H H H L_(A)1126 H HPh CD₃ H H H L_(A)1127 H H Me ^(i)Pr H H H L_(A)1128 H H CD₃ ^(i)Pr H HH L_(A)1129 H H ^(i)Pr ^(i)Pr H H H L_(A)1130 H H Ph ^(i)Pr H H HL_(A)1131 H H Me Ph H H H L_(A)1132 H H CD₃ Ph H H H L_(A)1133 H H^(i)Pr Ph H H H L_(A)1134 H H Ph Ph H H H L_(A)1135 H H Me H Me H HL_(A)1136 H H CD₃ H Me H H L_(A)1137 H H ^(i)Pr H Me H H L_(A)1138 H HPh H Me H H L_(A)1139 H H Me H CD₃ H H L_(A)1140 H H CD₃ H CD₃ H HL_(A)1141 H H ^(i)Pr H CD₃ H H L_(A)1142 H H Ph H CD₃ H H L_(A)1143 H HMe H ^(i)Pr H H L_(A)1144 H H CD₃ H ^(i)Pr H H L_(A)1145 H H ^(i)Pr H^(i)Pr H H L_(A)1146 H H Ph H ^(i)Pr H H L_(A)1147 H H Me H Ph H HL_(A)1148 L_(A)1149 L_(A)1150 L_(A)1151 L_(A)1152

H H H Me H H H H Me Me CD₃ ^(i)Pr Ph H Me H H H Me Me Ph Ph Ph H H H H HH H H H H H H L_(A)1153 CD₃ Me H Me H H H L_(A)1154 H Me CD₃ Me H H HL_(A)1155 ^(i)Pr Me H Me H H H L_(A)1156 H Me ^(i)Pr Me H H H L_(A)1157Ph Me H Me H H H L_(A)1158 H Me Ph Me H H H L_(A)1159 Me CD₃ H CD₃ H H HL_(A)1160 H CD₃ Me CD₃ H H H L_(A)1161 CD₃ CD₃ H CD₃ H H H L_(A)1162 HCD₃ CD₃ CD₃ H H H L_(A)1163 ^(i)Pr CD₃ H CD₃ H H H L_(A)1164 H CD₃^(i)Pr CD₃ H H H L_(A)1165 Ph CD₃ H CD₃ H H H L_(A)1166 H CD₃ Ph CD₃ H HH L_(A)1167 Me ^(i)Pr H ^(i)Pr H H H L_(A)1168 H ^(i)Pr Me ^(i)Pr H H HL_(A)1169 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)1170 H ^(i)Pr CD₃ ^(i)Pr H H HL_(A)1171 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)1172 H ^(i)Pr ^(i)Pr ^(i)PrH H H L_(A)1173 Ph ^(i)Pr H ^(i)Pr H H H L_(A)1174 H ^(i)Pr Ph ^(i)Pr HH H L_(A)1175 Me Ph H Ph H H H L_(A)1176 H Ph Me Ph H H H L_(A)1177 CD₃Ph H Ph H H H L_(A)1178 H Ph CD₃ Ph H H H L_(A)1179 ^(i)Pr Ph H Ph H H HL_(A)1180 H Ph ^(i)Pr Ph H H H L_(A)1181 Ph Ph H Ph H H H L_(A)1182 H PhPh Ph H H H L_(A)1183 L_(A)1184 L_(A)1185 L_(A)1186 L_(A)1187

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)1188 H H H H Me H H L_(A)1189 CD₃ H H H H H H L_(A)1190 H CD₃ H HH H H L_(A)1191 H H CD₃ H H H H L_(A)1192 H H H CD₃ H H H L_(A)1193 H HH H CD₃ H H L_(A)1194 ^(i)Pr H H H H H H L_(A)1195 H ^(i)Pr H H H H HL_(A)1196 H H ^(i)Pr H H H H L_(A)1197 H H H ^(i)Pr H H H L_(A)1198 H HH H ^(i)Pr H H L_(A)1199 Ph H H H H H H L_(A)1200 H Ph H H H H HL_(A)1201 H H Ph H H H H L_(A)1202 H H H Ph H H H L_(A)1203 L_(A)1204L_(A)1205 L_(A)1206 L_(A)1207

H Me Me Me Me H Me H H H H H Me H H H H H Me H Ph H H H Me H H H H H H HH H H L_(A)1208 Me CD₃ H H H H H L_(A)1209 Me H CD₃ H H H H L_(A)1210 MeH H CD₃ H H H L_(A)1211 Me H H H CD₃ H H L_(A)1212 Me ^(i)Pr H H H H HL_(A)1213 Me H ^(i)Pr H H H H L_(A)1214 Me H H ^(i)Pr H H H L_(A)1215 MeH H H ^(i)Pr H H L_(A)1216 Me Ph H H H H H L_(A)1217 Me H Ph H H H HL_(A)1218 Me H H Ph H H H L_(A)1219 Me H H H Ph H H L_(A)1220 CD₃ Me H HH H H L_(A)1221 CD₃ H Me H H H H L_(A)1222 CD₃ H H Me H H H L_(A)1223CD₃ H H H Me H H L_(A)1224 CD₃ CD₃ H H H H H L_(A)1225 CD₃ H CD₃ H H H HL_(A)1226 CD₃ H H CD₃ H H H L_(A)1227 CD₃ H H H CD₃ H H L_(A)1228 CD₃^(i)Pr H H H H H L_(A)1229 CD₃ H ^(i)Pr H H H H L_(A)1230 CD₃ H H ^(i)PrH H H L_(A)1231 CD₃ H H H ^(i)Pr H H L_(A)1232 CD₃ Ph H H H H HL_(A)1233 CD₃ H Ph H H H H L_(A)1234 CD₃ H H Ph H H H L_(A)1235 CD₃ H HH Ph H H L_(A)1236 ^(i)Pr Me H H H H H L_(A)1237 ^(i)Pr H Me H H H HL_(A)1238 ^(i)Pr H H Me H H H L_(A)1239 ^(i)Pr H H H Me H H L_(A)1240^(i)Pr CD₃ H H H H H L_(A)1241 ^(i)Pr H CD₃ H H H H L_(A)1242 ^(i)Pr H HCD₃ H H H L_(A)1243 ^(i)Pr H H H CD₃ H H L_(A)1244 ^(i)Pr ^(i)Pr H H H HH L_(A)1245 ^(i)Pr H ^(i)Pr H H H H L_(A)1246 ^(i)Pr H H ^(i)Pr H H HL_(A)1247 ^(i)Pr H H H ^(i)Pr H H L_(A)1248 ^(i)Pr Ph H H H H HL_(A)1249 ^(i)Pr H Ph H H H H L_(A)1250 ^(i)Pr H H Ph H H H L_(A)1251^(i)Pr H H H Ph H H L_(A)1252 Ph Me H H H H H L_(A)1253 Ph H Me H H H HL_(A)1254 Ph H H Me H H H L_(A)1255 Ph H H H Me H H L_(A)1256 Ph CD₃ H HH H H L_(A)1257 Ph H CD₃ H H H H L_(A)1258 L_(A)1259 L_(A)1260 L_(A)1261L_(A)1262

Ph Ph Ph Ph Ph H H ^(i)Pr H H H H H ^(i)Pr H CD₃ H H H ^(i)Pr H CD₃ H HH H H H H H H H H H H L_(A)1263 Ph H H H ^(i)Pr H H L_(A)1264 Ph Ph H HH H H L_(A)1265 Ph H Ph H H H H L_(A)1266 Ph H H Ph H H H L_(A)1267 Ph HH H Ph H H L_(A)1268 H Me Me H H H H L_(A)1269 H Me H Me H H H L_(A)1270H Me H H Me H H L_(A)1271 H Me CD₃ H H H H L_(A)1272 H Me H CD₃ H H HL_(A)1273 H Me H H CD₃ H H L_(A)1274 H Me ^(i)Pr H H H H L_(A)1275 H MeH ^(i)Pr H H H L_(A)1276 H Me H H ^(i)Pr H H L_(A)1277 H Me Ph H H H HL_(A)1278 H Me H Ph H H H L_(A)1279 H Me H H Ph H H L_(A)1280 H CD₃ Me HH H H L_(A)1281 H CD₃ H Me H H H L_(A)1282 H CD₃ H H Me H H L_(A)1283 HCD₃ CD₃ H H H H L_(A)1284 H CD₃ H CD₃ H H H L_(A)1285 H CD₃ H H CD₃ H HL_(A)1286 H CD₃ ^(i)Pr H H H H L_(A)1287 H CD₃ H ^(i)Pr H H H L_(A)1288H CD₃ H H ^(i)Pr H H L_(A)1289 H CD₃ Ph H H H H L_(A)1290 H CD₃ H Ph H HH L_(A)1291 H CD₃ H H Ph H H L_(A)1292 H ^(i)Pr Me H H H H L_(A)1293 H^(i)Pr H Me H H H L_(A)1294 H ^(i)Pr H H Me H H L_(A)1295 H ^(i)Pr CD₃ HH H H L_(A)1296 H ^(i)Pr H CD₃ H H H L_(A)1297 H ^(i)Pr H H CD₃ H HL_(A)1298 H ^(i)Pr ^(i)Pr H H H H L_(A)1299 H ^(i)Pr H ^(i)Pr H H HL_(A)1300 H ^(i)Pr H H ^(i)Pr H H L_(A)1301 H ^(i)Pr Ph H H H HL_(A)1302 H ^(i)Pr H Ph H H H L_(A)1303 H ^(i)Pr H H Ph H H L_(A)1304 HPh Me H H H H L_(A)1305 H Ph H Me H H H L_(A)1306 H Ph H H Me H HL_(A)1307 H Ph CD₃ H H H H L_(A)1308 H Ph H CD₃ H H H L_(A)1309 H Ph H HCD₃ H H L_(A)1310 H Ph ^(i)Pr H H H H L_(A)1311 H Ph H ^(i)Pr H H HL_(A)1312 H Ph H H ^(i)Pr H H L_(A)1313 L_(A)1314 L_(A)1315 L_(A)1316L_(A)1317

H H H H H Ph Ph Ph H H Ph H H Me CD₃ H Ph H Me Me H H Ph H H H H H H H HH H H H L_(A)1318 H H ^(i)Pr Me H H H L_(A)1319 H H Ph Me H H HL_(A)1320 H H Me CD₃ H H H L_(A)1321 H H CD₃ CD₃ H H H L_(A)1322 H H^(i)Pr CD₃ H H H L_(A)1323 H H Ph CD₃ H H H L_(A)1324 H H Me ^(i)Pr H HH L_(A)1325 H H CD₃ ^(i)Pr H H H L_(A)1326 H H ^(i)Pr ^(i)Pr H H HL_(A)1327 H H Ph ^(i)Pr H H H L_(A)1328 H H Me Ph H H H L_(A)1329 H HCD₃ Ph H H H L_(A)1330 H H ^(i)Pr Ph H H H L_(A)1331 H H Ph Ph H H HL_(A)1332 H H Me H Me H H L_(A)1333 H H CD₃ H Me H H L_(A)1334 H H^(i)Pr H Me H H L_(A)1335 H H Ph H Me H H L_(A)1336 H H Me H CD₃ H HL_(A)1337 H H CD₃ H CD₃ H H L_(A)1338 H H ^(i)Pr H CD₃ H H L_(A)1339 H HPh H CD₃ H H L_(A)1340 H H Me H ^(i)Pr H H L_(A)1341 H H CD₃ H ^(i)Pr HH L_(A)1342 H H ^(i)Pr H ^(i)Pr H H L_(A)1343 H H Ph H ^(i)Pr H HL_(A)1344 H H Me H Ph H H L_(A)1345 H H CD₃ H Ph H H L_(A)1346 H H^(i)Pr H Ph H H L_(A)1347 H H Ph H Ph H H L_(A)1348 Me Me H Me H H HL_(A)1349 H Me Me Me H H H L_(A)1350 CD₃ Me H Me H H H L_(A)1351 H MeCD₃ Me H H H L_(A)1352 ^(i)Pr Me H Me H H H L_(A)1353 H Me ^(i)Pr Me H HH L_(A)1354 Ph Me H Me H H H L_(A)1355 H Me Ph Me H H H L_(A)1356 Me CD₃H CD₃ H H H L_(A)1357 H CD₃ Me CD₃ H H H L_(A)1358 CD₃ CD₃ H CD₃ H H HL_(A)1359 H CD₃ CD₃ CD₃ H H H L_(A)1360 ^(i)Pr CD₃ H CD₃ H H H L_(A)1361H CD₃ ^(i)Pr CD₃ H H H L_(A)1362 Ph CD₃ H CD₃ H H H L_(A)1363 H CD₃ PhCD₃ H H H L_(A)1364 Me ^(i)Pr H ^(i)Pr H H H L_(A)1365 H ^(i)Pr Me^(i)Pr H H H L_(A)1366 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)1367 H ^(i)Pr CD₃^(i)Pr H H H L_(A)1368 L_(A)1369 L_(A)1370 L_(A)1371 L_(A)1372

^(i)Pr H Ph H Me ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr Ph H ^(i)Pr H Ph H ^(i)Pr^(i)Pr ^(i)Pr ^(i)Pr Ph H H H H H H H H H H H H H H H L_(A)1373 H Ph MePh H H H L_(A)1374 CD₃ Ph H Ph H H H L_(A)1375 H Ph CD₃ Ph H H HL_(A)1376 ^(i)Pr Ph H Ph H H H L_(A)1377 H Ph ^(i)Pr Ph H H H L_(A)1378Ph Ph H Ph H H H L_(A)1379 H Ph Ph Ph H H H L_(A)1380 L_(A)1381L_(A)1382 L_(A)1383 L_(A)1384 L_(A)1385

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)1386 CD₃ H H H H H H L_(A)1387 H CD₃ H H H H HL_(A)1388 H H CD₃ H H H H L_(A)1389 H H H CD₃ H H H L_(A)1390 H H H HCD₃ H H L_(A)1391 ^(i)Pr H H H H H H L_(A)1392 H ^(i)Pr H H H H HL_(A)1393 H H ^(i)Pr H H H H L_(A)1394 H H H ^(i)Pr H H H L_(A)1395 H HH H ^(i)Pr H H L_(A)1396 Ph H H H H H H L_(A)1397 H Ph H H H H HL_(A)1398 H H Ph H H H H L_(A)1399 H H H Ph H H H L_(A)1400 H H H H Ph HH L_(A)1401 Me Me H H H H H L_(A)1402 Me H Me H H H H L_(A)1403 Me H HMe H H H L_(A)1404 Me H H H Me H H L_(A)1405 Me CD₃ H H H H H L_(A)1406Me H CD₃ H H H H L_(A)1407 Me H H CD₃ H H H L_(A)1408 Me H H H CD₃ H HL_(A)1409 Me ^(i)Pr H H H H H L_(A)1410 Me H ^(i)Pr H H H H L_(A)1411 MeH H ^(i)Pr H H H L_(A)1412 Me H H H ^(i)Pr H H L_(A)1413 Me Ph H H H H HL_(A)1414 Me H Ph H H H H L_(A)1415 Me H H Ph H H H L_(A)1416 Me H H HPh H H L_(A)1417 CD₃ Me H H H H H L_(A)1418 CD₃ H Me H H H H L_(A)1419CD₃ H H Me H H H L_(A)1420 CD₃ H H H Me H H L_(A)1421 CD₃ CD₃ H H H H HL_(A)1422 CD₃ H CD₃ H H H H L_(A)1423 L_(A)1424 L_(A)1425 L_(A)1426L_(A)1427 L_(A)1428

CD₃ CD₃ CD₃ CD₃ CD₃ CD₃ H H ^(i)Pr H H H H H H ^(i)Pr H H CD₃ H H H^(i)Pr H H CD₃ H H H ^(i)Pr H H H H H H H H H H H H L_(A)1429 CD₃ Ph H HH H H L_(A)1430 CD₃ H Ph H H H H L_(A)1431 CD₃ H H Ph H H H L_(A)1432CD₃ H H H Ph H H L_(A)1433 ^(i)Pr Me H H H H H L_(A)1434 ^(i)Pr H Me H HH H L_(A)1435 ^(i)Pr H H Me H H H L_(A)1436 ^(i)Pr H H H Me H HL_(A)1437 ^(i)Pr CD₃ H H H H H L_(A)1438 ^(i)Pr H CD₃ H H H H L_(A)1439^(i)Pr H H CD₃ H H H L_(A)1440 ^(i)Pr H H H CD₃ H H L_(A)1441 ^(i)Pr^(i)Pr H H H H H L_(A)1442 ^(i)Pr H ^(i)Pr H H H H L_(A)1443 ^(i)Pr H H^(i)Pr H H H L_(A)1444 ^(i)Pr H H H ^(i)Pr H H L_(A)1445 ^(i)Pr Ph H H HH H L_(A)1446 ^(i)Pr H Ph H H H H L_(A)1447 ^(i)Pr H H Ph H H HL_(A)1448 ^(i)Pr H H H Ph H H L_(A)1449 Ph Me H H H H H L_(A)1450 Ph HMe H H H H L_(A)1451 Ph H H Me H H H L_(A)1452 Ph H H H Me H H L_(A)1453Ph CD₃ H H H H H L_(A)1454 Ph H CD₃ H H H H L_(A)1455 Ph H H CD₃ H H HL_(A)1456 Ph H H H CD₃ H H L_(A)1457 Ph ^(i)Pr H H H H H L_(A)1458 Ph H^(i)Pr H H H H L_(A)1459 Ph H H ^(i)Pr H H H L_(A)1460 Ph H H H ^(i)Pr HH L_(A)1461 Ph Ph H H H H H L_(A)1462 Ph H Ph H H H H L_(A)1463 Ph H HPh H H H L_(A)1464 Ph H H H Ph H H L_(A)1465 H Me Me H H H H L_(A)1466 HMe H Me H H H L_(A)1467 H Me H H Me H H L_(A)1468 H Me CD₃ H H H HL_(A)1469 H Me H CD₃ H H H L_(A)1470 H Me H H CD₃ H H L_(A)1471 H Me^(i)Pr H H H H L_(A)1472 H Me H ^(i)Pr H H H L_(A)1473 H Me H H ^(i)Pr HH L_(A)1474 H Me Ph H H H H L_(A)1475 H Me H Ph H H H L_(A)1476 H Me H HPh H H L_(A)1477 H CD₃ Me H H H H L_(A)1478 L_(A)1479 L_(A)1480L_(A)1481 L_(A)1482 L_(A)1483

H H H H H H CD₃ CD₃ CD₃ CD₃ CD₃ CD₃ H H CD₃ H H ^(i)Pr Me H H CD₃ H H HMe H H CD₃ H H H H H H H H H H H H H L_(A)1484 H CD₃ H ^(i)Pr H H HL_(A)1485 H CD₃ H H ^(i)Pr H H L_(A)1486 H CD₃ Ph H H H H L_(A)1487 HCD₃ H Ph H H H L_(A)1488 H CD₃ H H Ph H H L_(A)1489 H ^(i)Pr Me H H H HL_(A)1490 H ^(i)Pr H Me H H H L_(A)1491 H ^(i)Pr H H Me H H L_(A)1492 H^(i)Pr CD₃ H H H H L_(A)1493 H ^(i)Pr H CD₃ H H H L_(A)1494 H ^(i)Pr H HCD₃ H H L_(A)1495 H ^(i)Pr ^(i)Pr H H H H L_(A)1496 H ^(i)Pr H ^(i)Pr HH H L_(A)1497 H ^(i)Pr H H ^(i)Pr H H L_(A)1498 H ^(i)Pr Ph H H H HL_(A)1499 H ^(i)Pr H Ph H H H L_(A)1500 H ^(i)Pr H H Ph H H L_(A)1501 HPh Me H H H H L_(A)1502 H Ph H Me H H H L_(A)1503 H Ph H H Me H HL_(A)1504 H Ph CD₃ H H H H L_(A)1505 H Ph H CD₃ H H H L_(A)1506 H Ph H HCD₃ H H L_(A)1507 H Ph ^(i)Pr H H H H L_(A)1508 H Ph H ^(i)Pr H H HL_(A)1509 H Ph H H ^(i)Pr H H L_(A)1510 H Ph Ph H H H H L_(A)1511 H Ph HPh H H H L_(A)1512 H Ph H H Ph H H L_(A)1513 H H Me Me H H H L_(A)1514 HH CD₃ Me H H H L_(A)1515 H H ^(i)Pr Me H H H L_(A)1516 H H Ph Me H H HL_(A)1517 H H Me CD₃ H H H L_(A)1518 H H CD₃ CD₃ H H H L_(A)1519 H H^(i)Pr CD₃ H H H L_(A)1520 H H Ph CD₃ H H H L_(A)1521 H H Me ^(i)Pr H HH L_(A)1522 H H CD₃ ^(i)Pr H H H L_(A)1523 H H ^(i)Pr ^(i)Pr H H HL_(A)1524 H H Ph ^(i)Pr H H H L_(A)1525 H H Me Ph H H H L_(A)1526 H HCD₃ Ph H H H L_(A)1527 H H ^(i)Pr Ph H H H L_(A)1528 H H Ph Ph H H HL_(A)1529 H H Me H Me H H L_(A)1530 H H CD₃ H Me H H L_(A)1531 H H^(i)Pr H Me H H L_(A)1532 H H Ph H Me H H L_(A)1533 L_(A)1534 L_(A)1535L_(A)1536 L_(A)1537 L_(A)1538

H H H H H H H H H H H H Me CD₃ ^(i)Pr Ph Me CD₃ H H H H H H CD₃ CD₃ CD₃CD₃ ^(i)Pr ^(i)Pr H H H H H H H H H H H H L_(A)1539 H H ^(i)Pr H ^(i)PrH H L_(A)1540 H H Ph H ^(i)Pr H H L_(A)1541 H H Me H Ph H H L_(A)1542 HH CD₃ H Ph H H L_(A)1543 H H ^(i)Pr H Ph H H L_(A)1544 H H Ph H Ph H HL_(A)1545 Me Me H Me H H H L_(A)1546 H Me Me Me H H H L_(A)1547 CD₃ Me HMe H H H L_(A)1548 H Me CD₃ Me H H H L_(A)1549 ^(i)Pr Me H Me H H HL_(A)1550 H Me ^(i)Pr Me H H H L_(A)1551 Ph Me H Me H H H L_(A)1552 H MePh Me H H H L_(A)1553 Me CD₃ H CD₃ H H H L_(A)1554 H CD₃ Me CD₃ H H HL_(A)1555 CD₃ CD₃ H CD₃ H H H L_(A)1556 H CD₃ CD₃ CD₃ H H H L_(A)1557^(i)Pr CD₃ H CD₃ H H H L_(A)1558 H CD₃ ^(i)Pr CD₃ H H H L_(A)1559 Ph CD₃H CD₃ H H H L_(A)1560 H CD₃ Ph CD₃ H H H L_(A)1561 Me ^(i)Pr H ^(i)Pr HH H L_(A)1562 H ^(i)Pr Me ^(i)Pr H H H L_(A)1563 CD₃ ^(i)Pr H ^(i)Pr H HH L_(A)1564 H ^(i)Pr CD₃ ^(i)Pr H H H L_(A)1565 ^(i)Pr ^(i)Pr H ^(i)Pr HH H L_(A)1566 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)1567 Ph ^(i)Pr H ^(i)PrH H H L_(A)1568 H ^(i)Pr Ph ^(i)Pr H H H L_(A)1569 Me Ph H Ph H H HL_(A)1570 H Ph Me Ph H H H L_(A)1571 CD₃ Ph H Ph H H H L_(A)1572 H PhCD₃ Ph H H H L_(A)1573 ^(i)Pr Ph H Ph H H H L_(A)1574 H Ph ^(i)Pr Ph H HH L_(A)1575 Ph Ph H Ph H H H L_(A)1576 H Ph Ph Ph H H H L_(A)1577L_(A)1578 L_(A)1579 L_(A)1580 L_(A)1581 L_(A)1582

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)1583 CD₃ H H H H H H L_(A)1584 H CD₃ H H H H HL_(A)1585 H H CD₃ H H H H L_(A)1586 H H H CD₃ H H H L_(A)1587 H H H HCD₃ H H L_(A)1588 L_(A)1589 L_(A)1590 L_(A)1591

^(i)Pr H H H H ^(i)Pr H H H H ^(i)Pr H H H H ^(i)Pr H H H H H H H H H HH H L_(A)1592 H H H H ^(i)Pr H H L_(A)1593 Ph H H H H H H L_(A)1594 H PhH H H H H L_(A)1595 H H Ph H H H H L_(A)1596 H H H Ph H H H L_(A)1597 HH H H Ph H H L_(A)1598 Me Me H H H H H L_(A)1599 Me H Me H H H HL_(A)1600 Me H H Me H H H L_(A)1601 Me H H H Me H H L_(A)1602 Me CD₃ H HH H H L_(A)1603 Me H CD₃ H H H H L_(A)1604 Me H H CD₃ H H H L_(A)1605 MeH H H CD₃ H H L_(A)1606 Me ^(i)Pr H H H H H L_(A)1607 Me H ^(i)Pr H H HH L_(A)1608 Me H H ^(i)Pr H H H L_(A)1609 Me H H H ^(i)Pr H H L_(A)1610Me Ph H H H H H L_(A)1611 Me H Ph H H H H L_(A)1612 Me H H Ph H H HL_(A)1613 Me H H H Ph H H L_(A)1614 CD₃ Me H H H H H L_(A)1615 CD₃ H MeH H H H L_(A)1616 CD₃ H H Me H H H L_(A)1617 CD₃ H H H Me H H L_(A)1618CD₃ CD₃ H H H H H L_(A)1619 CD₃ H CD₃ H H H H L_(A)1620 CD₃ H H CD₃ H HH L_(A)1621 CD₃ H H H CD₃ H H L_(A)1622 CD₃ ^(i)Pr H H H H H L_(A)1623CD₃ H ^(i)Pr H H H H L_(A)1624 CD₃ H H ^(i)Pr H H H L_(A)1625 CD₃ H H H^(i)Pr H H L_(A)1626 CD₃ Ph H H H H H L_(A)1627 CD₃ H Ph H H H HL_(A)1628 CD₃ H H Ph H H H L_(A)1629 CD₃ H H H Ph H H L_(A)1630 ^(i)PrMe H H H H H L_(A)1631 ^(i)Pr H Me H H H H L_(A)1632 ^(i)Pr H H Me H H HL_(A)1633 ^(i)Pr H H H Me H H L_(A)1634 ^(i)Pr CD₃ H H H H H L_(A)1635^(i)Pr H CD₃ H H H H L_(A)1636 ^(i)Pr H H CD₃ H H H L_(A)1637 ^(i)Pr H HH CD₃ H H L_(A)1638 ^(i)Pr ^(i)Pr H H H H H L_(A)1639 ^(i)Pr H ^(i)Pr HH H H L_(A)1640 ^(i)Pr H H ^(i)Pr H H H L_(A)1641 ^(i)Pr H H H ^(i)Pr HH L_(A)1642 ^(i)Pr Ph H H H H H L_(A)1643 L_(A)1644 L_(A)1645 L_(A)1646L_(A)1647 L_(A)1648

^(i)Pr ^(i)Pr ^(i)Pr Ph Ph Ph H H H Me H H Ph H H H Me H H Ph H H H Me HH Ph H H H H H H H H H H H H H H H L_(A)1649 Ph H H H Me H H L_(A)1650Ph CD₃ H H H H H L_(A)1651 Ph H CD₃ H H H H L_(A)1652 Ph H H CD₃ H H HL_(A)1653 Ph H H H CD₃ H H L_(A)1654 Ph ^(i)Pr H H H H H L_(A)1655 Ph H^(i)Pr H H H H L_(A)1656 Ph H H ^(i)Pr H H H L_(A)1657 Ph H H H ^(i)Pr HH L_(A)1658 Ph Ph H H H H H L_(A)1659 Ph H Ph H H H H L_(A)1660 Ph H HPh H H H L_(A)1661 Ph H H H Ph H H L_(A)1662 H Me Me H H H H L_(A)1663 HMe H Me H H H L_(A)1664 H Me H H Me H H L_(A)1665 H Me CD₃ H H H HL_(A)1666 H Me H CD₃ H H H L_(A)1667 H Me H H CD₃ H H L_(A)1668 H Me^(i)Pr H H H H L_(A)1669 H Me H ^(i)Pr H H H L_(A)1670 H Me H H ^(i)Pr HH L_(A)1671 H Me Ph H H H H L_(A)1672 H Me H Ph H H H L_(A)1673 H Me H HPh H H L_(A)1674 H CD₃ Me H H H H L_(A)1675 H CD₃ H Me H H H L_(A)1676 HCD₃ H H Me H H L_(A)1677 H CD₃ CD₃ H H H H L_(A)1678 H CD₃ H CD₃ H H HL_(A)1679 H CD₃ H H CD₃ H H L_(A)1680 H CD₃ ^(i)Pr H H H H L_(A)1681 HCD₃ H ^(i)Pr H H H L_(A)1682 H CD₃ H H ^(i)Pr H H L_(A)1683 H CD₃ Ph H HH H L_(A)1684 H CD₃ H Ph H H H L_(A)1685 H CD₃ H H Ph H H L_(A)1686 H^(i)Pr Me H H H H L_(A)1687 H ^(i)Pr H Me H H H L_(A)1688 H ^(i)Pr H HMe H H L_(A)1689 H ^(i)Pr CD₃ H H H H L_(A)1690 H ^(i)Pr H CD₃ H H HL_(A)1691 H ^(i)Pr H H CD₃ H H L_(A)1692 H ^(i)Pr ^(i)Pr H H H HL_(A)1693 H ^(i)Pr H ^(i)Pr H H H L_(A)1694 H ^(i)Pr H H ^(i)Pr H HL_(A)1695 H ^(i)Pr Ph H H H H L_(A)1696 H ^(i)Pr H Ph H H H L_(A)1697 H^(i)Pr H H Ph H H L_(A)1698 L_(A)1699 L_(A)1700 L_(A)1701 L_(A)1702L_(A)1703

H H H H H H Ph Ph Ph Ph Ph Ph Me H H CD₃ H H H Me H H CD₃ H H H Me H HCD₃ H H H H H H H H H H H H L_(A)1704 H Ph ^(i)Pr H H H H L_(A)1705 H PhH ^(i)Pr H H H L_(A)1706 H Ph H H ^(i)Pr H H L_(A)1707 H Ph Ph H H H HL_(A)1708 H Ph H Ph H H H L_(A)1709 H Ph H H Ph H H L_(A)1710 H H Me MeH H H L_(A)1711 H H CD₃ Me H H H L_(A)1712 H H ^(i)Pr Me H H H L_(A)1713H H Ph Me H H H L_(A)1714 H H Me CD₃ H H H L_(A)1715 H H CD₃ CD₃ H H HL_(A)1716 H H ^(i)Pr CD₃ H H H L_(A)1717 H H Ph CD₃ H H H L_(A)1718 H HMe ^(i)Pr H H H L_(A)1719 H H CD₃ ^(i)Pr H H H L_(A)1720 H H ^(i)Pr^(i)Pr H H H L_(A)1721 H H Ph ^(i)Pr H H H L_(A)1722 H H Me Ph H H HL_(A)1723 H H CD₃ Ph H H H L_(A)1724 H H ^(i)Pr Ph H H H L_(A)1725 H HPh Ph H H H L_(A)1726 H H Me H Me H H L_(A)1727 H H CD₃ H Me H HL_(A)1728 H H ^(i)Pr H Me H H L_(A)1729 H H Ph H Me H H L_(A)1730 H H MeH CD₃ H H L_(A)1731 H H CD₃ H CD₃ H H L_(A)1732 H H ^(i)Pr H CD₃ H HL_(A)1733 H H Ph H CD₃ H H L_(A)1734 H H Me H ^(i)Pr H H L_(A)1735 H HCD₃ H ^(i)Pr H H L_(A)1736 H H ^(i)Pr H ^(i)Pr H H L_(A)1737 H H Ph H^(i)Pr H H L_(A)1738 H H Me H Ph H H L_(A)1739 H H CD₃ H Ph H HL_(A)1740 H H ^(i)Pr H Ph H H L_(A)1741 H H Ph H Ph H H L_(A)1742 Me MeH Me H H H L_(A)1743 H Me Me Me H H H L_(A)1744 CD₃ Me H Me H H HL_(A)1745 H Me CD₃ Me H H H L_(A)1746 ^(i)Pr Me H Me H H H L_(A)1747 HMe ^(i)Pr Me H H H L_(A)1748 Ph Me H Me H H H L_(A)1749 H Me Ph Me H H HL_(A)1750 Me CD₃ H CD₃ H H H L_(A)1751 H CD₃ Me CD₃ H H H L_(A)1752 CD₃CD₃ H CD₃ H H H L_(A)1753 L_(A)1754 L_(A)1755 L_(A)1756 L_(A)1757L_(A)1758

H ^(i)Pr H Ph H Me CD₃ CD₃ CD₃ CD₃ CD₃ ^(i)Pr CD₃ H ^(i)Pr H Ph H CD₃CD₃ CD₃ CD₃ CD₃ ^(i)Pr H H H H H H H H H H H H H H H H H H L_(A)1759 H^(i)Pr Me ^(i)Pr H H H L_(A)1760 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)1761 H^(i)Pr CD₃ ^(i)Pr H H H L_(A)1762 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)1763H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)1764 Ph ^(i)Pr H ^(i)Pr H H HL_(A)1765 H ^(i)Pr Ph ^(i)Pr H H H L_(A)1766 Me Ph H Ph H H H L_(A)1767H Ph Me Ph H H H L_(A)1768 CD₃ Ph H Ph H H H L_(A)1769 H Ph CD₃ Ph H H HL_(A)1770 ^(i)Pr Ph H Ph H H H L_(A)1771 H Ph ^(i)Pr Ph H H H L_(A)1772Ph Ph H Ph H H H L_(A)1773 H Ph Ph Ph H H H L_(A)1774 L_(A)1775L_(A)1776 L_(A)1777 L_(A)1778 L_(A)1779

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)1780 CD₃ H H H H H H L_(A)1781 H CD₃ H H H H HL_(A)1782 H H CD₃ H H H H L_(A)1783 H H H CD₃ H H H L_(A)1784 H H H HCD₃ H H L_(A)1785 ^(i)Pr H H H H H H L_(A)1786 H ^(i)Pr H H H H HL_(A)1787 H H ^(i)Pr H H H H L_(A)1788 H H H ^(i)Pr H H H L_(A)1789 H HH H ^(i)Pr H H L_(A)1790 Ph H H H H H H L_(A)1791 H Ph H H H H HL_(A)1792 H H Ph H H H H L_(A)1793 H H H Ph H H H L_(A)1794 H H H H Ph HH L_(A)1795 Me Me H H H H H L_(A)1796 Me H Me H H H H L_(A)1797 Me H HMe H H H L_(A)1798 Me H H H Me H H L_(A)1799 Me CD₃ H H H H H L_(A)1800Me H CD₃ H H H H L_(A)1801 Me H H CD₃ H H H L_(A)1802 Me H H H CD₃ H HL_(A)1803 Me ^(i)Pr H H H H H L_(A)1804 Me H ^(i)Pr H H H H L_(A)1805 MeH H ^(i)Pr H H H L_(A)1806 Me H H H ^(i)Pr H H L_(A)1807 Me Ph H H H H HL_(A)1808 L_(A)1809 L_(A)1810 L_(A)1811 L_(A)1812 L_(A)1813

Me Me Me CD₃ CD₃ CD₃ H H H Me H H Ph H H H Me H H Ph H H H Me H H Ph H HH H H H H H H H H H H H H L_(A)1814 CD₃ H H H Me H H L_(A)1815 CD₃ CD₃ HH H H H L_(A)1816 CD₃ H CD₃ H H H H L_(A)1817 CD₃ H H CD₃ H H HL_(A)1818 CD₃ H H H CD₃ H H L_(A)1819 CD₃ ^(i)Pr H H H H H L_(A)1820 CD₃H ^(i)Pr H H H H L_(A)1821 CD₃ H H ^(i)Pr H H H L_(A)1822 CD₃ H H H^(i)Pr H H L_(A)1823 CD₃ Ph H H H H H L_(A)1824 CD₃ H Ph H H H HL_(A)1825 CD₃ H H Ph H H H L_(A)1826 CD₃ H H H Ph H H L_(A)1827 ^(i)PrMe H H H H H L_(A)1828 ^(i)Pr H Me H H H H L_(A)1829 ^(i)Pr H H Me H H HL_(A)1830 ^(i)Pr H H H Me H H L_(A)1831 ^(i)Pr CD₃ H H H H H L_(A)1832^(i)Pr H CD₃ H H H H L_(A)1833 ^(i)Pr H H CD₃ H H H L_(A)1834 ^(i)Pr H HH CD₃ H H L_(A)1835 ^(i)Pr ^(i)Pr H H H H H L_(A)1836 ^(i)Pr H ^(i)Pr HH H H L_(A)1837 ^(i)Pr H H ^(i)Pr H H H L_(A)1838 ^(i)Pr H H H ^(i)Pr HH L_(A)1839 ^(i)Pr Ph H H H H H L_(A)1840 ^(i)Pr H Ph H H H H L_(A)1841^(i)Pr H H Ph H H H L_(A)1842 ^(i)Pr H H H Ph H H L_(A)1843 Ph Me H H HH H L_(A)1844 Ph H Me H H H H L_(A)1845 Ph H H Me H H H L_(A)1846 Ph H HH Me H H L_(A)1847 Ph CD₃ H H H H H L_(A)1848 Ph H CD₃ H H H H L_(A)1849Ph H H CD₃ H H H L_(A)1850 Ph H H H CD₃ H H L_(A)1851 Ph ^(i)Pr H H H HH L_(A)1852 Ph H ^(i)Pr H H H H L_(A)1853 Ph H H ^(i)Pr H H H L_(A)1854Ph H H H ^(i)Pr H H L_(A)1855 Ph Ph H H H H H L_(A)1856 Ph H Ph H H H HL_(A)1857 Ph H H Ph H H H L_(A)1858 Ph H H H Ph H H L_(A)1859 H Me Me HH H H L_(A)1860 H Me H Me H H H L_(A)1861 H Me H H Me H H L_(A)1862 H MeCD₃ H H H H L_(A)1863 L_(A)1864 L_(A)1865 L_(A)1866 L_(A)1867 L_(A)1868

H H H H H H Me Me Me Me Me Me H H ^(i)Pr H H Ph CD₃ H H ^(i)Pr H H H CD₃H H ^(i)Pr H H H H H H H H H H H H H L_(A)1869 H Me H Ph H H H L_(A)1870H Me H H Ph H H L_(A)1871 H CD₃ Me H H H H L_(A)1872 H CD₃ H Me H H HL_(A)1873 H CD₃ H H Me H H L_(A)1874 H CD₃ CD₃ H H H H L_(A)1875 H CD₃ HCD₃ H H H L_(A)1876 H CD₃ H H CD₃ H H L_(A)1877 H CD₃ ^(i)Pr H H H HL_(A)1878 H CD₃ H ^(i)Pr H H H L_(A)1879 H CD₃ H H ^(i)Pr H H L_(A)1880H CD₃ Ph H H H H L_(A)1881 H CD₃ H Ph H H H L_(A)1882 H CD₃ H H Ph H HL_(A)1883 H ^(i)Pr Me H H H H L_(A)1884 H ^(i)Pr H Me H H H L_(A)1885 H^(i)Pr H H Me H H L_(A)1886 H ^(i)Pr CD₃ H H H H L_(A)1887 H ^(i)Pr HCD₃ H H H L_(A)1888 H ^(i)Pr H H CD₃ H H L_(A)1889 H ^(i)Pr ^(i)Pr H H HH L_(A)1890 H ^(i)Pr H ^(i)Pr H H H L_(A)1891 H ^(i)Pr H H ^(i)Pr H HL_(A)1892 H ^(i)Pr Ph H H H H L_(A)1893 H ^(i)Pr H Ph H H H L_(A)1894 H^(i)Pr H H Ph H H L_(A)1895 H Ph Me H H H H L_(A)1896 H Ph H Me H H HL_(A)1897 H Ph H H Me H H L_(A)1898 H Ph CD₃ H H H H L_(A)1899 H Ph HCD₃ H H H L_(A)1900 H Ph H H CD₃ H H L_(A)1901 H Ph ^(i)Pr H H H HL_(A)1902 H Ph H ^(i)Pr H H H L_(A)1903 H Ph H H ^(i)Pr H H L_(A)1904 HPh Ph H H H H L_(A)1905 H Ph H Ph H H H L_(A)1906 H Ph H H Ph H HL_(A)1907 H H Me Me H H H L_(A)1908 H H CD₃ Me H H H L_(A)1909 H H^(i)Pr Me H H H L_(A)1910 H H Ph Me H H H L_(A)1911 H H Me CD₃ H H HL_(A)1912 H H CD₃ CD₃ H H H L_(A)1913 H H ^(i)Pr CD₃ H H H L_(A)1914 H HPh CD₃ H H H L_(A)1915 H H Me ^(i)Pr H H H L_(A)1916 H H CD₃ ^(i)Pr H HH L_(A)1917 H H ^(i)Pr ^(i)Pr H H H L_(A)1918 L_(A)1919 L_(A)1920L_(A)1921 L_(A)1922 L_(A)1923

H H H H H H H H H H H H Ph Me CD₃ ^(i)Pr Ph Me ^(i)Pr Ph Ph Ph Ph H H HH H H Me H H H H H H H H H H H H L_(A)1924 H H CD₃ H Me H H L_(A)1925 HH ^(i)Pr H Me H H L_(A)1926 H H Ph H Me H H L_(A)1927 H H Me H CD₃ H HL_(A)1928 H H CD₃ H CD₃ H H L_(A)1929 H H ^(i)Pr H CD₃ H H L_(A)1930 H HPh H CD₃ H H L_(A)1931 H H Me H ^(i)Pr H H L_(A)1932 H H CD₃ H ^(i)Pr HH L_(A)1933 H H ^(i)Pr H ^(i)Pr H H L_(A)1934 H H Ph H ^(i)Pr H HL_(A)1935 H H Me H Ph H H L_(A)1936 H H CD₃ H Ph H H L_(A)1937 H H^(i)Pr H Ph H H L_(A)1938 H H Ph H Ph H H L_(A)1939 Me Me H Me H H HL_(A)1940 H Me Me Me H H H L_(A)1941 CD₃ Me H Me H H H L_(A)1942 H MeCD₃ Me H H H L_(A)1943 ^(i)Pr Me H Me H H H L_(A)1944 H Me ^(i)Pr Me H HH L_(A)1945 Ph Me H Me H H H L_(A)1946 H Me Ph Me H H H L_(A)1947 Me CD₃H CD₃ H H H L_(A)1948 H CD₃ Me CD₃ H H H L_(A)1949 CD₃ CD₃ H CD₃ H H HL_(A)1950 H CD₃ CD₃ CD₃ H H H L_(A)1951 ^(i)Pr CD₃ H CD₃ H H H L_(A)1952H CD₃ ^(i)Pr CD₃ H H H L_(A)1953 Ph CD₃ H CD₃ H H H L_(A)1954 H CD₃ PhCD₃ H H H L_(A)1955 Me ^(i)Pr H ^(i)Pr H H H L_(A)1956 H ^(i)Pr Me^(i)Pr H H H L_(A)1957 CD₃ ^(i)Pr H ^(i)Pr H H H L_(A)1958 H ^(i)Pr CD₃^(i)Pr H H H L_(A)1959 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)1960 H ^(i)Pr^(i)Pr ^(i)Pr H H H L_(A)1961 Ph ^(i)Pr H ^(i)Pr H H H L_(A)1962 H^(i)Pr Ph ^(i)Pr H H H L_(A)1963 Me Ph H Ph H H H L_(A)1964 H Ph Me Ph HH H L_(A)1965 CD₃ Ph H Ph H H H L_(A)1966 H Ph CD₃ Ph H H H L_(A)1967^(i)Pr Ph H Ph H H H L_(A)1968 H Ph ^(i)Pr Ph H H H L_(A)1969 Ph Ph H PhH H H L_(A)1970 H Ph Ph Ph H H H L_(A)1971

H H H H H H H L_(A)1972 L_(A)1973 L_(A)1974 L_(A)1975 L_(A)1976L_(A)1977

Me H H H H CD₃ H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H H L_(A)1978 H CD₃ H H H H H L_(A)1979 H H CD₃ H H H HL_(A)1980 H H H CD₃ H H H L_(A)1981 H H H H CD₃ H H L_(A)1982 ^(i)Pr H HH H H H L_(A)1983 H ^(i)Pr H H H H H L_(A)1984 H H ^(i)Pr H H H HL_(A)1985 H H H ^(i)Pr H H H L_(A)1986 H H H H ^(i)Pr H H L_(A)1987 Ph HH H H H H L_(A)1988 H Ph H H H H H L_(A)1989 H H Ph H H H H L_(A)1990 HH H Ph H H H L_(A)1991 H H H H Ph H H L_(A)1992 Me Me H H H H HL_(A)1993 Me H Me H H H H L_(A)1994 Me H H Me H H H L_(A)1995 Me H H HMe H H L_(A)1996 Me CD₃ H H H H H L_(A)1997 Me H CD₃ H H H H L_(A)1998Me H H CD₃ H H H L_(A)1999 Me H H H CD₃ H H L_(A)2000 Me ^(i)Pr H H H HH L_(A)2001 Me H ^(i)Pr H H H H L_(A)2002 Me H H ^(i)Pr H H H L_(A)2003Me H H H ^(i)Pr H H L_(A)2004 Me Ph H H H H H L_(A)2005 Me H Ph H H H HL_(A)2006 Me H H Ph H H H L_(A)2007 Me H H H Ph H H L_(A)2008 CD₃ Me H HH H H L_(A)2009 CD₃ H Me H H H H L_(A)2010 CD₃ H H Me H H H L_(A)2011CD₃ H H H Me H H L_(A)2012 CD₃ CD₃ H H H H H L_(A)2013 CD₃ H CD₃ H H H HL_(A)2014 CD₃ H H CD₃ H H H L_(A)2015 CD₃ H H H CD₃ H H L_(A)2016 CD₃^(i)Pr H H H H H L_(A)2017 CD₃ H ^(i)Pr H H H H L_(A)2018 CD₃ H H ^(i)PrH H H L_(A)2019 CD₃ H H H ^(i)Pr H H L_(A)2020 CD₃ Ph H H H H HL_(A)2021 CD₃ H Ph H H H H L_(A)2022 CD₃ H H Ph H H H L_(A)2023 CD₃ H HH Ph H H L_(A)2024 ^(i)Pr Me H H H H H L_(A)2025 ^(i)Pr H Me H H H HL_(A)2026 ^(i)Pr H H Me H H H L_(A)2027 L_(A)2028 L_(A)2029 L_(A)2030L_(A)2031 L_(A)2032

^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr H CD₃ H H H ^(i)Pr H H CD₃ H HH H H H CD₃ H H Me H H H CD₃ H H H H H H H H H H H H H L_(A)2033 ^(i)PrH ^(i)Pr H H H H L_(A)2034 ^(i)Pr H H ^(i)Pr H H H L_(A)2035 ^(i)Pr H HH ^(i)Pr H H L_(A)2036 ^(i)Pr Ph H H H H H L_(A)2037 ^(i)Pr H Ph H H H HL_(A)2038 ^(i)Pr H H Ph H H H L_(A)2039 ^(i)Pr H H H Ph H H L_(A)2040 PhMe H H H H H L_(A)2041 Ph H Me H H H H L_(A)2042 Ph H H Me H H HL_(A)2043 Ph H H H Me H H L_(A)2044 Ph CD₃ H H H H H L_(A)2045 Ph H CD₃H H H H L_(A)2046 Ph H H CD₃ H H H L_(A)2047 Ph H H H CD₃ H H L_(A)2048Ph ^(i)Pr H H H H H L_(A)2049 Ph H ^(i)Pr H H H H L_(A)2050 Ph H H^(i)Pr H H H L_(A)2051 Ph H H H ^(i)Pr H H L_(A)2052 Ph Ph H H H H HL_(A)2053 Ph H Ph H H H H L_(A)2054 Ph H H Ph H H H L_(A)2055 Ph H H HPh H H L_(A)2056 H Me Me H H H H L_(A)2057 H Me H Me H H H L_(A)2058 HMe H H Me H H L_(A)2059 H Me CD₃ H H H H L_(A)2060 H Me H CD₃ H H HL_(A)2061 H Me H H CD₃ H H L_(A)2062 H Me ^(i)Pr H H H H L_(A)2063 H MeH ^(i)Pr H H H L_(A)2064 H Me H H ^(i)Pr H H L_(A)2065 H Me Ph H H H HL_(A)2066 H Me H Ph H H H L_(A)2067 H Me H H Ph H H L_(A)2068 H CD₃ Me HH H H L_(A)2069 H CD₃ H Me H H H L_(A)2070 H CD₃ H H Me H H L_(A)2071 HCD₃ CD₃ H H H H L_(A)2072 H CD₃ H CD₃ H H H L_(A)2073 H CD₃ H H CD₃ H HL_(A)2074 H CD₃ ^(i)Pr H H H H L_(A)2075 H CD₃ H ^(i)Pr H H H L_(A)2076H CD₃ H H ^(i)Pr H H L_(A)2077 H CD₃ Ph H H H H L_(A)2078 H CD₃ H Ph H HH L_(A)2079 H CD₃ H H Ph H H L_(A)2080 H ^(i)Pr Me H H H H L_(A)2081 H^(i)Pr H Me H H H L_(A)2082 L_(A)2083 L_(A)2084 L_(A)2085 L_(A)2086L_(A)2087

H H H H H H ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr ^(i)Pr H CD₃ H H ^(i)Pr HH H CD₃ H H ^(i)Pr Me H H CD₃ H H H H H H H H H H H H H H L_(A)2088 H^(i)Pr H H ^(i)Pr H H L_(A)2089 H ^(i)Pr Ph H H H H L_(A)2090 H ^(i)Pr HPh H H H L_(A)2091 H ^(i)Pr H H Ph H H L_(A)2092 H Ph Me H H H HL_(A)2093 H Ph H Me H H H L_(A)2094 H Ph H H Me H H L_(A)2095 H Ph CD₃ HH H H L_(A)2096 H Ph H CD₃ H H H L_(A)2097 H Ph H H CD₃ H H L_(A)2098 HPh ^(i)Pr H H H H L_(A)2099 H Ph H ^(i)Pr H H H L_(A)2100 H Ph H H^(i)Pr H H L_(A)2101 H Ph Ph H H H H L_(A)2102 H Ph H Ph H H H L_(A)2103H Ph H H Ph H H L_(A)2104 H H Me Me H H H L_(A)2105 H H CD₃ Me H H HL_(A)2106 H H ^(i)Pr Me H H H L_(A)2107 H H Ph Me H H H L_(A)2108 H H MeCD₃ H H H L_(A)2109 H H CD₃ CD₃ H H H L_(A)2110 H H ^(i)Pr CD₃ H H HL_(A)2111 H H Ph CD₃ H H H L_(A)2112 H H Me ^(i)Pr H H H L_(A)2113 H HCD₃ ^(i)Pr H H H L_(A)2114 H H ^(i)Pr ^(i)Pr H H H L_(A)2115 H H Ph^(i)Pr H H H L_(A)2116 H H Me Ph H H H L_(A)2117 H H CD₃ Ph H H HL_(A)2118 H H ^(i)Pr Ph H H H L_(A)2119 H H Ph Ph H H H L_(A)2120 H H MeH Me H H L_(A)2121 H H CD₃ H Me H H L_(A)2122 H H ^(i)Pr H Me H HL_(A)2123 H H Ph H Me H H L_(A)2124 H H Me H CD₃ H H L_(A)2125 H H CD₃ HCD₃ H H L_(A)2126 H H ^(i)Pr H CD₃ H H L_(A)2127 H H Ph H CD₃ H HL_(A)2128 H H Me H ^(i)Pr H H L_(A)2129 H H CD₃ H ^(i)Pr H H L_(A)2130 HH ^(i)Pr H ^(i)Pr H H L_(A)2131 H H Ph H ^(i)Pr H H L_(A)2132 H H Me HPh H H L_(A)2133 H H CD₃ H Ph H H L_(A)2134 H H ^(i)Pr H Ph H HL_(A)2135 H H Ph H Ph H H L_(A)2136 Me Me H Me H H H L_(A)2137 L_(A)2138L_(A)2139 L_(A)2140 L_(A)2141 L_(A)2142

H CD₃ H ^(i)Pr H Ph Me Me Me Me Me Me Me H CD₃ H ^(i)Pr H Me Me Me Me MeMe H H H H H H H H H H H H H H H H H H L_(A)2143 H Me Ph Me H H HL_(A)2144 Me CD₃ H CD₃ H H H L_(A)2145 H CD₃ Me CD₃ H H H L_(A)2146 CD₃CD₃ H CD₃ H H H L_(A)2147 H CD₃ CD₃ CD₃ H H H L_(A)2148 ^(i)Pr CD₃ H CD₃H H H L_(A)2149 H CD₃ ^(i)Pr CD₃ H H H L_(A)2150 Ph CD₃ H CD₃ H H HL_(A)2151 H CD₃ Ph CD₃ H H H L_(A)2152 Me ^(i)Pr H ^(i)Pr H H HL_(A)2153 H ^(i)Pr Me ^(i)Pr H H H L_(A)2154 CD₃ ^(i)Pr H ^(i)Pr H H HL_(A)2155 H ^(i)Pr CD₃ ^(i)Pr H H H L_(A)2156 ^(i)Pr ^(i)Pr H ^(i)Pr H HH L_(A)2157 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)2158 Ph ^(i)Pr H ^(i)Pr HH H L_(A)2159 H ^(i)Pr Ph ^(i)Pr H H H L_(A)2160 Me Ph H Ph H H HL_(A)2161 H Ph Me Ph H H H L_(A)2162 CD₃ Ph H Ph H H H L_(A)2163 H PhCD₃ Ph H H H L_(A)2164 ^(i)Pr Ph H Ph H H H L_(A)2165 H Ph ^(i)Pr Ph H HH L_(A)2166 Ph Ph H Ph H H H L_(A)2167 H Ph Ph Ph H H H L_(A)2168L_(A)2169 L_(A)2170 L_(A)2171 L_(A)2172 L_(A)2173

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)2174 CD₃ H H H H H H L_(A)2175 H CD₃ H H H H HL_(A)2176 H H CD₃ H H H H L_(A)2177 H H H CD₃ H H H L_(A)2178 H H H HCD₃ H H L_(A)2179 ^(i)Pr H H H H H H L_(A)2180 H ^(i)Pr H H H H HL_(A)2181 H H ^(i)Pr H H H H L_(A)2182 H H H ^(i)Pr H H H L_(A)2183 H HH H ^(i)Pr H H L_(A)2184 Ph H H H H H H L_(A)2185 H Ph H H H H HL_(A)2186 H H Ph H H H H L_(A)2187 H H H Ph H H H L_(A)2188 H H H H Ph HH L_(A)2189 Me Me H H H H H L_(A)2190 Me H Me H H H H L_(A)2191 Me H HMe H H H L_(A)2192 L_(A)2193 L_(A)2194 L_(A)2195 L_(A)2196 L_(A)2197

Me Me Me Me Me Me H CD₃ H H H ^(i)Pr H H CD₃ H H H H H H CD₃ H H Me H HH CD₃ H H H H H H H H H H H H H L_(A)2198 Me H ^(i)Pr H H H H L_(A)2199Me H H ^(i)Pr H H H L_(A)2200 Me H H H ^(i)Pr H H L_(A)2201 Me Ph H H HH H L_(A)2202 Me H Ph H H H H L_(A)2203 Me H H Ph H H H L_(A)2204 Me H HH Ph H H L_(A)2205 CD₃ Me H H H H H L_(A)2206 CD₃ H Me H H H H L_(A)2207CD₃ H H Me H H H L_(A)2208 CD₃ H H H Me H H L_(A)2209 CD₃ CD₃ H H H H HL_(A)2210 CD₃ H CD₃ H H H H L_(A)2211 CD₃ H H CD₃ H H H L_(A)2212 CD₃ HH H CD₃ H H L_(A)2213 CD₃ ^(i)Pr H H H H H L_(A)2214 CD₃ H ^(i)Pr H H HH L_(A)2215 CD₃ H H ^(i)Pr H H H L_(A)2216 CD₃ H H H ^(i)Pr H HL_(A)2217 CD₃ Ph H H H H H L_(A)2218 CD₃ H Ph H H H H L_(A)2219 CD₃ H HPh H H H L_(A)2220 CD₃ H H H Ph H H L_(A)2221 ^(i)Pr Me H H H H HL_(A)2222 ^(i)Pr H Me H H H H L_(A)2223 ^(i)Pr H H Me H H H L_(A)2224^(i)Pr H H H Me H H L_(A)2225 ^(i)Pr CD₃ H H H H H L_(A)2226 ^(i)Pr HCD₃ H H H H L_(A)2227 ^(i)Pr H H CD₃ H H H L_(A)2228 ^(i)Pr H H H CD₃ HH L_(A)2229 ^(i)Pr ^(i)Pr H H H H H L_(A)2230 ^(i)Pr H ^(i)Pr H H H HL_(A)2231 ^(i)Pr H H ^(i)Pr H H H L_(A)2232 ^(i)Pr H H H ^(i)Pr H HL_(A)2233 ^(i)Pr Ph H H H H H L_(A)2234 ^(i)Pr H Ph H H H H L_(A)2235^(i)Pr H H Ph H H H L_(A)2236 ^(i)Pr H H H Ph H H L_(A)2237 Ph Me H H HH H L_(A)2238 Ph H Me H H H H L_(A)2239 Ph H H Me H H H L_(A)2240 Ph H HH Me H H L_(A)2241 Ph CD₃ H H H H H L_(A)2242 Ph H CD₃ H H H H L_(A)2243Ph H H CD₃ H H H L_(A)2244 Ph H H H CD₃ H H L_(A)2245 Ph ^(i)Pr H H H HH L_(A)2246 Ph H ^(i)Pr H H H H L_(A)2247 L_(A)2248 L_(A)2249 L_(A)2250L_(A)2251 L_(A)2252

Ph Ph Ph Ph Ph Ph H H Ph H H H H H H Ph H H ^(i)Pr H H H Ph H H ^(i)Pr HH H Ph H H H H H H H H H H H H L_(A)2253 H Me Me H H H H L_(A)2254 H MeH Me H H H L_(A)2255 H Me H H Me H H L_(A)2256 H Me CD₃ H H H HL_(A)2257 H Me H CD₃ H H H L_(A)2258 H Me H H CD₃ H H L_(A)2259 H Me^(i)Pr H H H H L_(A)2260 H Me H ^(i)Pr H H H L_(A)2261 H Me H H ^(i)Pr HH L_(A)2262 H Me Ph H H H H L_(A)2263 H Me H Ph H H H L_(A)2264 H Me H HPh H H L_(A)2265 H CD₃ Me H H H H L_(A)2266 H CD₃ H Me H H H L_(A)2267 HCD₃ H H Me H H L_(A)2268 H CD₃ CD₃ H H H H L_(A)2269 H CD₃ H CD₃ H H HL_(A)2270 H CD₃ H H CD₃ H H L_(A)2271 H CD₃ ^(i)Pr H H H H L_(A)2272 HCD₃ H ^(i)Pr H H H L_(A)2273 H CD₃ H H ^(i)Pr H H L_(A)2274 H CD₃ Ph H HH H L_(A)2275 H CD₃ H Ph H H H L_(A)2276 H CD₃ H H Ph H H L_(A)2277 H^(i)Pr Me H H H H L_(A)2278 H ^(i)Pr H Me H H H L_(A)2279 H ^(i)Pr H HMe H H L_(A)2280 H ^(i)Pr CD₃ H H H H L_(A)2281 H ^(i)Pr H CD₃ H H HL_(A)2282 H ^(i)Pr H H CD₃ H H L_(A)2283 H ^(i)Pr ^(i)Pr H H H HL_(A)2284 H ^(i)Pr H ^(i)Pr H H H L_(A)2285 H ^(i)Pr H H ^(i)Pr H HL_(A)2286 H ^(i)Pr Ph H H H H L_(A)2287 H ^(i)Pr H Ph H H H L_(A)2288 H^(i)Pr H H Ph H H L_(A)2289 H Ph Me H H H H L_(A)2290 H Ph H Me H H HL_(A)2291 H Ph H H Me H H L_(A)2292 H Ph CD₃ H H H H L_(A)2293 H Ph HCD₃ H H H L_(A)2294 H Ph H H CD₃ H H L_(A)2295 H Ph ^(i)Pr H H H HL_(A)2296 H Ph H ^(i)Pr H H H L_(A)2297 H Ph H H ^(i)Pr H H L_(A)2298 HPh Ph H H H H L_(A)2299 H Ph H Ph H H H L_(A)2300 H Ph H H Ph H HL_(A)2301 H H Me Me H H H L_(A)2302 L_(A)2303 L_(A)2304 L_(A)2305L_(A)2306 L_(A)2307

H H H H H H H H H H H H CD₃ ^(i)Pr Ph Me CD₃ ^(i)Pr Me Me Me CD₃ CD₃ CD₃H H H H H H H H H H H H H H H H H H L_(A)2308 H H Ph CD₃ H H H L_(A)2309H H Me ^(i)Pr H H H L_(A)2310 H H CD₃ ^(i)Pr H H H L_(A)2311 H H ^(i)Pr^(i)Pr H H H L_(A)2312 H H Ph ^(i)Pr H H H L_(A)2313 H H Me Ph H H HL_(A)2314 H H CD₃ Ph H H H L_(A)2315 H H ^(i)Pr Ph H H H L_(A)2316 H HPh Ph H H H L_(A)2317 H H Me H Me H H L_(A)2318 H H CD₃ H Me H HL_(A)2319 H H ^(i)Pr H Me H H L_(A)2320 H H Ph H Me H H L_(A)2321 H H MeH CD₃ H H L_(A)2322 H H CD₃ H CD₃ H H L_(A)2323 H H ^(i)Pr H CD₃ H HL_(A)2324 H H Ph H CD₃ H H L_(A)2325 H H Me H ^(i)Pr H H L_(A)2326 H HCD₃ H ^(i)Pr H H L_(A)2327 H H ^(i)Pr H ^(i)Pr H H L_(A)2328 H H Ph H^(i)Pr H H L_(A)2329 H H Me H Ph H H L_(A)2330 H H CD₃ H Ph H HL_(A)2331 H H ^(i)Pr H Ph H H L_(A)2332 H H Ph H Ph H H L_(A)2333 Me MeH Me H H H L_(A)2334 H Me Me Me H H H L_(A)2335 CD₃ Me H Me H H HL_(A)2336 H Me CD₃ Me H H H L_(A)2337 ^(i)Pr Me H Me H H H L_(A)2338 HMe ^(i)Pr Me H H H L_(A)2339 Ph Me H Me H H H L_(A)2340 H Me Ph Me H H HL_(A)2341 Me CD₃ H CD₃ H H H L_(A)2342 H CD₃ Me CD₃ H H H L_(A)2343 CD₃CD₃ H CD₃ H H H L_(A)2344 H CD₃ CD₃ CD₃ H H H L_(A)2345 ^(i)Pr CD₃ H CD₃H H H L_(A)2346 H CD₃ ^(i)Pr CD₃ H H H L_(A)2347 Ph CD₃ H CD₃ H H HL_(A)2348 H CD₃ Ph CD₃ H H H L_(A)2349 Me ^(i)Pr H ^(i)Pr H H HL_(A)2350 H ^(i)Pr Me ^(i)Pr H H H L_(A)2351 CD₃ ^(i)Pr H ^(i)Pr H H HL_(A)2352 H ^(i)Pr CD₃ ^(i)Pr H H H L_(A)2353 ^(i)Pr ^(i)Pr H ^(i)Pr H HH L_(A)2354 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)2355 Ph ^(i)Pr H ^(i)Pr HH H L_(A)2356 H ^(i)Pr Ph ^(i)Pr H H H L_(A)2357 L_(A)2358 L_(A)2359L_(A)2360 L_(A)2361 L_(A)2362 L_(A)2363 L_(A)2364

Me H CD₃ H ^(i)Pr H Ph H Ph Ph Ph Ph Ph Ph Ph Ph H Me H CD₃ H ^(i)Pr HPh Ph Ph Ph Ph Ph Ph Ph Ph H H H H H H H H H H H H H H H H H H H H H H HH L_(A)2365 L_(A)2366 L_(A)2367 L_(A)2368 L_(A)2369 L_(A)2370

H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H H H H Me H H H HH H H H H H H H L_(A)2371 CD₃ H H H H H H L_(A)2372 H CD₃ H H H H HL_(A)2373 H H CD₃ H H H H L_(A)2374 H H H CD₃ H H H L_(A)2375 H H H HCD₃ H H L_(A)2376 ^(i)Pr H H H H H H L_(A)2377 H ^(i)Pr H H H H HL_(A)2378 H H ^(i)Pr H H H H L_(A)2379 H H H ^(i)Pr H H H L_(A)2380 H HH H ^(i)Pr H H L_(A)2381 Ph H H H H H H L_(A)2382 H Ph H H H H HL_(A)2383 H H Ph H H H H L_(A)2384 H H H Ph H H H L_(A)2385 H H H H Ph HH L_(A)2386 Me Me H H H H H L_(A)2387 Me H Me H H H H L_(A)2388 Me H HMe H H H L_(A)2389 Me H H H Me H H L_(A)2390 Me CD₃ H H H H H L_(A)2391Me H CD₃ H H H H L_(A)2392 Me H H CD₃ H H H L_(A)2393 Me H H H CD₃ H HL_(A)2394 Me ^(i)Pr H H H H H L_(A)2395 Me H ^(i)Pr H H H H L_(A)2396 MeH H ^(i)Pr H H H L_(A)2397 Me H H H ^(i)Pr H H L_(A)2398 Me Ph H H H H HL_(A)2399 Me H Ph H H H H L_(A)2400 Me H H Ph H H H L_(A)2401 Me H H HPh H H L_(A)2402 CD₃ Me H H H H H L_(A)2403 CD₃ H Me H H H H L_(A)2404CD₃ H H Me H H H L_(A)2405 CD₃ H H H Me H H L_(A)2406 CD₃ CD₃ H H H H HL_(A)2407 CD₃ H CD₃ H H H H L_(A)2408 CD₃ H H CD₃ H H H L_(A)2409 CD₃ HH H CD₃ H H L_(A)2410 CD₃ ^(i)Pr H H H H H L_(A)2411 L_(A)2412 L_(A)2413L_(A)2414 L_(A)2415

CD₃ CD₃ CD₃ CD₃ CD₃ H H H Ph H ^(i)Pr H H H Ph H ^(i)Pr H H H H H ^(i)PrH H H H H H H H H H H H L_(A)2416 CD₃ H H Ph H H H L_(A)2417 CD₃ H H HPh H H L_(A)2418 ^(i)Pr Me H H H H H L_(A)2419 ^(i)Pr H Me H H H HL_(A)2420 ^(i)Pr H H Me H H H L_(A)2421 ^(i)Pr H H H Me H H L_(A)2422^(i)Pr CD₃ H H H H H L_(A)2423 ^(i)Pr H CD₃ H H H H L_(A)2424 ^(i)Pr H HCD₃ H H H L_(A)2425 ^(i)Pr H H H CD₃ H H L_(A)2426 ^(i)Pr ^(i)Pr H H H HH L_(A)2427 ^(i)Pr H ^(i)Pr H H H H L_(A)2428 ^(i)Pr H H ^(i)Pr H H HL_(A)2429 ^(i)Pr H H H ^(i)Pr H H L_(A)2430 ^(i)Pr Ph H H H H HL_(A)2431 ^(i)Pr H Ph H H H H L_(A)2432 ^(i)Pr H H Ph H H H L_(A)2433^(i)Pr H H H Ph H H L_(A)2434 Ph Me H H H H H L_(A)2435 Ph H Me H H H HL_(A)2436 Ph H H Me H H H L_(A)2437 Ph H H H Me H H L_(A)2438 Ph CD₃ H HH H H L_(A)2439 Ph H CD₃ H H H H L_(A)2440 Ph H H CD₃ H H H L_(A)2441 PhH H H CD₃ H H L_(A)2442 Ph ^(i)Pr H H H H H L_(A)2443 Ph H ^(i)Pr H H HH L_(A)2444 Ph H H ^(i)Pr H H H L_(A)2445 Ph H H H ^(i)Pr H H L_(A)2446Ph Ph H H H H H L_(A)2447 Ph H Ph H H H H L_(A)2448 Ph H H Ph H H HL_(A)2449 Ph H H H Ph H H L_(A)2450 H Me Me H H H H L_(A)2451 H Me H MeH H H L_(A)2452 H Me H H Me H H L_(A)2453 H Me CD₃ H H H H L_(A)2454 HMe H CD₃ H H H L_(A)2455 H Me H H CD₃ H H L_(A)2456 H Me ^(i)Pr H H H HL_(A)2457 H Me H ^(i)Pr H H H L_(A)2458 H Me H H ^(i)Pr H H L_(A)2459 HMe Ph H H H H L_(A)2460 H Me H Ph H H H L_(A)2461 H Me H H Ph H HL_(A)2462 H CD₃ Me H H H H L_(A)2463 H CD₃ H Me H H H L_(A)2464 H CD₃ HH Me H H L_(A)2465 H CD₃ CD₃ H H H H L_(A)2466 L_(A)2467 L_(A)2468L_(A)2469 L_(A)2470

H H H H H CD₃ CD₃ CD₃ CD₃ CD₃ H H ^(i)Pr H H CD₃ H H ^(i)Pr H H CD₃ H H^(i)Pr H H H H H H H H H H L_(A)2471 H CD₃ Ph H H H H L_(A)2472 H CD₃ HPh H H H L_(A)2473 H CD₃ H H Ph H H L_(A)2474 H ^(i)Pr Me H H H HL_(A)2475 H ^(i)Pr H Me H H H L_(A)2476 H ^(i)Pr H H Me H H L_(A)2477 H^(i)Pr CD₃ H H H H L_(A)2478 H ^(i)Pr H CD₃ H H H L_(A)2479 H ^(i)Pr H HCD₃ H H L_(A)2480 H ^(i)Pr ^(i)Pr H H H H L_(A)2481 H ^(i)Pr H ^(i)Pr HH H L_(A)2482 H ^(i)Pr H H ^(i)Pr H H L_(A)2483 H ^(i)Pr Ph H H H HL_(A)2484 H ^(i)Pr H Ph H H H L_(A)2485 H ^(i)Pr H H Ph H H L_(A)2486 HPh Me H H H H L_(A)2487 H Ph H Me H H H L_(A)2488 H Ph H H Me H HL_(A)2489 H Ph CD₃ H H H H L_(A)2490 H Ph H CD₃ H H H L_(A)2491 H Ph H HCD₃ H H L_(A)2492 H Ph ^(i)Pr H H H H L_(A)2493 H Ph H ^(i)Pr H H HL_(A)2494 H Ph H H ^(i)Pr H H L_(A)2495 H Ph Ph H H H H L_(A)2496 H Ph HPh H H H L_(A)2497 H Ph H H Ph H H L_(A)2498 H H Me Me H H H L_(A)2499 HH CD₃ Me H H H L_(A)2500 H H ^(i)Pr Me H H H L_(A)2501 H H Ph Me H H HL_(A)2502 H H Me CD₃ H H H L_(A)2503 H H CD₃ CD₃ H H H L_(A)2504 H H^(i)Pr CD₃ H H H L_(A)2505 H H Ph CD₃ H H H L_(A)2506 H H Me ^(i)Pr H HH L_(A)2507 H H CD₃ ^(i)Pr H H H L_(A)2508 H H ^(i)Pr ^(i)Pr H H HL_(A)2509 H H Ph ^(i)Pr H H H L_(A)2510 H H Me Ph H H H L_(A)2511 H HCD₃ Ph H H H L_(A)2512 H H ^(i)Pr Ph H H H L_(A)2513 H H Ph Ph H H HL_(A)2514 H H Me H Me H H L_(A)2515 H H CD₃ H Me H H L_(A)2516 H H^(i)Pr H Me H H L_(A)2517 H H Ph H Me H H L_(A)2518 H H Me H CD₃ H HL_(A)2519 H H CD₃ H CD₃ H H L_(A)2520 H H ^(i)Pr H CD₃ H H L_(A)2521L_(A)2522 L_(A)2523 L_(A)2524 L_(A)2525

H H H H H H H H H H Ph Me CD₃ ^(i)Ph Ph H H H H H CD₃ ^(i)Pr ^(i)Pr^(i)Pr ^(i)Pr H H H H H H H H H H L_(A)2526 H H Me H Ph H H L_(A)2527 HH CD₃ H Ph H H L_(A)2528 H H ^(i)Pr H Ph H H L_(A)2529 H H Ph H Ph H HL_(A)2530 Me Me H Me H H H L_(A)2531 H Me Me Me H H H L_(A)2532 CD₃ Me HMe H H H L_(A)2533 H Me CD₃ Me H H H L_(A)2534 ^(i)Pr Me H Me H H HL_(A)2535 H Me ^(i)Pr Me H H H L_(A)2536 Ph Me H Me H H H L_(A)2537 H MePh Me H H H L_(A)2538 Me CD₃ H CD₃ H H H L_(A)2539 H CD₃ Me CD₃ H H HL_(A)2540 CD₃ CD₃ H CD₃ H H H L_(A)2541 H CD₃ CD₃ CD₃ H H H L_(A)2542^(i)Pr CD₃ H CD₃ H H H L_(A)2543 H CD₃ ^(i)Pr CD₃ H H H L_(A)2544 Ph CD₃H CD₃ H H H L_(A)2545 H CD₃ Ph CD₃ H H H L_(A)2546 Me ^(i)Pr H ^(i)Pr HH H L_(A)2547 H ^(i)Pr Me ^(i)Pr H H H L_(A)2548 CD₃ ^(i)Pr H ^(i)Pr H HH L_(A)2549 H ^(i)Pr CD₃ ^(i)Pr H H H L_(A)2550 ^(i)Pr ^(i)Pr H ^(i)Pr HH H L_(A)2551 H ^(i)Pr ^(i)Pr ^(i)Pr H H H L_(A)2552 Ph ^(i)Pr H ^(i)PrH H H L_(A)2553 H ^(i)Pr Ph ^(i)Pr H H H L_(A)2554 Me Ph H Ph H H HL_(A)2555 H Ph Me Ph H H H L_(A)2556 CD₃ Ph H Ph H H H L_(A)2557 H PhCD₃ Ph H H H L_(A)2558 ^(i)Pr Ph H Ph H H H L_(A)2559 H Ph ^(i)Pr Ph H HH L_(A)2560 Ph Ph H Ph H H H L_(A)2561 H Ph Ph Ph H H H L_(A)2562L_(A)2563 L_(A)2564 L_(A)2565 L_(A)2566

H Me H H H H H Me H H H H H Me H H H H H Me H H H H H H H H H H H H H HH L_(A)2567 H H H H Me H H L_(A)2568 CD₃ H H H H H H L_(A)2569 H CD₃ H HH H H L_(A)2570 H H CD₃ H H H H L_(A)2571 H H H CD₃ H H H L_(A)2572 H HH H CD₃ H H L_(A)2573 ^(i)Pr H H H H H H L_(A)2574 H ^(i)Pr H H H H HL_(A)2575 H H ^(i)Pr H H H H L_(A)2576 L_(A)2577 L_(A)2578 L_(A)2579L_(A)2580

H H Ph H H H H H Ph H H H H H Ph ^(i)Ph H H H H H ^(i)Ph H H H H H H H HH H H H H L_(A)2581 H H H Ph H H H L_(A)2582 H H H H Ph H H L_(A)2583 MeMe H H H H H L_(A)2584 Me H Me H H H H L_(A)2585 Me H H Me H H HL_(A)2586 Me H H H Me H H L_(A)2587 Me CD₃ H H H H H L_(A)2588 Me H CD₃H H H H L_(A)2589 Me H H CD₃ H H H L_(A)2590 Me H H H CD₃ H H L_(A)2591Me ^(i)Pr H H H H H L_(A)2592 Me H ^(i)Pr H H H H L_(A)2593 Me H H^(i)Pr H H H L_(A)2594 Me H H H ^(i)Pr H H L_(A)2595 Me Ph H H H H HL_(A)2596 Me H Ph H H H H L_(A)2597 Me H H Ph H H H L_(A)2598 Me H H HPh H H L_(A)2599 CD₃ Me H H H H H L_(A)2600 CD₃ H Me H H H H L_(A)2601CD₃ H H Me H H H L_(A)2602 CD₃ H H H Me H H L_(A)2603 CD₃ CD₃ H H H H HL_(A)2604 CD₃ H CD₃ H H H H L_(A)2605 CD₃ H H CD₃ H H H L_(A)2606 CD₃ HH H CD₃ H H L_(A)2607 CD₃ ^(i)Pr H H H H H L_(A)2608 CD₃ H ^(i)Pr H H HH L_(A)2609 CD₃ H H ^(i)Pr H H H L_(A)2610 CD₃ H H H ^(i)Pr H HL_(A)2611 CD₃ Ph H H H H H L_(A)2612 CD₃ H Ph H H H H L_(A)2613 CD₃ H HPh H H H L_(A)2614 CD₃ H H H Ph H H L_(A)2615 ^(i)Pr Me H H H H HL_(A)2616 ^(i)Pr H Me H H H H L_(A)2617 ^(i)Pr H H Me H H H L_(A)2618^(i)Pr H H H Me H H L_(A)2619 ^(i)Pr CD₃ H H H H H L_(A)2620 ^(i)Pr HCD₃ H H H H L_(A)2621 ^(i)Pr H H CD₃ H H H L_(A)2622 ^(i)Pr H H H CD₃ HH L_(A)2623 ^(i)Pr ^(i)Pr H H H H H L_(A)2624 ^(i)Pr H ^(i)Pr H H H HL_(A)2625 ^(i)Pr H H ^(i)Pr H H H L_(A)2626 ^(i)Pr H H H ^(i)Pr H HL_(A)2627 ^(i)Pr Ph H H H H H L_(A)2628 ^(i)Pr H Ph H H H H L_(A)2629^(i)Pr H H Ph H H H L_(A)2630 ^(i)Pr H H H Ph H H L_(A)2631 L_(A)2632L_(A)2633 L_(A)2634 L_(A)2635

Ph Ph Ph Ph Ph Me H H H CD₃ H Me H H H H H Me H H H H H Me H H H H H H HH H H H L_(A)2636 Ph H CD₃ H H H H L_(A)2637 Ph H H CD₃ H H H L_(A)2638Ph H H H CD₃ H H L_(A)2639 Ph ^(i)Pr H H H H H L_(A)2640 Ph H ^(i)Pr H HH H L_(A)2641 Ph H H ^(i)Pr H H H L_(A)2642 Ph H H H ^(i)Pr H HL_(A)2643 Ph Ph H H H H H L_(A)2644 Ph H Ph H H H H L_(A)2645 Ph H H PhH H H L_(A)2646 Ph H H H Ph H H L_(A)2647 H Me Me H H H H L_(A)2648 H MeH Me H H H L_(A)2649 H Me H H Me H H L_(A)2650 H Me CD₃ H H H HL_(A)2651 H Me H CD₃ H H H L_(A)2652 H Me H H CD₃ H H L_(A)2653 H Me^(i)Pr H H H H L_(A)2654 H Me H ^(i)Pr H H H L_(A)2655 H Me H H ^(i)Pr HH L_(A)2656 H Me Ph H H H H L_(A)2657 H Me H Ph H H H L_(A)2658 H Me H HPh H H L_(A)2659 H CD₃ Me H H H H L_(A)2660 H CD₃ H Me H H H L_(A)2661 HCD₃ H H Me H H L_(A)2662 H CD₃ CD₃ H H H H L_(A)2663 H CD₃ H CD₃ H H HL_(A)2664 H CD₃ H H CD₃ H H L_(A)2665 H CD₃ ^(i)Pr H H H H L_(A)2666 HCD₃ H ^(i)Pr H H H L_(A)2667 H CD₃ H H ^(i)Pr H H L_(A)2668 H CD₃ Ph H HH H L_(A)2669 H CD₃ H Ph H H H L_(A)2670 H CD₃ H H Ph H H L_(A)2671 H^(i)Pr Me H H H H L_(A)2672 H ^(i)Pr H Me H H H L_(A)2673 H ^(i)Pr H HMe H H L_(A)2674 H ^(i)Pr CD₃ H H H H L_(A)2675 H ^(i)Pr H CD₃ H H HL_(A)2676 H ^(i)Pr H H CD₃ H H L_(A)2677 H ^(i)Pr ^(i)Pr H H H HL_(A)2678 H ^(i)Pr H ^(i)Pr H H H L_(A)2679 H ^(i)Pr H H ^(i)Pr H HL_(A)2680 H ^(i)Pr Ph H H H H L_(A)2681 H ^(i)Pr H Ph H H H L_(A)2682 H^(i)Pr H H Ph H H L_(A)2683 H Ph Me H H H H L_(A)2684 H Ph H Me H H HL_(A)2685 H Ph H H Me H H L_(A)2686 L_(A)2687 L_(A)2688 L_(A)2689L_(A)2690

H H H H H Ph Ph Ph Ph Ph CD₃ H H ^(i)Pr H H CD₃ H H ^(i)Pr H H CD₃ H H HH H H H H H H H H L_(A)2691 H Ph H H ^(i)Pr H H L_(A)2692 H Ph Ph H H HH L_(A)2693 H Ph H Ph H H H L_(A)2694 H Ph H H Ph H H L_(A)2695 H H MeMe H H H L_(A)2696 H H CD₃ Me H H H L_(A)2697 H H ^(i)Pr Me H H HL_(A)2698 H H Ph Me H H H L_(A)2699 H H Me CD₃ H H H L_(A)2700 H H CD₃CD₃ H H H L_(A)2701 H H ^(i)Pr CD₃ H H H L_(A)2702 H H Ph CD₃ H H HL_(A)2703 H H Me ^(i)Pr H H H L_(A)2704 H H CD₃ ^(i)Pr H H H L_(A)2705 HH ^(i)Pr ^(i)Pr H H H L_(A)2706 H H Ph ^(i)Pr H H H L_(A)2707 H H Me PhH H H L_(A)2708 H H CD₃ Ph H H H L_(A)2709 H H ^(i)Pr Ph H H H L_(A)2710H H Ph Ph H H H L_(A)2711 H H Me H Me H H L_(A)2712 H H CD₃ H Me H HL_(A)2713 H H ^(i)Pr H Me H H L_(A)2714 H H Ph H Me H H L_(A)2715 H H MeH CD₃ H H L_(A)2716 H H CD₃ H CD₃ H H L_(A)2717 H H ^(i)Pr H CD₃ H HL_(A)2718 H H Ph H CD₃ H H L_(A)2719 H H Me H ^(i)Pr H H L_(A)2720 H HCD₃ H ^(i)Pr H H L_(A)2721 H H ^(i)Pr H ^(i)Pr H H L_(A)2722 H H Ph H^(i)Pr H H L_(A)2723 H H Me H Ph H H L_(A)2724 H H CD₃ H Ph H HL_(A)2725 H H ^(i)Pr H Ph H H L_(A)2726 H H Ph H Ph H H L_(A)2727 Me MeH Me H H H L_(A)2728 H Me Me Me H H H L_(A)2729 CD₃ Me H Me H H HL_(A)2730 H Me CD₃ Me H H H L_(A)2731 ^(i)Pr Me H Me H H H L_(A)2732 HMe ^(i)Pr Me H H H L_(A)2733 Ph Me H Me H H H L_(A)2734 H Me Ph Me H H HL_(A)2735 Me CD₃ H CD₃ H H H L_(A)2736 H CD₃ Me CD₃ H H H L_(A)2737 CD₃CD₃ H CD₃ H H H L_(A)2738 H CD₃ CD₃ CD₃ H H H L_(A)2739 ^(i)Pr CD₃ H CD₃H H H L_(A)2740 H CD₃ ^(i)Pr CD₃ H H H L_(A)2741 L_(A)2742 L_(A)2743L_(A)2744 L_(A)2745

Ph H Me H CD₃ CD₃ CD₃ ^(i)Pr ^(i)Pr ^(i)Pr H Ph H Me H CD₃ CD₃ ^(i)Pr^(i)Pr ^(i)Pr H H H H H H H H H H H H H H H L_(A)2746 H ^(i)Pr CD₃^(i)Pr H H H L_(A)2747 ^(i)Pr ^(i)Pr H ^(i)Pr H H H L_(A)2748 H ^(i)Pr^(i)Pr ^(i)Pr H H H L_(A)2749 Ph ^(i)Pr H ^(i)Pr H H H L_(A)2750L_(A)2751 L_(A)2752 L_(A)2753 L_(A)2754

H Me H CD₃ H ^(i)Ph Ph Ph Ph Ph Ph H Me H CD₃ ^(i)Ph Ph Ph Ph Ph H H H HH H H H H H H H H H H L_(A)2755 ^(i)Pr Ph H Ph H H H L_(A)2756 H Ph^(i)Ph Ph H H H L_(A)2757 Ph Ph H Ph H H H L_(A)2758 H Ph Ph Ph H H H

In some embodiments of the compound of Formula 1, the ligand L isselected from the group consisting of:

wherein each X¹ to X¹³ are independently selected from the groupconsisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR′, NR′, PR′, O, S,Se, C═O, S═O, SO₂, CR′R″, SiR′R″, and GeR′R″;

wherein R′ and R″ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from monosubstitution to the possible maximum number of substitution, or nosubstitution;

wherein R′, R″, R_(a), R_(b), R_(c), and R_(d) are each independentlyselected from the group consisting of hydrogen, deuterium, halide,alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino,silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl,acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl,sulfinyl, sulfonyl, phosphino, and combinations thereof; and

wherein any two adjacent substitutents of R_(a), R_(b), R_(c), and R_(d)are optionally fused or joined to form a ring or form a multidentateligand.

In some embodiments of the compound of Formula 1, the ligand L isselected from the group consisting of:

wherein R_(a) and R_(b) are as defined above.

In some embodiments of the compound of Formula 1, the ligand L isselected from the group consisting of:

wherein R_(a) and R_(b) are as defined above.

In some embodiments of the compound of Formula 1, the ligand L isselected from the group consisting of:

wherein R_(a), R_(b), and R_(c) are as defined above.

In some embodiments of the compound of Formula 1, ligand L is selectedfrom the group consisting of:

In some embodiments of the compound of Formula 1, the compound is(L_(A))₃Ir, wherein L_(A) is as defined above.

In some embodiments of the compound of Formula 1, the compound is(L_(A))Ir(L)₂ or (L_(A))₂Ir(L), wherein LA and L are as defined above.

In some embodiments of the compound of Formula 1, where L_(A) is asdefined above, the compound is Compound Ax having the formulaIr(L_(Ai))₃; wherein x=i, i is an integer from 1 to 2758.

In some embodiments of the compound of Formula 1, where L_(A) is asdefined above, the compound is Compound By having the formulaIr(L_(Ai))(L_(j))₂ or Compound Cz having the formula Ir(L_(Ai))₂(L_(j));

wherein y=39i+j−39, i is an integer from 1 to 2758, and j is an integerfrom 1 to 39;

wherein z=39i+j−39, i is an integer from 1 to 2758, and j is an integerfrom 1 to 39; and wherein L₁ to L₃₉ have the following structure:

In some embodiments of the compound of Formula 1, the compound isselected from the group consisting of:

In some embodiments of the compound of Formula 1, the compound has astructure of Formula 2:

wherein M is Pt;

wherein A¹ and A² are each independently a first linking group havingtwo to three linking atoms, wherein the linking atoms are eachindependently selected from the group consisting of C, Si, O, S, N, B orcombinations thereof;

wherein R^(1b) to R^(1f) and R^(2b) to R^(2f) are each independentlyselected from the group consisting of hydrogen, deuterium, alkyl,cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl,cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R,C(O)NR₂, NR₂, NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, aheterocyclic group, and combinations thereof;

wherein each R is independently selected from the group consisting ofhydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aralkyl, aryl, heteroaryl, and combinations thereof;

wherein any one of the ring atoms to which R^(1b) to R^(1f) and R^(2b)to R^(2f) are attached may be replaced with a nitrogen atom, whereinwhen the ring atom is replaced with a nitrogen atom the corresponding Rgroup is not present; and

wherein R^(ab) and R^(ac) and/or R^(ga) and R^(gb) may bond to form asecond linking group having one to three linking atoms eachindependently selected from the group consisting of B, N, P, O, S, Se,C, Si, Ge or combinations thereof.

In some embodiments of the compound of Formula 2, each of the firstlinking groups A¹ and A² is independently selected from the groupconsisting of —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—, —CR¹R²—NR³—,—CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—, and —C—SiR¹R²—,wherein each R¹ to R⁶ can be same or different, and are independentlyselected from the group consisting of hydrogen, deuterium, alkyl,cycloalkyl, aryl, heteroaryl, and combinations thereof; and wherein anyadjacent R¹ to R⁶ are optionally connected to form a saturated fivemembered ring or a saturated six membered ring.

In some embodiments of the compound of Formula 2, the compound has atriplet excited state and wherein the linking group stabilizes the bondbetween N² and C^(1b) from cleavage when the compound is in the tripletexcited state.

In some embodiments of the compound of Formula 2, the compound has apeak emissive wavelength less than 500 nm. In some embodiments, thecompound has a peak emissive wavelength less than 480 nm. In someembodiments, the compound has a peak emissive wavelength ranging from400 nm to 500 nm.

In some embodiments of the compound of Formula 2, each of the firstlinking groups A¹ and A² is independently selected from the Linker Groupconsisting of:

In some embodiments of the compound of Formula 2, the second linkinggroup is independently selected from the group consisting of: BR¹, NR¹,PR¹, O, S, Se, C═O, S═O, SO₂, CR¹R², —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—,—CR¹R²—NR³—, —CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—,—C—SiR¹R²—, SiR¹R², and GeR¹R², wherein each R¹ to R⁶ can be same ordifferent, and are independently selected from the group consisting ofhydrogen, deuterium, alkyl, cycloalkyl, alkenyl, alkenyl, alkynyl,heteroalkyl, aralkyl, aryl, heteroaryl, and combinations thereof; andwherein any adjacent R¹ to R⁶ are optionally connected to form asaturated five membered ring or a saturated six membered ring.

In some embodiments of the compound of Formula 2, the compound isselected from the group consisting of:

In some embodiments of the compound of Formula 1, the compound hasFormula 3:

wherein M is Pt;

wherein L² and L³ are each independently selected from the groupconsisting of a single bond, BR, NR, PR, O, S, Se, C—O, S—O, SO₂, CR¹R²,SiR¹R², and GeR¹R²;

wherein R^(3a) to R^(3f), are each independently selected from the groupconsisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl,alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂, NO₂, OR, SR, SO₂,SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclic group, andcombinations thereof;

wherein each R is independently selected from the group consisting ofhydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aralkyl, aryl, heteroaryl, and combinations thereof;

wherein any two adjacent R^(1f), R^(3a), R^(3c), R^(3d), R¹ and R² areoptionally joined to form a ring; wherein L² and R^(1f), L² and R^(3a),or L² and both R^(1f) and R^(3a) are optionally joined to form one ormore rings; and

wherein L³ and R^(3c), L³ and R^(3d), or L³ and both R^(3c) and R^(3d)are optionally joined to form one or more rings.

In some embodiments of the compound of Formula 3, L² and L³ are eachindpendently selected from the group consisting of BR¹, NR¹, PR¹, O, S,Se, C═O, S═O, SO₂, CR¹R², SiR¹R², and GeR¹R². In some embodiments of thecompound of Formula 3, R^(1f) or R^(3a) and R¹ or R² are joined to forma ring. In some embodiments of the compound of Formula 3, R^(3c) orR^(3d) and R¹¹ or R² are joined to form a ring.

In some embodiments of the compound of Formula 3, the compound isselected from the group consisting of:

According to another aspect of the present disclosure, an organic lightemitting device (OLED) is disclosed. The OLED comprises an anode; acathode; and an organic layer disposed between the anode and thecathode, wherein the organic layer comprising a compound having astructure (L_(A))_(n)ML_(m) according to Formula 1:

wherein M is a metal having an atomic weight greater than 40, n has avalue of at least 1 and m+n is the maxiumn number of ligands that may beattached to the metal;

wherein A is a linking group having two to three linking atoms, whereinthe linking atoms are each independently selected from the groupconsisting of C, Si, , S, N, B or combinations thereof;

wherein the linking atoms form at least one single bond between twolinking atoms; wherein R^(1a) to R^(1g) are each independently selectedfrom the group consisting of hydrogen, deuterium, alkyl, cycloalkyl,heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂,NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclicgroup, and combinations thereof;

wherein each R is independently selected from the group consisting ofhydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aralkyl, aryl, heteroaryl, and combinations thereof;

wherein any one of the ring atoms to which R^(1b) to R^(1g) are attachedmay be replaced with a nitrogen atom, wherein when the ring atom isreplaced with a nitrogen atom the corresponding R group is not present;and

wherein L is a substituted or unsubstituted cyclometallated ligand.

In some embodiments of the OLED, the OLED is incorporated into a deviceselected from the group consisting of a consumer product, an electroniccomponent module, and a lighting panel.

In some embodiments of the OLED, the organic layer is an emissive layerand the compound is an emissive dopant or a non-emissive dopant.

In some embodiments of the OLED, the organic layer further comprises ahost, wherein the host comprises a triphenylene containing benzo-fusedthiophene or benzo-fused furan;

wherein any substituent in the host is an unfused substituentindependently selected from the group consisting of C_(n)H_(2n+1),OC_(n)H_(2n+1), OAr₁, N(C_(n)H_(2n+1))₂, N(Ar₁)(Ar₂),CH═CH—C_(n)H_(2n+1), C≡CC_(n)H_(2n+1), Ar₁, Ar₁-Ar₂, C_(n)H_(2n)—Ar₁, orno substitution;

wherein n is from 1 to 10; and

wherein Ar₁ and Ar₂ are independently selected from the group consistingof benzene, biphenyl, naphthalene, triphenylene, carbazole, andheteroaromatic analogs thereof.

In some embodiments of the OLED, the organic layer further comprises ahost, wherein host comprises at least one chemical group selected fromthe group consisting of triphenylene, carbazole, dibenzothiphene,dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole,aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.

In some embodiments of the OLED, the organic layer further comprises ahost, wherein the host is selected from the group consisting of:

and combinations thereof.

In some embodiments of the OLED, the organic layer further comprises ahost, wherein the host comprises a metal complex.

According to another aspect of the present disclosure, a formulationcomprising a compound of Formula 1 is also disclosed. The formulationcan include one or more components selected from the group consisting ofa solvent, a host, a hole injection material, hole transport material,and an electron transport layer material, disclosed herein.

According to another aspect of the present disclosure, a compound havingFormula (1a) shown below is disclosed.

In Formula (1a), A is a linking group having two to three linking atoms,wherein the linking atoms are each independently selected from the groupconsisting of C, Si, O, S, N, B or combinations thereof;

wherein R^(ab), R^(ga), R^(1b) to R^(1f) are each independently selectedfrom the group consisting of hydrogen, deuterium, alkyl, cycloalkyl,heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂,NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclicgroup, and combinations thereof;

wherein each R is independently selected from the group consisting ofhydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aralkyl, aryl, heteroaryl, and combinations thereof; and

wherein any one of the ring atoms to which R^(ab), R^(ga), R^(1b) toR^(1f) are attached may be replaced with a nitrogen atom, wherein whenthe ring atom is replaced with a nitrogen atom the corresponding R groupis not present.

In some embodiments of the compound of Formula la, the linking group Ais independently selected from the group consisting of —CR¹R²—CR³R⁴—,—CR¹R²—CR³R⁴—CR⁵ _(R) ⁶—, —CR¹R²—NR³—, —CR¹═CR²—CR³ _(R) ⁴—, —O—SiR¹R²—,—CR¹R²—S—, —CR¹R²—O—, and —C—SiR¹R²—, wherein each R¹ to R⁶ can be sameor different, and are independently selected from the group consistingof hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, andcombinations thereof; wherein any adjacent R¹ to R⁶ are optionallyconnected to form a saturated five membered ring or a saturated sixmembered ring.

In some embodiments of the compound of Formula (1a), the compound has atriplet excited state and wherein the linking group stabilizes the bondbetween N² and C^(1b) from cleavage when the compound is in the tripletexcited state.

In some embodiments of the compound of Formula (1a), the linking group Ais selected from the Linker Group defined above.

In some embodiments of the compound of Formula (1a), the compound isselected from the group consisting of:

In some embodiments of the compound having Formula (1a), the compoundhas the structure of Formula (2a) and Formula (2b) tethered together asdefined below:

wherein A¹ and A² are each a first linking group having two to threelinking atoms, wherein the linking atoms are each independently selectedfrom the group consisting of C, Si, O, S, N, B and combinations thereof,and

wherein R^(ac), R^(gb), and R^(2b) to R^(2f) are each independentlyselected from the group consisting of hydrogen, deuterium, alkyl,cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl,cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R,C(O)NR₂, NR₂, NO₂, OR, SR, SO₂, SOR, SO₃R, halo, aryl, heteroaryl, aheterocyclic group, and combinations thereof;

wherein the compound is tethered together via at least one secondlinking group formed between R^(ab) and R^(ac) and/or R^(ga) and R^(gb),wherein at least one second linking group has one to three linking atomsand each linking atom is independently selected from the groupconsisting of B, N, P, O, S, Se, C, Si, Ge and combinations thereof; andany one of the ring atoms to which R^(1b) to R^(1f) and R^(2b) to R^(2f)are attached may be replaced with a nitrogen atom, wherein when the ringatom is replaced with a nitrogen atom the corresponding R group is notpresent.

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the at least onesecond linking group is formed between R^(ab) and R^(ac).

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the at least onesecond linking group is formed between R^(ga) and R^(gb).

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the at least onesecond linking group are formed between R^(ga) and R^(gb) and R^(ab) andR^(ac).

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, each of the firstlinking groups A¹ and A² is independently selected from the groupconsisting of —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—, —CR¹R²—NR³—,—CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—, and —C—SiR¹R²—,wherein each R¹ to R⁶ can be same or different, and are independentlyselected from the group consisting of hydrogen, deuterium, alkyl,cycloalkyl, aryl, heteroaryl, and combinations thereof; wherein anyadjacent R¹ to R⁶ are optionally connected to form a saturated fivemembered ring or a saturated six membered ring.

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, each of the firstlinking groups A¹ and A² is independently selected from the Linker Groupdefined above.

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the second linkinggroup is independently selected from the group consisting of BR¹, NR¹,PR¹, O, S, Se, C═O, S═O, SO₂, CR¹R², —CR¹R²—CR³R⁴—, —CR¹R²—CR³R⁴—CR⁵R⁶—,—CR¹R²—NR³—, —CR¹═CR²—CR³R⁴—, —O—SiR¹R²—, —CR¹R²—S—, —CR¹R²—O—,—C—SiR¹R²—, SiR¹R², and GeR¹R², wherein each R¹ to R⁶ can be same ordifferent, and are independently selected from the group consisting ofhydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, andcombinations thereof; wherein any adjacent R¹ to R⁶ are optionallyconnected to form a saturated five membered ring or a saturated sixmembered ring.

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the compound isselected from the group consisting of:

In some embodiments of the compound having the structure of Formula (2a)and Formula (2b) tethered together as defined above, the compound hasFormula (3a):

wherein L² and L³ are each independently selected from the groupconsisting of a single bond, BR¹, NR¹, PR¹, O, S, Se, C═O, S═O, SO₂,CR¹R², SiR¹R², and GeR¹R²;

wherein R^(3a)-R^(3f), are each independently selected from the groupconsisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl,alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aralkyl, CN, CF₃, CO₂R, C(O)R, C(O)NR₂, NR₂, NO₂, OR, SR, SO₂,SOR, SO₃R, halo, aryl, heteroaryl, a heterocyclic group, andcombinations thereof;

wherein each R¹ and R² is independently selected from the groupconsisting of hydrogen, deuterium, halo, alkyl, cycloalkyl, heteroalkyl,alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aralkyl, aryl, heteroaryl, and combinations thereof;

wherein any two adjacent R^(1f), R^(3a), R^(3c), R^(3d), R¹ and R² areoptionally joined to form a ring; wherein L² and R^(1f) , L² and R^(3a),or L² and both R^(1f) and R^(3a) are optionally joined to form one ormore rings; and

wherein L³ and R^(3c), L³ and R^(3d), or L³ and both R^(3c) and R^(3d)are optionally joined to form one or more rings.

In some embodiments of the compound having Formula (3a), L² and L³ areindpendently selected from the group consisting of BR¹, NR¹, PR¹, O, S,Se, C═O, S═O, SO₂, CR¹R², SiR¹R², and GeR¹R².

In some embodiments of the compound having Formula (3a), R^(1f) orR^(3a) and R¹ or R² are joined to form a ring.

In some embodiments of the compound having Formula (3a), R^(3c) orR^(3d) and R¹ or R² are joined to form a ring.

In some embodiments of the compound having Formula (3a), the compound isselected from the group consisting of:

The metal complexes according to various embodiments of the presentinvention can exhibit a number of desirable characteristics. In someembodiments, the metal complexes having the structures of Formula 1,Formula 2, or Formula 3 can exhibit photoluminescence with a highquantum efficiency, with a narrow spectral width, and/or with a peakemission wavelength located within a desirable range of wavelengths,such as the visible range or the near infrared range. Also, thesephotoluminescent characteristics can be relatively invariant over a widerange of excitation wavelengths. In some embodiments, the metalcomplexes of Formula 1, Formula 2, or Formula 3 can have other desirablecharacteristics, such as relating to their band gap energies andelectrical conductivities. Also, advantageously, the metal complexes ofFormula 1, Formula 2, or Formula 3 can be inexpensively and readilysynthesized from commercially available starting materials. In someembodiments, the metal complexes of Formula 1, Formula 2, or Formula 3can exhibit photoluminescence with a relatively low quantum efficiencybut this may still be sufficient for certain applications.

In some embodiments, a metal complex having the structure of Formula 1,Formula 2, or Formula 3 has a peak emissive wavelength less than 500 nm.In some embodiments, a metal complexes having the structure of Formula1, Formula 2, or Formula 3 has a peak emissive wavelength less than 480nm. In some embodiments, a metal complex having the structure of Formula1, Formula 2, or Formula 3 has a peak emissive wavelength of 400 nm to500 nm inclusive.

In some embodiments, metal complexes having the structure of Formula 1,Formula 2, or Formula 3 have a triplet excited state and the linkinggroup A that stabilizes the bond between N² and C^(1b), shown below,from cleavage when the compound is in the triplet excited state.

Accordingly, in some embodiments, the metal complex having the structureof Formula 1, Formula 2, or Formula 3 is a phosphorescent light emittingsubstance. In some embodiments, the metal complex having the structureof Formula 1, Formula 2, or Formula 3 is a fluorescent light emittingsubstance. In some embodiments, the metal complex having the structureof Formula 1, Formula 2, or Formula 3 is both a fluorescent and aphosphorescent light emitting substance.

Metal complexes having the structure of Formula 1, Formula 2, or Formula3 are suitable, for example, for use in OLEDs, which exploit thepropensity of materials to emit light when they are excited by anelectrical current. Accordingly, in some aspects, the present inventionprovides an organic light-emitting material comprising at least onemetal complex having the structure of Formula 1, Formula 2, or Formula3. In some embodiments, the present invention provides an organiclight-emitting material comprising at least two metal complexes selectedfrom compounds having the structure of Formula 1, Formula 2, or Formula3.

Organic light-emitting materials according to various embodiments of theinvention can exhibit a number of desirable characteristics. In someembodiments, the organic light-emitting materials can exhibitphotoluminescence with a high quantum efficiency, with a narrow spectralwidth, and with a peak emission wavelength located within a desirablerange of wavelengths, such as the visible range or the near infraredrange. Also, these photoluminescent characteristics can be relativelyinvariant over a wide range of excitation wavelengths. The organiclight-emitting materials can have other desirable characteristics, suchas relating to their band gap energies and electrical conductivities.Advantageously, the organic light-emitting materials can beinexpensively and readily formed for use in various applications,including consumer products and lighting panels.

In some embodiments, the content of a photoluminescent substance in alight emitting material according to the present invention (e.g., one ormore metal complexes having the structure of Formula 1, Formula 2, orFormula 3) is between 0.1% by mass to 50% by mass inclusive with respectto the total mass of a light emitting layer comprising the lightemitting material. In some embodiments, the content of aphotoluminescent substance in a light emitting material according to thepresent invention is between 0.3% by mass to 40% by mass inclusive withrespect to the total mass of a light emitting layer comprising the lightemitting material. In some embodiments, the content of aphotoluminescent substance in a light emitting material according to thepresent invention is between 0.5% by mass to 30% by mass inclusive withrespect to the total mass of a light emitting layer comprising the lightemitting material. In some embodiments, the photoluminescent substancein a light emitting material according to the present invention isappended to a polymer chain or incorportated in a denrimer material.

IV. Devices

In some aspects, the present invention provides an organicelectroluminescence device which comprises at least one metal complexhaving the structure of Formula 1, Formula 2, or Formula 3. In someembodiments, an organic electroluminescence device according to thepresent invention comprises a first organic light emitting device, whichfurther comprises an anode; a cathode; an organic layer disposed betweenthe anode and the cathode, and comprising at least one metal complexhaving the structure of Formula 1, Formula 2, or Formula 3. In somepreferred embodiments of the organic electroluminescence device, theorganic layer further comprises a host material. In some preferredembodiments of the organic electroluminescence device, the host materialcomprises an organic compound. In some preferred embodiments of theorganic electroluminescence device, the host material comprises anorganic compound having a molecule containing at least one groupselected from the group consisting of carbazole, dibenzothiphene,dibenzofuran, azacarbazole, aza-dibenzothiophene, and aza-dibenzofuran.

Generally, an organic layer suitable for use in the organicelectroluminescence device of the present may have any suitableconfiguration of layer depending, for example, on application andpurpose of the organic electroluminescence device. Accordingly, in someembodiments of the organic electroluminescence device, the organic layeris formed on a transparent electrode or a semitransparent electrode. Insome such embodiments, the organic layer is formed on a top surface orany suitable surface of the transparent electrode or the semitransparentelectrode. Also, suitable shape, size and/or thickness of the organiclayer may be employed depending, for example, on application and thepurpose of the organic electroluminescence device. Specific examples ofconfigurations of an organic electroluminescence device of the presentinvention, having a substrate, a cathode, an anode and an organic layerinclude, but are not limited to, the following:

-   -   (A) Anode/hole transporting layer/light emitting layer/electron        transporting layer/cathode;    -   (B) Anode/hole transporting layer/light emitting layer/block        layer/electron transporting layer/cathode;    -   (C) Anode/hole transporting layer/light emitting layer/block        layer/electron transporting layer/electron injection        layer/cathode;    -   (D) Anode/hole injection layer/hole transporting layer/light        emitting layer/block layer/electron transporting layer/cathode;        and    -   (E) Anode/hole injection layer/hole transporting layer/light        emitting layer/block layer/electron transporting layer/electron        injection layer/cathode.    -   (F) Anode/hole injection layer/electron blocking layer/hole        transporting layer/light emitting layer/block layer/electron        transporting layer/electron injection layer/cathode.

Additional device configuration, including substrate, cathode and anodeof an organic electroluminescence device, is described in JapanesePatent Publication No. 2008-270736.

<Substrate>

A suitable substrate usable in an organic electroluminescence device ofthe present invention is preferably a substrate which does not scatteror decrease light emitted from an organic layer when used for displayapplications. When used for lighting or certain display applications,substrates that scatter light are acceptable. In some embodiments, thesubstrate preferably is composed of an organic material which exhibitssuperior heat resistance, dimensional stability, solvent resistance,electrical insulating property and/or processability.

The substrate suitable for use in the present invention is preferablyone which does not scatter or attenuate light emitted from the organiccompound layer. Specific examples of materials for the substrate,include but are not limited to, inorganic materials such aszirconia-stabilized yttrium (YSZ) and glass; polyesters such aspolyethylene terephthalate, polybutylene phthalate, and polyethylenenaphthalate; and organic materials such as polystyrene, polycarbonate,polyethersulfone, polyarylate, polyimide, polycycloolefin, norborneneresin, polychlorotrifluoroethylene, and the like.

In some embodiments, when glass is used as the substrate, alkali freeglass is preferably used. Specific examples of suitable alkali freeglass are found in US patent application publication no. 2013/0237401 byTakahiro Kawaguchi, which published Sep. 12, 2013. In some embodiments,when soda-lime glass is used as the substrate, it is preferred to useglass on which a barrier coat of silica or the like has been applied. Insome embodiments, when an organic material is used as the substrate, itis preferred to use a material having one or more of the attributes:excellent in heat resistance, dimensional stability, solvent resistance,electric insulation performance, and workability.

Generally, there is no particular limitation as to the shape, thestructure, the size or the like of the substrate, but any of theseattributes may be suitably selected according to the application,purposes and the like of the light-emitting element. n general, aplate-like substrate is preferred as the shape of the substrate. Astructure of the substrate may be a monolayer structure or a laminatestructure. Furthermore, the substrate may be formed from a single memberor two or more members.

Although the substrate may be transparent and colorless, or transparentand colored, it is preferred that the substrate is transparent andcolorless from the viewpoint that the substrate does not scatter orattenuate light emitted from the organic light-emitting layer. In someembodiments, a moisture permeation preventive layer (gas barrier layer)may be provided on the top surface or the bottom surface of thesubstrate. Examples of a material of the moisture permeation preventivelayer (gas barrier layer), include, but are not limited to, inorganicsubstances such as silicon nitride and silicon oxide. The moisturepermeation preventive layer (gas barrier layer) may be formed inaccordance with, for example, a high-frequency sputtering method or thelike.

In the case of applying a thermoplastic substrate, a hard-coat layer oran under-coat layer may be further provided as needed.

<Anode>

Any anode may be used in an organic electroluminescence device of thepresent invention so long as it serves as an electrode supplying holesinto an organic layer. In some embodiments of the organicelectroluminescence device of the present invention, any suitable shape,structure and/or size of known electrode material may be used depending,for example, on the application and purpose of the organicelectroluminescence device. In some embodiments, a transparent anode ispreferred.

The anode may generally be any material as long as it has a function asan electrode for supplying holes to the organic compound layer, andthere is no particular limitation as to the shape, the structure, thesize or the like. However, it may be suitably selected from amongwell-known electrode materials according to the application and purposeof the light-emitting element. In some embodiments, the anode isprovided as a transparent anode.

Materials for the anode preferably include, for example, metals, alloys,metal oxides, electric conductive compounds, and mixtures thereof.Materials having a work function of 4.0 eV or more are preferable.Specific examples of the anode materials include electric conductivemetal oxides such as tin oxides doped with antimony, fluorine or thelike (ATO and FTO), tin oxide, zinc oxide, indium oxide, indium tinoxide (ITO), and indium zinc oxide (IZO); metals such as gold, silver,chromium, aluminum, copper, and nickel; mixtures or laminates of thesemetals and the electric conductive metal oxides; inorganic electricconductive materials such as copper iodide and copper sulfide; organicelectric conductive materials such as polyaniline, polythiophene, andpolypyrrole; and laminates of these inorganic or organicelectron-conductive materials with ITO. Among these, the electricconductive metal oxides are preferred, and particularly, ITO ispreferable in view of productivity, high electric conductivity,transparency and the like.

The anode may be formed on the substrate in accordance with a methodwhich is appropriately selected from among wet methods such as printingmethods, coating methods and the like; physical methods such as vacuumdeposition methods, sputtering methods, ion plating methods and thelike; and chemical methods such as CVD (chemical vapor deposition) andplasma CVD methods and the like, in consideration of the suitability toa material constituting the anode. For instance, when ITO is selected asa material for the anode, the anode may be formed in accordance with aDC or high-frequency sputtering method, a vacuum deposition method, anion plating method or the like.

In the organic electroluminescence element of the present invention, aposition at which the anode is to be formed is not particularly limited,but it may be suitably selected according to the application and purposeof the light-emitting element. The anode may be formed on either thewhole surface or a part of the surface on either side of the substrate.

For patterning to form the anode, a chemical etching method such asphotolithography, a physical etching method such as etching by laser, amethod of vacuum deposition or sputtering through superposing masks, ora lift-off method or a printing method may be applied.

A thickness of the anode may be suitably selected according to thematerial constituting the anode and is therefore not definitely decided,but it is usually in a range of from 10 nm to 50 μm, and preferably from50 nm to 20 μm. The thickness of the anode layer may be properlycontrolled depending on the material used therefor. The resistance ofthe anode is preferably 10³ Ω/square or less, and more preferably 10²Ω/square or less, more preferably 30 Ω/square or less. In the case wherethe anode is transparent, it may be either transparent and colorless, ortransparent and colored. For extracting luminescence from thetransparent anode side, it is preferred that a light transmittance ofthe anode is 60% or higher, and more preferably 70% or higher. Adetailed description of transparent anodes can be found in “TOUMEIDENNKYOKU-MAKU NO SHINTENKAI (Novel Developments in TransparentElectrode Films)” edited by Yutaka Sawada, published by C.M.C. in 1999.

In the case where a plastic substrate having a low heat resistance isused in the present invention, it is preferred that ITO or IZO is usedto obtain a transparent anode prepared by forming the film at a lowtemperature of 150° C. or lower.

<Cathode>

Any cathode may be used in an organic electroluminescence device of thepresent invention so long as it serves as an electrode supplyingelectrons into the organic layer. In some embodiments of the organicelectroluminescence device of the present invention, any suitable shape,structure and/or size of known electrode material may be used depending,for example, on the application and purpose of the organicelectroluminescence device. In some embodiments, a transparent cathodeis preferred.

The cathode may generally be any material as long as it has a functionas an electrode for injecting electrons to the organic compound layer,and there is no particular limitation as to the shape, the structure,the size or the like. However it may be suitably selected from amongwell-known electrode materials according to the application and purposeof the light-emitting element.

Materials constituting the cathode include, for example, metals, alloys,metal oxides, electric conductive compounds, and mixtures thereof.Materials having a work function of 4.0 eV or more are preferable.Specific examples thereof include alkali metals (e.g., Li, Na, K, Cs orthe like), alkaline earth metals (e.g., Mg, Ca or the like), gold,silver, lead, aluminum, sodium-potassium alloys, lithium-aluminumalloys, magnesium-silver alloys, rare earth metals such as indium, andytterbium, and the like. They may be used alone, but it is preferredthat two or more of them are used in combination from the viewpoint ofsatisfying both stability and electron injectability.

In some embodiments, as the materials for constituting the cathode,alkaline metals or alkaline earth metals are preferred in view ofelectron injectability, and materials containing aluminum as a majorcomponent are preferred in view of excellent preservation stability.

The term “material containing aluminum as a major component” refers to amaterial constituted by aluminum alone; alloys comprising aluminum and0.01% by weight to 10% by weight of an alkaline metal or an alkalineearth metal; or mixtures thereof (e.g., lithium-aluminum alloys,magnesium-aluminum alloys and the like). Exemplary materials for thecathode are described in detail in JP-A Nos. 2-15595 and 5-121172.

A method for forming the cathode is not particularly limited, but it maybe formed in accordance with a well-known method. For instance, thecathode may be formed in accordance with a method which is appropriatelyselected from among wet methods such as printing methods, coatingmethods and the like; physical methods such as vacuum depositionmethods, sputtering methods, ion plating methods and the like; andchemical methods such as CVD and plasma CVD methods and the like, inconsideration of the suitability to a material constituting the cathode.For example, when a metal (or metals) is (are) selected as a material(or materials) for the cathode, one or two or more of them may beapplied at the same time or sequentially in accordance with a sputteringmethod or the like.

For patterning to form the cathode, a chemical etching method such asphotolithography, a physical etching method such as etching by laser, amethod of vacuum deposition or sputtering through superposing masks, ora lift-off method or a printing method may be applied.

In the present invention, a position at which the cathode is to beformed is not particularly limited, and it may be formed on either thewhole or a part of the organic compound layer.

Furthermore, a dielectric material layer made of fluorides, oxides orthe like of an alkaline metal or an alkaline earth metal may be insertedbetween the cathode and the organic compound layer with a thickness offrom 0.1 nm to 5 nm. The dielectric material layer may be considered tobe a kind of electron injection layer. The dielectric material layer maybe formed in accordance with, for example, a vacuum deposition method, asputtering method, an ionplating method or the like.

A thickness of the cathode may be suitably selected according tomaterials for constituting the cathode and is therefore not definitelydecided, but it is usually in a range of from 10 nm to 5 μm, andpreferably from 50 nm to 1 μm.

Moreover, the cathode may be transparent or opaque. A transparentcathode may be formed by preparing a material for the cathode with asmall thickness of from 1 nm to 10 nm, and further laminating atransparent electric conductive material such as ITO or IZO thereon.

<Protective Layer>

A whole body of the organic EL element of the present invention may beprotected by a protective layer. Any materials may be applied in theprotective layer as long as the materials have a function to protect apenetration of ingredients such as moisture, oxygen or the like whichaccelerates deterioration of the element into the element. Specificexamples of materials for the protective layer include metals such asIn, Sn, Pb, Au, Cu, Ag, Al, Ti, Ni and the like; metal oxides such asMgO, SiO, SiO₂, Al₂O₃, GeO, NiO, CaO, BaO, Fe₂O₃, Y₂O₃, TiO₂ and thelike; metal nitrides such as SiN_(x), SiN_(x)O_(y) and the like; metalfluorides such as MgF₂, LiF, AlF₃, CaF₂ and the like; polyethylene;polypropylene; polymethyl methacrylate; polyimide; polyurea;polytetrafluoroethylene; polychlorotrifluoroethylene;polydichlorodifluoroethylene; a copolymer of chlorotrifluoroethylene anddichlorodifluoroethylene; copolymers obtained by copolymerizing amonomer mixture containing tetrafluoroethylene and at least onecomonomer; fluorine-containing copolymers each having a cyclic structurein the copolymerization main chain; water-absorbing materials eachhaving a coefficient of water absorption of 1% or more; moisturepermeation preventive substances each having a coefficient of waterabsorption of 0.1% or less; and the like.

There is no particular limitation as to a method for forming theprotective layer. For instance, a vacuum deposition method, a sputteringmethod, a reactive sputtering method, an MBE (molecular beam epitaxial)method, a cluster ion beam method, an ion plating method, a plasmapolymerization method (high-frequency excitation ion plating method), aplasma CVD method, a laser CVD method, a thermal CVD method, a gassource CVD method, a coating method, a printing method, or a transfermethod may be applied.

<Sealing>

The whole organic electroluminescence element of the present inventionmay be sealed with a sealing cap. Furthermore, a moisture absorbent oran inert liquid may be used to seal a space defined between the sealingcap and the light-emitting element. Although the moisture absorbent isnot particularly limited, specific examples thereof include bariumoxide, sodium oxide, potassium oxide, calcium oxide, sodium sulfate,calcium sulfate, magnesium sulfate, phosphorus pentaoxide, calciumchloride, magnesium chloride, copper chloride, cesium fluoride, niobiumfluoride, calcium bromide, vanadium bromide, molecular sieve, zeolite,magnesium oxide and the like. Although the inert liquid is notparticularly limited, specific examples thereof include paraffins;liquid paraffins; fluorine-based solvents such as perfluoroalkanes,perfluoroamines, perfluoroethers and the like; chlorine-based solvents;silicone oils; and the like.

<Driving>

In the organic electroluminescence element of the present invention,when a DC (AC components may be contained as needed) voltage (usually 2volts to 15 volts) or DC is applied across the anode and the cathode,luminescence can be obtained. For the driving method of the organicelectroluminescence element of the present invention, driving methodsdescribed in JP-A Nos. 2-148687, 6-301355, 5-29080, 7-134558, 8-234685,and 8-241047; Japanese Patent No. 2784615, U.S. Pat. Nos. 5,828,429 and6,023,308 are applicable.

<Applications>

Devices fabricated in accordance with embodiments of the inventionsdescribed herein may be incorporated into a wide variety of consumerproducts, including but not limited to flat panel displays, computermonitors, televisions, billboards, lights for interior or exteriorillumination and/or signaling, heads up displays, fully transparentdisplays, flexible displays, laser printers, telephones, cell phones,personal digital assistants (PDAs), laptop computers, digital cameras,camcorders, viewfinders, micro-displays, vehicles, a large area wall,theater or stadium screen, or a sign.

<Organic Layer>

An organic layer suitable for use in an organic electroluminescencedevice of the present invention may comprise a plurality of layers,including, for example, light emitting layer, host material, electriccharge transporting layer, hole injection layer, and hole transportinglayer. Blocking layers may also be included e.g. hole (and or exciton)blocking layers (HBL) or electron (and or exciton) blocking layers(EBL). In some embodiments of an organic electroluminescence device ofthe present invention, each organic layer may be formed by a dry-typefilm formation method such as a deposition method or a sputteringmethod, or a solution coating process such as a transfer method, aprinting method, a spin coating method, or a bar coating method. In someembodiments of an organic electroluminescence device of the presentinvention, at least one layer of the organic layer is preferably formedby a solution coating process.

A. Light Emitting Layer

Light Emitting Material:

A light emitting material in accordance with the present inventionpreferably includes at least one metal complex having the structure ofFormula 1, Formula 2, or Formula 3. Some embodiments of an organicelectroluminescence device of the present invention comprises the lightemitting material in an amount of about 0.1% by mass to about 50% bymass with respect to the total mass of the compound constituting thelight emitting layer. In some embodiments, an organicelectroluminescence device of the present invention comprises the lightemitting material in an amount of about 1% by mass to about 50% by masswith respect to the total mass of the compound constituting the lightemitting layer. In some embodiments, an organic electroluminescencedevice of the present invention comprises the light emitting material inan amount of about 2% by mass to about 40% by mass with respect to thetotal mass of the compound constituting the light emitting layer. Insome embodiments, a total amount of the light-emitting materials in thelight-emitting layer is preferably from about 0.1% by weight to about30% by weight with respect to the entire amount of compounds containedin the light-emitting layer. In some embodiments, a total amount of thelight-emitting materials in the light-emitting layer is preferably fromabout 1% by weight to about 20% by weight in view of durability andexternal quantum efficiency. In some embodiments, a total amount of thehost materials in the light-emitting layer is preferably from about 70%by weight to about 99.9% by weight. In some embodiments, a total amountof the host materials in the light-emitting layer is preferably fromabout 80% by weight to 99% by weight in view of durability and externalquantum efficiency. In some embodiments, graded light emitting layers orgraded interfaces within the light emitting layer may be used. Gradingmay be formed, for example, by mixing two or more distinct materials ina fashion that an abrupt change from one layer to another is not formed.Graded light emitting layers and or interfaces have been shown toimprove device lifetime and this device architecture may be beneficialto improving PHOLED lifetime and general performance. In this instancethe the light emitting material may be present in an amount of about 0%by mass to about 100% by mass at any given position within the lightemitting layer.

In some embodiments, a light-emitting layer in the present invention mayinclude the light-emitting materials and a host material contained inthe light-emitting layer as a combination of a fluorescentlight-emitting material which emits light (fluorescence) through asinglet exciton and a host material, or a combination of aphosphorescent light-emitting material which emits light(phosphorescence) through a triplet exciton and a host material. In someembodiments, a light-emitting layer in the present invention may includethe light-emitting materials and a host material contained in thelight-emitting layer as a combination of a phosphorescent light-emittingmaterial and a host material.

In some embodiments, the first compound can be an emissive dopant. Insome embodiments, the compound can produce emissions viaphosphorescence, fluorescence, thermally activated delayed fluorescence,i.e., TADF (also referred to as E-type delayed fluorescence),triplet-triplet annihilation, or combinations of these processes.

B. Host Material

A suitable host material for use in the present invention, may be a holetransporting host material (sometimes referred to as a hole transportinghost), and/or an electron transporting host material (sometimes referredto as an electron transporting host).

The organic layer can also include a host. In some embodiments, two ormore hosts are preferred. In some embodiments, the hosts used maybe a)bipolar, b) electron transporting, c) hole transporting or d) wide bandgap materials that play little role in charge transport. In someembodiments, the host can include a metal complex. The host can be atriphenylene containing benzo-fused thiophene or benzo-fused furan. Anysubstituent in the host can be an unfused substituent independentlyselected from the group consisting of C_(n)H_(2n+1), OC_(n)H_(2n+1),OAr₁, N(C_(n)H_(2n+1))₂, N(Ar₁)(Ar₂), CH═CH—C_(n)H_(2n+1),C≡C—C_(n)H_(2n+1), Ar₁Ar₁-Ar₂, and C_(n)H_(2n)—Ar₁, or no substitution.In the preceding substituents n can range from 1 to 10; and An and Aracan be independently selected from the group consisting of benzene,biphenyl, naphthalene, triphenylene, carbazole, and heteroaromaticanalogs thereof. In some embodiment, the host can also be an inorganiccompound. For example a Zn containing inorganic material, e.g. ZnS.

The host can be a compound comprising at least one chemical groupselected from the group consisting of triphenylene, carbazole,dibenzothiophene, dibenzofuran, dibenzoselenophene, azatriphenylene,azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, andaza-dibenzoselenophene. The host can include a metal complex. The hostcan be a specific compound selected from the group consisting of:

-   -   and combinations thereof.

Hole Transporting Host Material

Specific examples of the hole transporting host materials include, butare not limited to pyrrole, carbazole, azacarbazole, pyrazole, indole,azaindole, imidazole, polyarylalkane, pyrazoline, pyrazolone,phenylenediamine, arylamine, amino-substituted chalcone,styrylanthracene, fluorenone, hydrazone, stilbene, silazane, aromatictertiary amine compounds, styrylamine compounds, aromatic dimethylidinecompounds, porphyrin compounds, polysilane compounds,poly(N-vinylcarbazole), aniline copolymers, electric conductivehigh-molecular oligomers such as thiophene oligomers, polythiophenes andthe like, organic silanes, carbon films, derivatives thereof, and thelike. Some preferred host materials include carbazole derivatives,indole derivatives, imidazole derivatives, aromatic tertiary aminecompounds, and thiophene derivatives.

Specific examples of the electron transporting host materials include,but are not limited to pyridine, pyrimidine, triazine, imidazole,pyrazole, triazole, oxazole, oxadiazole, fluorenone,anthraquinonedimethane, anthrone, diphenylquinone, thiopyrandioxide,carbodiimide, fluorenylidenemethane, di styrylpyrazine,fluorine-substituted aromatic compounds, aromacyclic tetracarboxylicanhydrides of naphthalene, perylene or the like, phthalocyanine,derivatives thereof , including a variety of metal complexes representedby metal complexes of 8-quinolinol derivatives, metal phthalocyanine,and metal complexes having benzoxazole or benzothiazole as the ligand.

Preferable electron transporting hosts are metal complexes, azolederivatives (benzimidazole derivatives, imidazopyridine derivatives andthe like), and azine derivatives (pyridine derivatives, pyrimidinederivatives, triazine derivatives and the like).

C. Film Thickness

In some embodiments, the film thickness of the light-emitting layer ispreferably from about 10 nm to about 500 nm. In some embodiments, thefilm thickness of the light-emitting layer is preferably from about 20nm to about 100 nm depending, for example, on desired brightnessuniformity, driving voltage and brightness. In some embodiments, thelight-emitting layer is configured to have a thickness that optimizespassage of charges from the light-emitting layer to adjacent layerswithout lowering light-emission efficiency. In some embodiments, thelight-emitting layer is configured to have a thickness that maintainsminimum driving voltage maximum light-emission efficiency.

D. Layer Configuration

The light-emitting layer may be composed of a single layer or two ormore layers, and the respective layers may cause light emission indifferent light-emitting colors. Also, in the case where thelight-emitting layer has a laminate structure, though the film thicknessof each of the layers configuring the laminate structure is notparticularly limited, it is preferable that a total film thickness ofeach of the light-emitting layers falls within the foregoing range. Insome embodiments, graded layers or graded interfaces within the layersmay be used.

E. Hole Injection Layer and Hole Transport Layer

The hole injection layer and hole transport layer are layers functioningto receive holes from an anode or from an anode side and to transportthe holes to the emitting layer. Materials to be introduced into a holeinjection layer or a hole transport layer is not particularly limited,but either of a low molecular compound or a high molecular compound maybe used.

Specific examples of the material contained in the hole injection layerand the hole transport layer include, but are not limited to, pyrrolederivatives, carbazole derivatives, azacarbazole derivatives, indolederivatives, azaindole derivatives, imidazole derivatives,polyarylalkane derivatives, pyrazoline derivatives, pyrazolonederivatives, phenylenediamine derivatives, arylamine derivatives,amino-substituted chalcone derivatives, styrylanthracene derivatives,fluorenone derivatives, hydrazone derivatives, stilbene derivatives,silazane derivatives, aromatic tertiary amine compounds, styrylaminecompounds, aromatic dimethylidine compounds, phthalocyanine compounds,porphyrin compounds, organosilane derivatives, carbon, and the like.

An electron-accepting dopant may be introduced into the hole injectionlayer or the hole transport layer in the organic EL element of thepresent invention. As the electron-accepting dopant to be introducedinto the hole injection layer or the hole transport layer, either of aninorganic compound or an organic compound may be used as long as thecompound has electron accepting property and a function for oxidizing anorganic compound.

Specifically, the inorganic compound includes metal halides such asferric chloride, aluminum chloride, gallium chloride, indium chloride,antimony pentachloride and the like, and metal oxides such as vanadiumpentaoxide, molybdenum trioxide and the like.

In case of employing the organic compounds, compounds having asubstituent such as a nitro group, a halogen, a cyano group, atrifluoromethyl group or the like; quinone compounds; acid anhydridecompounds; fullerenes; and the like may be preferably applied.

Specific examples hole injection and hole transport materials includecompounds described in patent documents such as JP-A Nos. 6-212153,11-111463, 11-251067, 2000-196140, 2000-286054, 2000-315580,2001-102175, 2001-160493, 2002-252085, 2002-56985, 2003-157981,2003-217862, 2003-229278, 2004-342614, 2005-72012, 2005-166637,2005-209643 and the like.

Specific examples of hole injection and hole transport materials includethe organic compounds: hexacyanobutadiene, hexacyanobenzene,tetracyanoethylene, tetracyanoquinodimethane,tetrafluorotetracyanoquinodimethane, p-fluoranil, p-chloranil,p-bromanil, p-benzoquinone, 2,6-dichlorobenzoquinone,2,5-dichlorobenzoquinone, 1,2,4,5-tetracyanobenzene,n1,4-dicyanotetrafluorobenzene, 2,3-dichloro-5,6-dicyanobenzoquinone,p-dinitrobenzene, m-dinitrobenzene, o-dinitrobenzene,1,4-naphthoquinone, 2,3-dichloronaphthoquinone, 1,3-dinitronaphthalene,1,5-dinitronaphthalene, 9,10-anthraquinone, 1,3,6,8-tetranitrocarbazole,2,4,7-trinitro-9-fluorenone, 2,3,5,6-tetracyanopyridine and fullereneC60. Among these, hexacyanobutadiene, hexacyanobenzene,tetracyanoethylene, tetracyanoquinodimethane,tetrafluorotetracyanoquinodimethane, p-fluoranil, p-chloranil,p-bromanil, 2,6-dichlorobenzoquinone, 2,5-dichlorobenzoquinone,2,3-dichloronaphthoquinone, 1,2,4,5-tetracyanobenzene,2,3-dichloro-5,6-dicyanobenzoquinone and 2,3,5,6-tetracyanopyridine aremore preferable, and tetrafluorotetracyanoquinodimethane.

As one or more electron-accepting dopants may be introduced into thehole injection layer or the hole transport layer in the organic ELelement of the present invention, these electron-accepting dopants maybe used alone or in combinations of two or more. Although precise amountof these electron-accepting dopants used will depend on the type ofmaterial, about 0.01% by weight to about 50% by weight of the totalweight of the hole transport layer or the hole injection layer ispreferred. In some embodiments, the amount of these electron-acceptingdopants range from about 0.05% by weight to about 20% by weight of thetotal weight of the hole transport layer or the hole injection layer. Insome embodiments, the amount of these electron-accepting dopants rangefrom about 0.1% by weight to about 10% by weight of the total weight ofthe hole transport layer or the hole injection layer.

In some embodiments, a thickness of the hole injection layer and athickness of the hole transport layer are each preferably about 500 nmor less in view of decreasing driving voltage or optimizing for opticaloutcoupling. In some embodiments, the thickness of the hole transportlayer is preferably from about 1 nm to about 500 nm. In someembodiments, the thickness of the hole transport layer is preferablyfrom about 5 nm to about 50 nm. In some embodiments, the thickness ofthe hole transport layer is preferably from about 10 nm to about 40 nm.In some embodiments, the thickness of the hole injection layer ispreferably from about 0.1 nm to about 500 nm. In some embodiments, thethickness of the hole injection layer is preferably from about 0.5 nm toabout 300 nm. In some embodiments, the thickness of the hole injectionlayer is preferably from about 1 nm to about 200 nm.

The hole injection layer and the hole transport layer may be composed ofa monolayer structure comprising one or two or more of theabove-mentioned materials, or a multilayer structure composed of plurallayers of a homogeneous composition or a heterogeneous composition.

F. Electron Injection Layer and Electron Transport Layer

The electron injection layer and the electron transport layer are layershaving functions for receiving electrons from a cathode or a cathodeside, and transporting electrons to the light emitting layer. Anelectron injection material or an electron transporting material usedfor these layers may be a low molecular compound or a high molecularcompound. Specific examples of the materials suitable for use inelectron injection and electron transport layers include, but are notlimited to, pyridine derivatives, quinoline derivatives, pyrimidinederivatives, pyrazine derivatives, phthalazine derivatives,phenanthroline derivatives, triazine derivatives, triazole derivatives,oxazole derivatives, oxadiazole derivatives, imidazole derivatives,fluorenone derivatives, anthraquinodimethane derivatives, anthronederivatives, diphenylquinone derivatives, thiopyrandioxide derivatives,carbodiimide derivatives, fluorenylidenemethane derivatives,distyrylpyrazine derivatives, aromacyclic tetracarboxylic anhydrides ofperylene, naphthalene or the like, phthalocyanine derivatives, metalcomplexes represented by metal complexes of 8-quinolinol derivatives,metal phthalocyanine, and metal complexes containing benzoxazole, orbenzothiazole as the ligand, organic silane derivatives exemplified bysilole, and the like.

The electron injection layer or the electron transport layer may containan electron donating dopant. Suitable electron donating dopant for usein the electron injection layer or the electron transport layer, includeany suitable material that may be used as long as it has anelectron-donating property and a property for reducing an organiccompound. Specific examples of electron donating dopants include analkaline metal such as Li, an alkaline earth metal such as Mg, atransition metal including a rare-earth metal, and a reducing organiccompound. Other examples of metal donating dopants include, metalshaving a work function of 4.2 V or less, for example, Li, Na, K, Be, Mg,Ca, Sr, Ba, Y, Cs, La, Sm, Gd, Yb, and the like. Specific examples ofthe reducing organic compounds include nitrogen-containing compounds,sulfur-containing compounds, phosphorus-containing compounds, and thelike.

The electron donating dopants may be used alone or in combinations oftwo or more. In some embodiments, an electron donating dopant iscontained in the electron injection layer or the electron transportlayer in an amount ranging from about 0.1% by weight to about 99% byweight of the total weight of the electron transport layer material orthe electron injecting layer mater. In some embodiments, an electrondonating dopant is contained in the electron injection layer or theelectron transport layer in an amount ranging from about 1.0% by weightto about 80% by weight of the total weight of the electron transportlayer material or the electron injecting layer material. In someembodiments, an electron donating dopant is contained in the electroninjection layer or the electron transport layer in an amount rangingfrom about 2.0% by weight to about 70% by weight of the total weight ofthe electron transport layer material or the electron injecting layermaterial.

A thickness of the electron injection layer and a thickness of theelectron transport layer are each preferably 500 nm or less in view ofdecrease in driving voltage. The thickness of the electron transportlayer is preferably from 1 nm to 500 nm, more preferably from 5 nm to200 nm, and even more preferably from 10 nm to 100 nm. A thickness ofthe electron injection layer is preferably from 0.1 nm to 200 nm, morepreferably from 0.2 nm to 100 nm, and even more preferably from 0.5 nmto 50 nm.

The electron injection layer and the electron-transport may be composedof a monolayer structure comprising one or two or more of theabove-mentioned materials, or a multilayer structure composed of plurallayers of a homogeneous composition or a heterogeneous composition.

Combination with Other Materials

The materials described herein as useful for a particular layer in anorganic light emitting device may be used in combination with a widevariety of other materials present in the device. For example, emissivedopants disclosed herein may be used in conjunction with a wide varietyof hosts, transport layers, blocking layers, injection layers,electrodes and other layers that may be present. The materials describedor referred to below are non-limiting examples of materials that may beuseful in combination with the compounds disclosed herein, and one ofskill in the art can readily consult the literature to identify othermaterials that may be useful in combination.

HIL/HTL:

A hole injecting/transporting material to be used in the presentinvention is not particularly limited, and any compound may be used aslong as the compound is typically used as a hole injecting/transportingmaterial. Examples of the material include, but are not limited to: aphthalocyanine or porphyrin derivative; an aromatic amine derivative; anindolocarbazole derivative; a polymer containing fluorohydrocarbon; apolymer with conductivity dopants; a conducting polymer, such asPEDOT/PSS; a self-assembly monomer derived from compounds such asphosphonic acid and silane derivatives; a metal oxide derivative, suchas MoO_(x); a p-type semiconducting organic compound, such as1,4,5,8,9,12-Hexaazatriphenylenehexacarbonitrile; a metal complex, and across-linkable compound.

Examples of aromatic amine derivatives used in HIL or HTL include, butare not limited to the following general structures:

Each of Ar¹ to Ar⁹ is selected from the group consisting of aromatichydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl,triphenylene, naphthalene, anthracene, phenalene, phenanthrene,fluorene, pyrene, chrysene, perylene, and azulene; the group consistingof aromatic heterocyclic compounds such as dibenzothiophene,dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran,benzothiophene, benzoselenophene, carbazole, indolocarbazole,pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole,oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole,pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine,oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine,benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline,cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine,pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine,benzofuropyridine, furodipyridine, benzothienopyridine,thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine;and the group consisting of 2 to 10 cyclic structural units which aregroups of the same type or different types selected from the aromatichydrocarbon cyclic group and the aromatic heterocyclic group and arebonded to each other directly or via at least one of oxygen atom,nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom,chain structural unit and the aliphatic cyclic group. Wherein each Ar isfurther substituted by a substituent selected from the group consistingof hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl,arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylicacids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl,phosphino, and combinations thereof.

In one aspect, Ar¹ to Ar⁹ is independently selected from the groupconsisting of:

wherein k is an integer from 1 to 20; X¹⁰¹ to X¹⁰⁸ is C (including CH)or N; Z¹⁰¹ is NAr¹, O, or S; Ar¹ has the same group defined above.

Examples of metal complexes used in HIL or HTL include, but are notlimited to the following general formula:

wherein Met is a metal, which can have an atomic weight greater than 40;(Y¹⁰¹-Y¹⁰²) is a bidentate ligand, Y¹⁰¹ and Y¹⁰² are independentlyselected from C, N, O, P, and S; L¹⁰¹ is an ancillary ligand; k′ is aninteger value from 1 to the maximum number of ligands that may beattached to the metal; and k′+k″ is the maximum number of ligands thatmay be attached to the metal.

In one aspect, (Y¹⁰¹-Y¹⁰²) is a 2-phenylpyridine derivative. In anotheraspect, (Y¹⁰¹-Y^(l02)) is a carbene ligand. In another aspect, Met isselected from Ir, Pt, Os, and Zn. In a further aspect, the metal complexhas a smallest oxidation potential in solution vs. Fc⁺/Fc couple lessthan about 0.6 V.

EBL:

An electron blocking layer (EBL) may be used to reduce the number ofelectrons and/or excitons that leave the emissive layer. The presence ofsuch a blocking layer in a device may result in substantially higherefficiencies, and or longer lifetime, as compared to a similar devicelacking a blocking layer. Also, a blocking layer may be used to confineemission to a desired region of an OLED. In some embodiments, the EBLmaterial has a higher LUMO (closer to the vacuum level) and or highertriplet energy than the emitter closest to the EBL interface. In someembodiments, the EBL material has a higher LUMO (closer to the vacuumlevel) and or higher triplet energy than one or more of the hostsclosest to the EBL interface. In one aspect, compound used in EBLcontains the same molecule or the same functional groups used as one ofthe hosts described below.

Host:

The light emitting layer of the organic EL device of the presentinvention preferably contains at least a metal complex as light emittingmaterial, and may contain a host material using the metal complex as adopant material. In some embodiments, two or more hosts are preferred.In some embodiments, the hosts used maybe a) bipolar, b) electrontransporting, c) hole transporting or d) wide band gap materials thatplay little role in charge transport. Examples of the host material arenot particularly limited, and any metal complexes or organic compoundsmay be used as long as the triplet energy of the host is larger thanthat of the dopant. While the Table below categorizes host materials aspreferred for devices that emit various colors, any host material may beused with any dopant so long as the triplet criteria is satisfied.

Examples of metal complexes used as host are preferred to have thefollowing general formula:

wherein Met is a metal; (Y¹⁰³-Y¹⁰⁴) is a bidentate ligand, Y¹⁰³ and Y¹⁰⁴are independently selected from C, N, O, P, and S; L¹⁰¹ is an anotherligand; k′ is an integer value from 1 to the maximum number of ligandsthat may be attached to the metal; and k′+k″ is the maximum number ofligands that may be attached to the metal.

In one aspect, the metal complexes are:

wherein (O—N) is a bidentate ligand, having metal coordinated to atoms Oand N.

In another aspect, Met is selected from Ir and Pt. In a further aspect,(Y¹⁰³-Y¹⁰⁴) is a carbene ligand.

Examples of organic compounds used as host are selected from the groupconsisting of aromatic hydrocarbon cyclic compounds such as benzene,biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene,phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; thegroup consisting of aromatic heterocyclic compounds such asdibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene,benzofuran, benzothiophene, benzoselenophene, carbazole,indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole,triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole,thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine,oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole,indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline,isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine,phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine,phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine,thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine;and the group consisting of 2 to 10 cyclic structural units which aregroups of the same type or different types selected from the aromatichydrocarbon cyclic group and the aromatic heterocyclic group and arebonded to each other directly or via at least one of oxygen atom,nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom,chain structural unit and the aliphatic cyclic group. Wherein each groupis further substituted by a substituent selected from the groupconsisting of hydrogen, deuterium, halide, alkyl, cycloalkyl,heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl,cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl,carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl,sulfonyl, phosphino, and combinations thereof.

In one aspect, the host compound contains at least one of the followinggroups in the molecule:

wherein R¹⁰¹ to R¹⁰⁷ is independently selected from the group consistingof hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl,arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylicacids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl,phosphino, and combinations thereof, when it is aryl or heteroaryl, ithas the similar definition as Ar's mentioned above. k is an integer from0 to 20 or 1 to 20; k′″ is an integer from 0 to 20. X¹⁰¹ to X¹⁰⁸ isselected from C (including CH) or N.

-   Z¹⁰¹ and Z¹⁰² is selected from NR¹⁰¹, O, or S.    HBL:

A hole blocking layer (HBL) may be used to reduce the number of holesand/or excitons that leave the emissive layer. The presence of such ablocking layer in a device may result in substantially higherefficiencies and/or longer lifetime as compared to a similar devicelacking a blocking layer. Also, a blocking layer may be used to confineemission to a desired region of an OLED. In some embodiments, the HBLmaterial has a lower HOMO and or higher triplet energy than the emitterclosest to the HBL interface.

In one aspect, compound used in HBL contains the same molecule or thesame functional groups used as host described above.

In another aspect, compound used in HBL contains at least one of thefollowing groups in the molecule:

wherein k is an integer from 1 to 20; L¹⁰¹ is an another ligand, k′ isan integer from 1 to 3.ETL:

Electron transport layer (ETL) may include a material capable oftransporting electrons. Electron transport layer may be intrinsic(undoped), or doped. Doping may be used to enhance conductivity.Examples of the ETL material are not particularly limited, and any metalcomplexes or organic compounds may be used as long as they are typicallyused to transport electrons.

In one aspect, compound used in ETL contains at least one of thefollowing groups in the molecule:

wherein R¹⁰¹ is selected from the group consisting of hydrogen,deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy,aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl,aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile,isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinationsthereof, when it is aryl or heteroaryl, it has the similar definition asAr's mentioned above. Ar¹ to Ar³ has the similar definition as Ar'smentioned above. k is an integer from 1 to 20. X¹⁰¹ to X¹⁰⁸ is selectedfrom C (including CH) or N.

In another aspect, the metal complexes used in ETLinclude, but are notlimited to the following general formula:

wherein (O—N) or (N—N) is a bidentate ligand, having metal coordinatedto atoms O, N or N, N; L¹⁰¹ is another ligand; k′ is an integer valuefrom 1 to the maximum number of ligands that may be attached to themetal.Charge Generation Layer (CGL):

In tandem or stacked OLEDs, the CGL plays an essential role in theperformance, which is composed of an n-doped layer and a p-doped layerfor injection of electrons and holes, respectively. Electrons and holesare supplied from the CGL and electrodes. The consumed electrons andholes in the CGL are refilled by the electrons and holes injected fromthe cathode and anode, respectively; then, the bipolar currents reach asteady state gradually. Typical CGL materials include n and pconductivity dopants used in the transport layers.

In any above-mentioned compounds used in each layer of the OLED device,the hydrogen atoms can be partially or fully deuterated. Thus, anyspecifically listed substituent, such as, without limitation, methyl,phenyl, pyridyl, etc. encompasses undeuterated, partially deuterated,and fully deuterated versions thereof. Similarly, classes ofsubstituents such as, without limitation, alkyl, aryl, cycloalkyl,heteroaryl, etc. also encompass undeuterated, partially deuterated, andfully deuterated versions thereof.

In addition to and/or in combination with the materials disclosedherein, many hole injection materials, hole transporting materials, hostmaterials, dopant materials, exciton/hole blocking layer materials,electron transporting and electron injecting materials may be used in anOLED. Non-limiting examples of the materials that may be used in an OLEDin combination with materials disclosed herein are listed in Table Abelow. Table A lists non-limiting classes of materials, non-limitingexamples of compounds for each class, and references that disclose thematerials.

TABLE A MATE- PUBLI- RIAL EXAMPLES OF MATERIAL CATIONS Hole injectionmaterials Phtha- locya- nine and por- phy- rin com- pounds

Appl. Phys. Lett. 69, 2160 (1996) Star- burst tri- aryl- amines

J. Lumin 72-74, 985 (1997) CF_(x) —[CH_(x)F_(y)]_(n)— Appl. Phys.Fluoro- Lett. 78, hydro- 673 (2001) carbon poly- mer Con- duct- ingpoly- mers (e.g., PE- DOT: PSS, poly- aniline

Synth. Met. 87, 171 (1997) WO2007002683 poly- thio- phene) Phos- phonicacid and silane SAMs

US20030162053 Tri- aryl- amine or poly- thio- phene poly- mers with con-duc- tivity do- pants

EP1725079A1

Or- ganic com- pounds with con- duc- tive inor- ganic com-

US20050123751 SID Symposium Digest, 37, 923 (2006) WO2009018009 pounds,such as molyb- denum and tung- sten oxides n-type semi- con- duct- ingor- ganic com- plexes

US20020158242 Metal or- gano- metal- lic com- plexes

US20060240279 Cross- link- able com- pounds

US20080220265 Poly- thio- phene based poly- mers and co- poly- mers

WO 2011075644 EP2350216 Hole transporting materials Tri- aryl- amines(e.g., TPD, α-NPD)

Appl. Phys. Lett. 51, 913 (1987)

US5061569

EP650955

J. Mater. Chem. 3, 319 (1993)

Appl. Phys. Lett. 90, 183503 (2007)

Appl. Phys. Lett. 90, 183503 (2007) Tri- aryl- amine on spiro- fluor-ene core

Synth. Met. 91, 209 (1997) Aryl- amine carba- zole com- pounds

Adv. Mater. 6, 677 (1994), US20080124572 Tri- aryl- amine with (di)-benzo- thio- phene/ (di)- benzo- furan

US20070278938, US20080106190 US20110163302 Indolo- carba- zoles

Synth. Met. 111, 421 (2000) Iso- indole com- pounds

Chem. Mater. 15, 3148 (2003) Metal car- bene com- plexes

US20080018221 Phosphorescent OLED host materials Red hosts Aryl- carba-zoles

Appl. Phys. Lett. 78, 1622 (2001) Metal 8- hy- droxy- quino- lates(e.g., Alq₃, BAlq)

Nature 395, 151 (1998)

US20060202194

WO2005014551

WO2006072002 Metal phen- oxy- benzo- thia- zole com- pounds

Appl. Phys. Lett. 90, 123509 (2007) Con- ju- gated oligo- mers and poly-mers

Org. Electron 1, 15 (2000) (e.g., ploy- fluor- ene) Aro- matic fusedrings

WO2009066779, WO2009066778, WO2009063833, US20090045731, US20090045730,WO2009008311, US20090008605, US20090009065 Zinc com- plexes

WO2010056066 Chry- sene based com- pounds

WO2011086863 Green hosts Aryl- carba- zoles

Appl. Phys. Lett 78, 1622 (2001)

US20030175553

WO2001039234 Aryl- tri- phenyl- ene com- pounds

US20060280965

US20060280965

WO2009021126 Poly- fused hetero- aryl com- pounds

US20090309488 US20090302743 US20100012931 Donor ac- ceptor type mole-cules

WO2008056746

WO2010107244 Aza- carba- zole/ DBT/ DBF

JP2008074939

US20100187984 Poly- mers (e.g., PVK)

Appl. Phys. Lett 77, 2280 (2000) Spiro- fluor- ene com- pounds

WO2004093207 Metal phen- oxy- benzo- oxazole com- pounds

WO2005089025

WO2006132173

JP200511610 Spiro- fluor- ene- carba- zole com- pounds

JP2007254297

JP2007254297 Indolo- carba- zoles

WO2007063796

WO2007063754 5- member ring elec- tron defi- cient hetero- cycles (e.g.,

J. Appl. Phys. 902, 5048 (2001) triazole, oxa- diazole)

WO2004107822 Tetra- phenyl- ene com- plexes

US20050112407 Metal phen- oxy- pyridine com- pounds

WO2005030900 Metal coor- dina- tion com- plexes (e.g., Zn, Al withN{circumflex over ( )}N li- gands)

US20040137268, US20040137267 Blue hosts Aryl- carba- zoles

Appl. Phys. Lett 82, 2422 (2003)

US20070190359 Di- benzo- thio- phene/ Di- benzo- furan- carba- zole com-pounds

WO2006114966, US20090167162

US20090167162

WO2009086028

US20090030202, US20090017330

US20100084966 Sili- con aryl com- pounds

US20050238919

WO2009003898 Sili- con/ Ger- man- ium aryl com- pounds

EP2034538A Aryl benz- oyl ester

WO2006100298 Carba- zole linked by non- con- ju- gated groups

US20040115476 Aza- carba- zoles

US20060121308 High- trip- let metal or- gano- metal- lic com- plex

US7154114 Phosphorescent dopants Red dopants Heavy metal por- phy- rins(e.g., PtOEP)

Nature 395, 151 (1998) Iri- dium (III) or- gano- metal- lic com- plexes

Appl. Phys. Lett 78, 1622 (2001)

US20030072964

US20030072964

US20060202194

US20060202194

US20070087321

US20080261076 US20100090591

US20070087321

Adv. Mater. 19, 739 (2007)

WO2009100991

WO2008101842

US7232618 Plati- num (II) or- gano- metal- lic com- plexes

WO2003040257

US20070103060 Os- mium (III) com- plexes

Chem. Mater. 17, 3532 (2005) Ruth- enium (II) com- plexes

Adv. Mater. 17, 1059 (2005) Rhe- nium (I), (II), and (III) com- plexes

US20050244673 Green dopants Iri- dium (III) or- gano- metal- lic com-plexes

Inorg. Chem. 40, 1704 (2001)

US200202234656

US7332232

US20090108737

WO2010028151

EP1841834B

US20060127696

US20090039776

US6921915

US20100244004

US6687266

Chem. Mater. 16, 2480 (2004)

US20070190359

US 20060008670 JP2007123392

WO2010086089, WO2011044988

Adv. Mater. 16, 2003 (2004)

Angew. Chem. Int. Ed. 2006, 45, 7800

WO2009050290

US20090165846

US20080015355

US20010015432

US20100295032 Mono- mer for poly- meric metal or- gano- metal- lic com-pounds

US7250226, US7396598 Pt(II) or- gano- metal- lic com- plexes, in- clud-ing poly- den- tate li- gands

Appl. Phys. Lett 86, 153505 (2005)

Appl. Phys. Lett 86, 153505 (2005)

Chem. Lett. 34, 592 (2005)

WO2002015645

US20060263635

US20060182992 US20070103060 Cu com- plexes

WO2009000673

US20070111026 Gold com- plexes

Chem. Commun. 2906 (2005) Rhe- nium (III) com- plexes

Inorg. Chem. 42, 1248 (2003) Os- mium (II) com- plexes

US7279704 Deu- terated or- gano- metal- lic com- plexes

US20030138657 Or- gano- metal- lic com- plexes with two or more metalcenters

US20030152802

US7090928 Blue dopants Iri- dium (III) or- gano- metal- lic com- plexes

WO2002002714

WO2006009024

US20060251923 US20110057559 US20110204333

US7393599, WO2006056418, US20050260441, WO2005019373

US7534505

WO2011051404

US7445855

US20070190359, US20080297033 US20100148663

US7338722

US20020134984

Angew. Chem. Int. Ed. 47, 4542 (2008)

Chem. Mater. 18, 5119 (2006)

Inorg. Chem. 46, 4308 (2007)

WO2005123873

WO2005123873

WO2007004380

WO2006082742 Os- mium (II) com- plexes

US7279704

Organo- metallics 23, 3745 (2004) Gold com- plexes

Appl. Phys. Lett. 74, 1361, (1999) Plati- num (II) com- plexes

WO2006098120, WO2006103874 Pt tetra- den- tate com- plexes with at leastone metal- car- bene bond

US7655323 Exciton/hole blocking layer materials Batho- cu- proine com-pounds (e.g., BCP, BPhen)

Appl. Phys. Lett. 75, 4 (1999)

Appl. Phys. Lett. 79, 449 (2001) Metal 8- hy- droxy- quino- lates (e.g.,BAlq)

Appl. Phys. Lett. 81, 162 (2002) 5- mem- ber ring elec- tron defi- cienthetero- cycles such as tri- azole, oxa- diazole, imi- dazole, benzo-imida- zole

Appl. Phys. Lett. 81, 162 (2002) Tri- phenyl- ene com- pounds

US20050025993 Fluori- nated aro- matic com- pounds

Appl. Phys. Lett. 79, 156 (2001) Pheno- thia- zine-S- oxide

WO2008132085 Silyl- ated five- mem- bered nitro- gen, oxy- gen, sulfuror phos-

WO2010079051 phorus di- benzo- hetero- cycles Aza- carba- zoles

US20060121308 Electron transporting materials An- thra- cene- benzo-imida- zole com- pounds

WO2003060956

US20090179554 Aza tri- phenyl- ene deri- vatives

US20090115316 An- thra- cene- benzo- thia- zole com- pounds

Appl. Phys. Lett. 89, 063504 (2006) Metal 8- hy- droxy- quino- lates(e.g., Alq₃,

Appl. Phys. Lett. 51, 913 (1987) US7230107 Zrq₄) Metal hy- droxy- benzo-quino- lates

Chem. Lett. 5, 905 (1993) Batho- cu- proine com- pounds such as BCP,BPhen, etc

Appl. Phys. Lett. 91, 263503 (2007)

Appl. Phys. Lett. 79, 449 (2001) 5-mem- ber ring elec- tron defi- cienthetero- cylcles (e.g., tri- azole, oxa- diazole, imi- dazole, benzo-imida- zole)

Appl. Phys. Lett. 74, 865 (1999)

Appl. Phys. Lett. 55, 1489 (1989)

Jpn. J. Apply. Phys. 32, L917 (1993) Silole com- pounds

Org. Electron. 4, 113 (2003) Aryl- borane com- pounds

J. Am. Chem. Soc. 120, 9714 (1998) Fluori- nated aro- matic com- pounds

J. Am. Chem. Soc. 122, 1832 (2000) Fuller- ene (e.g., C₆₀)

US20090101870 Tria- zine com- plexes

US20040036077 Zn (N{circumflex over ( )}N) com- plexes

US6528187

The invention is explained in greater detail by the following examples,without wishing to restrict it thereby. The person skilled in the artwill be able to produce further electronic devices on the basis of thedescriptions without inventive step and will thus be able to carry outthe invention throughout the range claimed.

EXAMPLES

The following syntheses are carried out, unless indicated otherwise, indried solvents under a protective-gas atmosphere. The metal complexesare additionally handled with exclusion of light. The solvents andreagents can be purchased, for example, from Sigma-ALDRICH or ABCR.

Example 1 Synthesis of3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine was prepared inaccordance with Scheme 1

A. Synthesis of 4-chlorobutanal

A solution of oxalyl chloride (22.54 ml, 263 mmol) in DCM (400 ml) wascooled in an ^(i)PrOH/CO₂ bath. DMSO (37.3 ml, 525 mmol) was slowly viasyringe and stirred cold for 1 hour. A solution of 4-chlorobutan-1-ol(19 g, 175 mmol) in 50 mL DCM was added dropwise. The col mixture wasstirred for one hour, then, triethylamine (110 ml, 788 mmol) was slowlyadded. The suspension was stirred cold for 30 minutes, then allowed towarm to room temperature. The reaction was quenched with water,acidified and organics separated. Solvent removal followed bydistillation yielded the product as a colorless oil, 8 g.

B. Synthesis of 2-bromo-4-chlorobutanal

4-chlorobutanal (7.939 g, 74.5 mmol) was dissolved in DCM (300 ml) andcooled in an ice bath. A solution of dibromine (4.00 ml, 78 mmol) in DCM(50 ml) was added over about 1 hr. After addition the red solution wasstirred cold for 30 minutes, then warmed slowly to room temperature andstirred one more hour. Water was added, the organics were separated, anddrying and solvent removal yielded the crude product as a pale yellowoil, 1.57 g (80%).

C. Synthesis of 4-bromophenanthridin-6-amine

2,6-dibromoaniline (15.33 g, 61.1 mmol),2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (7.0 g, 30.6mmol), and potassium phosphate monohydrate (21.11 g, 92 mmol) werecombined in dioxane (120 ml) and water (7.49 ml). The mixture wasdegassed, then added (dppf)PdCl₂ complex with DCM (0.749 g, 0.917 mmol)was added and the mixture was refluxed for 4 hours. The black mixturewas partitioned between EtOAc and water/brine. The organic layer waswashed with brine, dried, and solvent was removed. Dissolution in 500 mLEtOAc followed by elution through a silica plug using EtOAc and solventremoval yielded an orange residue that was purified by columnchromatography to yield the product as a yellow/orange solid, 5.86 g,70%.

D. Synthesis of 5-bromo-3-(2-chloroethyl)imidazo[1,2-f]phenanthridine

4-bromophenanthridin-6-amine (5.86, 21.46 mmol), 2-bromo-4-chlorobutanal(5.36 g, 28.9 mmol), and sodium bicarbonate (3.60 g, 42.9 mmol) werecombined in 2-propanol (102 ml) and water (5.11 ml). The suspension wasstirred at room temperature for 4 hours, then at reflux for 16 hours.Solvent was removed under vacuum and the residue coated on celite.Column chromatography yielded a mixture of the product and startingamidine, which was treated with excess acetyl chloride and triethylaminein DCM. After workup the desired product was extracted from theacetamide by repeated extraction into heptanes, yielding 3.93 g ofyellow, tacky residue (51%).

E. Synthesis of 3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

5-bromo-3-((2-chloroethyl)imidazo[1,2-f]phenanthridine (3.93 g, 10.93mmol) was dissolved in THF (200 ml), cooled in an ice bath, andisopropylmagnesium chloride solution in THF (2.0M, 6.01 ml, 12.02 mmol)was slowly added. The solution was stirred for 30 minutes cold, thenwarmed to room temperature and stirred for 2 more hours. The reactionwas quenched, extracted into DCM, and the reaction product was purifiedusing column chromatography to yield 1.90 g of a pale beige, crystallinesolid (71%).

An X-ray structure of3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine is shown in FIG. 5.The crystal structure of3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine may be defined byone or more of the characteristics listed in the following table.

Formula C₁₇H₁₂N₂ Data/restr./param. 2107/0/173 MW 244.29 T [K] 100(1)   Crystal system Orthorhombic ρ_(cald) [g cm⁻³] 1.410 Space group P2₁2₁2₁μ_(calcd) [mm⁻¹] 0.084 Color Colorless Total reflections 22768      a[Å] 6.6974(5) Z 4    b [Å] 11.0502(8) F(000) 512     c [Å] 15.5459(10)T_(min)/T_(max) 0.894 α [°] 90 Cryst. Size [mm³] 0.42 × 0.22 × 0.08 β[°] 90 R₁ [I > 2σ(I)]^(a)  0.0405 γ [°] 90 wR₂ (all data)^(a)  0.1173 V[Å³] 1150.52(14) GOF^(a) 1.075 ^(a)R₁ = Σ||F_(o)| − |F_(c)||/Σ|F_(o)|;wR₂ = [Σ[w(F_(o) ² − F_(c) ²)²]/Σ[w(F_(o) ²)²]]^(1/2); GOF = [Σw(|F_(o)|− |F_(c)|)²/(n − m)]^(1/2)

Example 2 Synthesis of4,4-dimethyl-3,4-dihydro-1,2a1-diaza-4-silabenzo[fg]aceanthrylene and3,3 -dimethyl-3,4-dihydro-1,2a1-diaza-3 -silabenzo[fg]aceanthrylene

The ligands above are prepared in accordance with Scheme 2 below.

A. Synthesis of 5-bromoimidazo[1,2-f]phenanthridine

4-bromophenanthridin-6-amine (4.0 g, 14.7 mmol) was dissolved in 100 mLof iPrOH. Chloroacetaldehyde (50% in water, 3.6 g, 22 mmol, 1.5 equiv.)was added, followed by NaHCO₃ (2.5 g, 2 equiv.), and the mixture wasrefluxed for 2 hours, then cooled in an ice bath. The tan solid wasfiltered off, washing with MeOH. The receiving flask was changed and thesolid was washed with water, resulting in clean, off-white product, 3.2g. The aqueous washes were extracted with EtOAc and these extracts werecombined with the alcoholic washes from the initial filtration. Solventwas removed to yield 1.3 g of an orange solid which was recrystallizedfrom EtOAc, yielding more clean product as tan needles, 0.46 g. Totalyield: 3.5 g (80%).

B. Synthesis of 3,5-dibromoimidazo[1,2-f]phenanthridine

Dissolved 5-bromoimidazo[1,2-f]phenanthridine (2.0 g, 6.73 mmol) in DMF(125 ml), then added a solution of NBS (1.318 g, 7.40 mmol) in 10 mL ofDMF slowly under nitrogen. After stirring for 3 hours at roomtemperature, then gentle heating for 16 hours, the reaction mixture waspartitioned between 300 mL of water and EtOAc. The aqueous layer wasfurther extracted with EtOAc, the organics washed with water, and theproduct was isolated by column chromatography as a pale yellow solid,1.99g (79%).

C. Synthesis of5-bromo-3-((chloromethyl)dimethylsilyl)imidazo[1,2-f]phenanthridine

3,5-dibromoimidazo[1,2-f]phenanthridine (0.48 g, 1.28 mmol) andchloro(chloromethyl)dimethylsilane (0.17 ml, 1.28 mmol) were dissolvedin in THF (25 ml) and cooled in iPrOH/CO2 bath. Butyllithium solution inhexanes (2.5 M, 0.51 ml, 1.28 mmol) was added slowly, the mixture wasstirred cold for 30 minutes, then allowed to warm to room temperature.Brine was added to quench the reaction, the organics were extracted intoEtOAc and purified by column chromatography to yield the product as acolorless, tacky residue, 0.16 g (31%).

D. Synthesis of4,4-dimethyl-3,4-dihydro-1,2a1-diaza-4-silabenzo[fg]aceanthrylene and3,3-dimethyl-3,4-dihydro-1,2a1-diaza-3-silabenzo[fg]aceanthrylene

5-bromo-3-((chloromethyl)dimethylsilyl)imidazo[1,2-f]phenanthridine(0.13 g, 0.322 mmol) was dissolved in THF (25 ml) and cooled in an icebath. Isopropylmagnesium chloride solution in THF (2.0 M, 0.18 ml, 0.36mmol) was added slowly, then warmed to room temperature. The reactionwas quenched with brine, organics were extracted with DCM, and themixture chromatographed to yield 16 mg of4,4-dimethyl-3,4-dihydro-1,2a1-diaza-4-silabenzo[fg]aceanthrylene as atacky residue (17%), and 33 mg of3,3-dimethyl-3,4-dihydro-1,2a1-diaza-3-silabenzo[fg]aceanthrylene as acrystalline solid (36%).

Furthermore, all organic materials used in this example weresublimation-purified and analyzed by high-performance liquidchromatography (Tosoh TSKgel ODS-100Z), and materials having 99.9% orhigher of an absorption intensity area ratio at 254 nm were used.

An X-ray structure of3,3-dimethyl-3,4-dihydro-1,2a1-diaza-3-silabenzo[fg]aceanthrylene isshown in FIG. 6. The crystal structure of3,3-dimethyl-3,4-dihydro-1,2a1-diaza-3-silabenzo[fg]aceanthrylene may bedefined by one or more of the characteristics listed in the followingtable.

Formula C₁₈H₁₆N₂Si Data/restr./param. 5211/0/384 MW 288.42 T [K]100(1)    Crystal system Triclinic ρ_(cald) [g cm⁻³] 1.341 Space groupP-1 μ_(calcd) [mm⁻¹] 0.159 Color Colorless Total reflections 54823     a [Å] 9.1888(8) Z 4    b [Å] 12.5217(11) F(000) 608     c [Å]12.5428(12) T_(min)/T_(max) 0.954 α [°] 82.769(4) Cryst. Size [mm³] 0.28× 0.18 × 0.15 β [°] 89.062(4) R₁ [I > 2σ(I)]^(a)  0.0324 γ [°] 86.121(2)wR₂ (all data)^(a)  0.0892 V [Å³] 1428.4(2) GOF^(a) 1.055 ^(a)R₁ =Σ||F_(o)| − |F_(c)||/Σ|F_(o)|; wR₂ = [Σ[w(F_(o) ² − F_(c) ²)²]/Σ[w(F_(o)²)²]]^(1/2); GOF = [Σw(|F_(o)| − |F_(c)|)²/(n − m)]^(1/2)

Example 3 Synthesis of platinum(II) complex of6-isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A. Synthesis of 2-Bromo-5-methoxybenzonitrile

A mixture of 2-bromo-5-methoxybenzaldehyde (100 g, 0.47 mol, 1 equiv),hydroxylamine hydrochloride (64.8 g, 0.93 mol, 2 equiv), sodium acetate(76.42 g, 0.93 mol, 2 equiv) and glacial acetic acid (500 mL) wasrefluxed for 16 hours. The acetic acid was removed under reducedpressure and the residue was extracted with dichloromethane (˜400 mL).The organic layer was washed with saturated brine (3×200 mL), dried oversodium sulfate and concentrated under reduced pressure. The resultingresidue was triturated with heptanes (50 mL) and solids washed withadditional heptanes (2×50 mL) to give the desired product as a whitepowder (82.6 g, 86% yield).

B. Synthesis of5-Methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

A mixture of 2-bromo-5-methoxybenzonitrile (82.6 g, 0.39 mol, 1 equiv),bis(pinacolato)diboron (109.1 g, 0.43 mol, 1.1 equiv) and potassiumacetate (115.3 g, 1.17 mol, 3 equiv) in a mixture of 1,4-dioxane (400mL) and DMSO (40 mL) was sparged with nitrogen for 1 hour. Pd(dppf)Cl₂(7.13 g, 5 mol %) was added and reaction mixture was gently heated at60° C. for 2 hours then refluxed for 16 hours. The mixture was filteredthrough celite and the solids isolated from the filtrates were washedwith isopropanol and heptanes to give the desired product as anoff-white solid (57.41 g, 57% yield). Additional product (˜10 g) wasisolated from the filtrates.

C. Synthesis of 4-Bromo-2-isopropyl-8-methoxyphenanthridin-6-amine

A mixture of5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo-nitrile(57.41 g, 0.22 mol, 1 equiv), 2,6-dibromo-4-iso-propylaniline (64.92 g,0.22 mol, 1 equiv) and potassium phosphate (153.1 g, 0.66 mol, 3 equiv)in a 4:1 mixture of toluene and water (1250 mL) was sparged withnitrogen for 1 hour. trans-Pd(PPh₃)₂Cl₂ (7.8 g, 11 mmol, 0.05 equiv) wasadded and the reaction mixture was refluxed for 20 hours. Additionalpotassium phosphate (77 g, 0.33 mol, 1.5 equiv) and trans-Pd(PPh₃)₂Cl₂(1 g, 1.43 mmol, 0.0065 equiv) were added and the reaction mixture wasrefluxed for an additional 3 hours. The layers were separated and theorganic layer was washed with hot water (2×400 mL). The organic layerwas dried over sodium sulfate and concentrated under reduced pressure.The resulting solid was triturated sequentially with dichloromethane andheptanes. Column chromatography gave the desired product (30 g).

D. Synthesis of6-Isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4dihydro-dibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A suspension of 4-bromo-2-isopropyl-8-methoxyphenanthridin-6-amine (8.9g, 25.8 mmol, 1 equiv), p-toluenesulfonic acid monohydrate (348 mg),freshly prepared 2-bromo-4-chlorobutanal (24 g, 129 mmol, 5 equiv) andiso-propanol (500 mL) was stirred at room temperature for 2.5 hours.Sodium carbonate (6.5 g, 77.4 mmol, 3 equiv) and deionized water (32 ml)were added, and the reaction mixture was refluxed for 16 hours. Aftercooling to room temperature, the volume of reaction mixture was reducedto ˜100 mL under reduced pressure. The mixture was diluted with ethylacetate (350 mL) and washed with saturated brine (200 mL). The organiclayer was dried over sodium sulfate and concentrated under reducedpressure. The crude product was purified by column chromatography toyield 8.44 g of product (76% yield).

E. Synthesis of6-Isopropyl-10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinoli-zine

A solution of6-Isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4dihydro-dibenzo[b,ij]imidazo[2,1,5-de]quinolizine(8.44 g, 19.6 mmol, 1.0 equiv) in dry THF (250 mL) was sparged withnitrogen for 30 minutes). After cooling to 0° C., 2M isopropylmagnesiumchloride (14.7 mL, 29.4 mmol, 1.5 equiv) in THF was added dropwise. Thereaction mixture was warmed up to room temperature and stirred for 16hours. The reaction was quenched with water (10 mL) and the THF wasremoved under reduced pressure. The residue was diluted with ethylacetate (400 mL) and washed with saturated brine (2×200 mL). The organiclayer was dried over sodium sulfate and the residue was purified bycolumn chromatography to give 3.6 g of product (58% yield).

F. Synthesis of6-Isopropyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-10-ol

Boron tribromide (5.4 mL, 56.78 mmol, 5 equiv) was added dropwise at−78° C. to a solution of6-Isopropyl-10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinoli-zine(3.6 g, 11.36 mmol, 1 equiv) in dichloromethane (200 mL). The reactionwas warmed to room temperature and stirred for 16 hours. The reactionmixture was carefully poured into 300 ml of ice water and the resultingsolid was filtered and washed sequentially with water (70 mL), ethylacetate (40 mL) and heptanes (40 mL) to give 3.6 g of product(quantitative yield).

G. Synthesis of 4′-Bromo-2-nitro-1,1′-biphenyl

A solution of potassium carbonate (84 g, 608 mmol, 3.0 equiv) in water(450 mL) was added to a mixture of 2-iodo-nitrobenzene (50 g, 200 mmol,1.0 equiv) and 4-bromobenzeneboronic acid (40.7 g, 202 mol, 1.0 equiv)in 1,2-dimethoxyethane (660 mL). The reaction was sparged with nitrogenfor 5.0 minutes. Tetrakis(triphenylphosphine)palladium(0) (2.32 g, 2mmol, 1 mol %) was added and the mixture was sparged with nitrogen foran additional 10 minutes. After refluxing for 16 hours, the reaction wascooled to room temperature and the layers were separated. The aqueouslayer was extracted with ethyl acetate (500 mL). The combined organicextracts were washed with saturated brine (500 mL), dried over sodiumsulfate, filtered and concentrated under reduced pressure. The residuewas dissolved in 25% ethyl acetate in heptanes (300 mL) and vacuumfiltered through a pad of silica gel (135 g). The pad was rinsed with25% ethyl acetate in heptanes (3×350 mL). The combined filtrates wereconcentrated under reduced pressure giving an orange solid. This residuewas suspended in heptanes (150 mL) and heated to 40° C. for 20 minutes.The suspension was allowed to cool to room temperature for 1.0 hour. Thesolid was collected by vacuum filtration, washed with heptanes (50 mL)and dried to give 4′-bromo-2-nitro-1,1′-biphenyl as a yellow solid(49.16 g, 88.4% yield).

H. Synthesis of 2-Bromo-9H-carbazole

Triphenylphosphine (156.3 g, 596 mmol, 2.5 equiv) was added over 5minutes to a solution 4′-bromo-2-nitro-1,1′-biphenyl (66.25 g, 238 mmol,1.0 equiv) in 1,2-dichlorobenzene (460 mL). The reaction was spargedwith nitrogen 5 minutes, then refluxed for 16 hours. The reaction wascooled to room temperature and vacuum distilled to remove most of the1,2-dichlorobenzene (450 mL). This dark residue was dissolved in ethylacetate (1.5 L) and treated with decolorizing carbon (50 g) at 50° C.for 30 minutes. After cooling, the mixture was filtered through Celite(200 g), then washed with ethyl acetate washes (2×650 mL). The combinedfiltrates were concentrated under reduced pressure to a volume of ˜500mL. The solution was cooled to room temperature and after 1.5 hours, theresulting pale tan solid (triphenylphosphine oxide) was removed byfiltration and discarded. The filtrate was concentrated under reducedpressure. The residue was dissolved in methanol (600 mL) and stored atroom temperature for 16 hours. The resulting tan solid was filtered,washed with methanol (2×100 mL) and dried under vacuum at 40° C. to give2-bromo-9H-carbazole as a pale tan solid (33.5 g, 57.2% yield).

I. Synthesis of 2-Bromo-9-(4-isopropylpyridin-2-yl)-9H-carbazole

A suspension of 2-bromo-9H-carbazole (13.9 g, 56.5 mmol, 1 equiv),4-isopropyl-2-chloropyridine (15.86 g, 101.7 mmol, 1.8 equiv), L-proline(1.3 g, 11.3 mmol, 0.2 equiv), copper (1) iodide (0.95 g, 5.65 mmol, 0.1equiv), potassium carbonate (19.48 g, 141.25 mmol, 2.5 equiv) and DMSO(80 mL) was sparged with nitrogen for 5 minutes. The mixture was heatedat 95° C. for 16 hours. Additional 4-isopropyl-2-chloropyridine (1.58 g,10.12 mmol, 0.18 equiv) was added, the reaction mixture was heated at155° C. for an additional 24 hours. The reaction mixture was cooled toroom temperature, diluted with ethyl acetate (750 mL), and vacuumfiltered through celite (70 g). The celite pad was washed with ethylacetate washes (2×100 mL). The combined filtrates were washed withsaturated brine (3×500 mL), dried over sodium sulfate, filtered andconcentrated under reduced pressure. This residue was purified by columnchromatography to give 1.8 g of product as a brown oil (8.6% yield).

J. Synthesis of6-Isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A mixture of6-Isopropyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-10-ol(1.5 g, 4.93 mmol, 1 equiv),2-Bromo-9-(4-isopropylpyridin-2-yl)-9H-carbazole (1.8 g, 4.93 mmol, 1equiv), potassium phosphate (5.68 g, 24.65 mmol, 5 equiv), copper(I)iodide (0.47 g, 2.47 mmol, 0.5 equiv), picolinic acid (1.52 g, 12.33mmol, 2.5 equiv) and DMSO (150 mL) was heated at 150° C. for 4.5 hours.After cooling to room temperature, the reaction mixture was poured intowater (700 mL) and extracted with ethyl acetate (4×150 mL). The combinedorganic layers were dried over sodium sulfate and concentrated in underreduced pressure. The crude product was purified by columnchromatography to yield product as a tan solid, 1.25 g (43% yield).

K. Synthesis of platinum(II) complex of6-isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

6-Isopropyl-10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(400 mg, 0.68 mmol, 1 equiv) was dissolved in 60 ml of glacial aceticacid and sparged with nitrogen for 30 minutes. Then K₂PtCl₄ (283 mg,0.68 mmol, 1 equiv) was added, and the reaction mixture was refluxed for40 hours. After cooling to room temperature, the orange precipitate wasfiltered and washed sequentially with water (3×15 mL) and heptanes (10ml×2 times). The crude product (340 mg) was dissolved in 10 ml ofdichloromethane and filtered through a plug of silica gel to removeresidual K₂PtCl₄, eluting with additional dichloromethane (10 mL). Thefiltrate was reduced to half its volume and diluted with heptanes (10mL). The product was filtered and triturated with a 10% solution ofdichloromethane in heptanes (10 mL) to give product as a light yellowsolid (140 mg, 26% yield). Additional product was isolated from theacetic acid and dichloromethane/heptane filtrates.

Example 4 Synthesis of (3-phenyl-1H-pyrazole)₂Ir(MeOH)₂(OTf)

A. Synthesis of (3-phenyl-1H-pyrazole)₂IrCl₂ dimer

Iridium chloride hydrate (6.00 g, 17.02 mmol) and 1-phenyl-1H-pyrazole(5.89 g, 40.9 mmol) were combined in 2-ethoxyethanol (120 ml) and water(40 ml). The reaction mixture was heated to reflux for 16 hours undernitrogen. The resulting solid was filtered off and washed with methanoland dried to yield 8.3 g of the iridium dimer.

The iridium dimer of Example 4A (8.3 g, 8.07 mmol) was dissolved in 100mL of DCM and a solution of silver triflate (4.36 g, 16.96 mmol) in 20mL of methanol was added. The reaction mixture was stirred at roomtemperature under nitrogen for 1 hour. The mixture was filtered throughcelite and the cake was washed with DCM. The filtrates were evaporatedto yield 10.85 g of (3-phenyl-1H-pyrazole)₂Ir(MeOH)₂(OTf) (97%).

Example 5 Exemplary Compound 35 was prepared according to Scheme 5

A. Synthesis of imidazo[1,2-f]phenanthridine

A mixture of 2-phenyl-1H-imidazole (10.0 g, 69.3 mmol, 1 equiv),1,2-dibromobenzene (19.63 g, 83.2 mmol, 1.2 equiv), cesium carbonate(67.79 g, 208.0 mmol, 3 equiv), Xantphos (4.01 g, 6.9 mmol, 0.1 equiv)and tetrakis(triphenylphosphine)palladium (8.01 g, 6.9 mmol, 0.1 equiv)in DMF (550 mL) was sparged with a stream of nitrogen for 15 minutes.The mixture was heated at 140° C. for 24 hours, then concentrated underreduced pressure. The residue was purified by column chromatography toimidazo[1,2-f]phenanthridine (10 g, 67% yield) as pale yellow solid.

B. Synthesis of 3-Bromoimidazo[1,2-f]phenanthridine

N-bromosuccinimide (1.62 g, 9.1 mmol, 1 equiv) was added to a solutionof 15 (1.99 g, 9.1 mmol, 1 equiv) in DMF (32 mL) at 0° C. After stirringat room temperature for 18 hours, the reaction was diluted with water(300 mL) and sequentially extracted with 10% dichloromethane in methylt-butyl ether (3×500 mL), ethyl acetate (2×300 mL) and dichloromethane(400 mL). The combined organic layers were dried over sodium sulfate,filtered and concentrated under reduced pressure. The residue waspurified by column chromatography to yield3-Bromoimidazo[1,2-f]phenanthridine (1.66 g, 65% yield) as an off-whitesolid.

C. Synthesis of tert-Butyl 2-(imidazo[1,2-f]phenanthridin-3-yl)acetate

Di-μ-bromobis(tri-t-butylphosphino)dipalladium (I) (2.01 g, 2.5 mmol,0.05 equiv) was added to a solution of 16 (15.4 g, 51.8 mmol, 1 equiv)in anhydrous tetrahydrofuran (220 mL) and the solution was sparged witha stream of nitrogen for 15 minutes. 0.5M 2-tert-butoxy-2-oxoethylzincbromide in diethyl ether (155 mL, 77.7 mmol, 1.5 equiv) was added undernitrogen. The reaction was stirred at 60° C. for 16 hours. Additional0.5M 2-tert-butoxy-2-oxoethylziinc chloride solution (155 mL, 77.7 mmol,1.5 equiv) and di-μ-bromobis(tri-t-butylphosphino)-dipalladium (I) (2.01g, 2.5 mmol, 0.05 equiv) were added and the reaction was stirred at 60°C. until LC/MS analysis indicated it was complete. The reaction mixturewas concentrated under reduced pressure. The residue was dissolved indichloromethane (1 L) and filtered through a Celite pad. The filtratewas concentrated under reduced pressure. The residue was purified bycolumn chromatography to give tert-Butyl2-(imidazo[1,2-f]phenanthridin-3-yl)acetate (5 g, 30% yield) as anorange solid.

D. Synthesis of Methyl 2-(imidazo[1,2-f]phenanthridin-3-yl)acetatehydrochloride

A solution of 17 (2.8 g, 8.4 mmol, 1 equiv) in 1.25M HCl (55 mL, 68.7mmol, 6.5 equiv) in methanol was stirred at 60° C. for 16 hours. Thereaction mixture was concentrated under reduced pressure. The residuewas washed with diethyl ether and dried under vacuum for 16 hours at 40°C. to give methyl 2-(imidazo[1,2-f]phenanthridin-3-yl)acetatehydrochloride (2.5 g, 100% yield) as an off-white solid.

E. Synthesis of Methyl2-(imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoate

A 60% dispersion of sodium hydride in mineral oil (2.45 g, 61.2 mmol, 5equiv) and iodomethane (2 mL, 32.1 mmol, 2.6 equiv) were sequentiallyadded to a solution of methyl2-(imidazo[1,2-f]phenanthridin-3-yl)acetate hydrochloride (4.0 g, 12.24mmol, 1 equiv) in anhydrous DMF (45 mL) at 5° C. The mixture was stirredin a cooling bath for 30 minutes, warmed to room temperature and stirredfor 6 hours. Additional iodomethane (1.2 mL, 19.2 mmol, 1.6 equiv) wasadded. The reaction was stirred at room temperature over a weekend,quenched with methanol (32 mL) and concentrated under reduced pressure.The residual oil was diluted with dichloromethane (350 mL) and washedwith water (100 mL). The aqueous layer was extracted withdichloromethane (2×100 mL). The combined organic layers were washed withsaturated ammonium chloride (100 mL), dried over sodium sulfate,filtered and concentrated under reduced pressure. The residue waspurified by column chromatography to give methyl2-(imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoate (1.6 g, 41%yield) as an off-white solid.

F. Synthesis of 2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoicacid

A solution of methyl2-(imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoate (1.6 g, 5.0mmol, 1 equiv) in methanol (100 mL) was treated with aqueous 1N sodiumhydroxide (30 mL, 30 mmol, 6 equiv) and further diluted with water (100mL). After refluxing for 5 days, the reaction was concentrated underreduced pressure. The residue was dissolved in water (100 mL) andacidified with conc. HCl to pH 5-6. The resulting white suspension wasextracted with 1 to 2 mixture of isopropanol and dichloro-methane (4×200mL). The combined organic layers were dried over sodium sulfate,filtered, concentrated under reduced pressure. The residue was driedunder high vacuum at 40° C. for 16 hours to give2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoic acid (1.3 g, 82%yield) as white solid.

G. Synthesis of 2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoylchloride

Thionyl chloride (1 mL, 13.7 mmol, 2 equiv) and anhydrous DMF (0.05 mL,0.6 mmol, 0.11 equiv) were added to a suspension of2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoic acid (1.3 g, 4.2mmol, 1 equiv) in anhydrous dichloromethane (100 mL). After stirring atroom temperature for 16 hours, the mixture was concentrated underreduced pressure to give the2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoyl chloride (1.37 g,100% yield) as an off-white solid.

H. Synthesis of3,3-Dimethyldibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4(3H)-one

A mixture of 2-(Imidazo[1,2-f]phenanthridin-3-yl)-2-methylpropanoylchloride (1.37 g, 4.2 mmol, 1 equiv) and anhydrous aluminum chloride(6.0 g, 44.9 mmol, 10 equiv) in anhydrous dichloromethane (60 mL) wasstirred at room temperature for 6 hours. The reaction was cooled with anice-water bath, quenched with ice, diluted with saturated sodiumbicarbonate (300 mL) and extracted with dichloromethane (4×400 mL). Thecombined organic layers were dried over sodium sulfate, filtered andconcentrated under reduced pressure. The residue was purified usingcolumn chromatography to give3,3-dimethyldibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4(3H)-one (1 g, 81%yield) as a white solid.

I. Synthesis of3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-ol

Sodium borohydride (0.24 g, 6.3 mmol, 2 equiv) was added in one portionto a solution of3,3-dimethyldibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4(3H)-one (0.9 g,3.1 mmol, 1 equiv) in ethanol (70 mL) at 5° C. The reaction was stirredat room temperature for 1.5 hours and then quenched with acetone (2 mL).The reaction mixture was concentrated under reduced pressure. Theresidue was dissolved in methyl t-butyl ether (300 mL), washed withsaturated sodium bicarbonate (2×60 mL) and saturated brine (60 mL). Theorganic layer was dried over sodium sulfate, filtered and concentratedunder reduced pressure. The crude product was purified by columnchromatography to give3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-ol(0.9 g, 100% yield) as a white solid.

J.o-(3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-yl)S-methyl carbonodithioate

A 60% dispersion of sodium hydride (0.48 g, 20.2 mmol, 5 equiv) inmineral oil was added to a solution of3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-ol(0.71 g, 2.46 mmol, 1 equiv) in anhydrous THF (70 mL) at 0° C. Afterstirring for 30 minutes at 5° C., a solution of imidazole (0.0168 g,0.24 mmol, 0.1 equiv) in anhydrous tetrahydrofuran (3.2 mL) was added,followed by the dropwise addition of carbon disulfide (0.89 mL, 14.8mmol, 6 equiv). The reaction was allowed to slowly warm to 12° C. over30 minutes. Iodomethane (0.92 mL, 14.7 mmol, 6 equiv) was added dropwise(exothermic) and the reaction was stirred at room temperature for 1hour. The reaction mixture was cooled to 5° C., diluted with saturatedbrine (140 mL) and extracted with dichloromethane (5×100 mL). Thecombined organic layers were dried over sodium sulfate, filtered andconcentrated under reduced pressure. The crude product was purified bycolumn chromatography to giveo-(3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-yl)S-methyl carbonodithioate (0.86 g, 93% yield) as a white solid.

K. Synthesis of3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A solution ofo-(3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-4-yl)S-methyl carbonodithioate (0.98 g, 2.6 mmol, 1 equiv),2,2′-azabis(2-methylpropionitrile) (0.098 g, 0.6 mmol, 0.2 equiv) andtributyltin hydride (1.81 mL, 6.7 mmol, 2.6 equiv) in anhydrous toluene(70 mL) was stirred at 80° C. for 3.5 hours. After cooling to roomtemperature, the reaction mixture was concentrated under reducedpressure at 35° C. and absorbed onto silica gel (10 g). The crudematerial was purified by column chromatography to give3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine (0.53g, 72% yield) as a white solid.

L. Synthesis of (3-chloropropyl)(methyl)sulfane

Sodium methanethiolate (6.14 g, 88 mmol) was dissolved in 150 mL ofEtOH, cooled in an ice bath, then 1-bromo-3-chloropropane (8.6 ml, 87mmol) was added. The solution was warmed to room temperature and stirredfor 2 hours. The precipitated solids were filtered and the filtratescondensed under vacuum. The residue was distilled under vacuum to yieldthe product as a colorless oil, 36%.

M. Synthesis of tris-[(3-methylthio)propyl]iridium(III)

(3-chloropropyl)(methyl)sulfane was synthesized by stirring the Grignardmade from (3-chloropropyl)(methyl)sulfane and magnesium turnings withIrCl₃(THT)₃ in THF, followed by column chromatography to yield a whitesolid, 32%.

N. Synthesis of Compound 35

tris-[(3-methylthio)propyl]iridium(III) from Example 5M (0.020 g, 0.044mmol) and3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine fromExample 5K (0.036 g, 0.131 mmol) were combined in ethylene glycol (0.5ml), degassed by vacuum/backfill cycles, and stirred at reflux, turningyellow then black. The cooled residue was partitioned between water andDCM, the organics were dried and coated on celite. Purification bycolumn chromatography yielded 4 mg of Compound 35 as a beige solid (9%).

Example 6 Synthesis of Compound 48 was carried out as in Scheme 6

(3-phenyl-1H-pyrazole)₂Ir(MeOH)₂(OTf) from Example 4 (0.031 g, 0.045mmol) and3,3-Dimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine fromExample 5K (0.024 g, 0.090 mmol) were combined in 2-ethoxyethanol (0.5ml), vacuum/backfill quickly three times, then heated at reflux undernitrogen for 2 hours. The reaction mixture was dissolved in DCM, coatedon celite, and purified by column chromatography to yield Compound 35 asa nearly colorless residue, 6 mg (18%).

Example 7 Synthesis of Compound 49 was Carried Out According to Scheme 7Below

A. Synthesis of 1-Methylphenanthridin-6-amine

A mixture of 2-bromo-3-methylaniline (38.8 g, 208 mmol, 1 equiv),(chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(2.99 g, 4.16 mmol, 0.02 equiv),2-dicyclohexyl-phosphino-2′,6′-dimethoxybiphenyl (1.71 g, 4.16 mmol,0.02 equiv) in THF (832 mL) was sparged with nitrogen for 15 minutes.(2-Cyanophenyl)zinc bromide solution (500 mL, 0.5 M in THF, 250 mmol,1.2 equiv) was added to the mixture and the reaction was refluxed for 16hours. After cooling to room temperature, the reaction was diluted withsaturated brine (10 mL) and concentrated under reduced pressure. Thesolids were dissolved in 10% methanol in dichloromethane (500 mL) and24% wt. aqueous sodium hydroxide (500 mL). The layers were separated andthe aqueous was extracted with dichloromethane (3×500 mL). The combinedorganic layers were dried over sodium sulfate, and concentrated underreduced pressure. The brown solid was sequentially triturated with 25%MTBE in heptanes (1.5 L) and dichloromethane (5×25 mL) to give 26 (10.7g, 25% yield, >95% purity) as a pale yellow solid.

B. Synthesis of 8-Methylimidazo[1,2-f]phenanthridine

A mixture of 1-methylphenanthridin-6-amine (10.7 g, 51 mmol, 1 equiv),50% wt chloroacetaldehyde in water (16 mL, 102 mmol, 2 equiv), sodiumcarbonate (13.5 g, 128 mmol, 2.5 equiv) in isopropanol (340 mL) wasrefluxed for 2 hours. The reaction was cooled to 4° C. and diluted withdichloromethane (250 mL) and saturated sodium bicarbonate (500 mL). Thelayers were separated and the aqueous layer was extracted withdichloromethane (3×250 mL). The combined organics layers were dried oversodium sulfate, and concentrated under reduced pressure to give crude8-methylimidazo[1,2-f]phenanthridine (23.8 g) as a brown solid, whichwas used subsequently.

C. Synthesis of 3-Bromo-8-methylimidazo[1,2-f]phenanthridine

A mixture of crude 8-methylimidazo[1,2-f]phenanthridine (23.8 g),N-bromosuccinimide (9.1 g, 51 mmol, 1 equiv) in dichloromethane (306 mL)was stirred at room temperature for 2 hours. Water (500 mL) was addedand the layers were separated. The aqueous was extracted withdichloromethane (3×500 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The solids werepre-absorbed onto silica gel and purified by column chromatography togive 3-bromo-8-methylimidazo[1,2-f]phenanthridine (12 g, 98% purity) asa light brown solid.

D. Synthesis of8-Methyl-3-(2-methylprop-1-en-1-yl)imidazo[1,2-f]phenanthridine

A mixture of 3-bromo-8-methylimidazo[1,2-f]phenanthridine (12 g, 38.5mmol, 1 equiv),4,4,5,5-tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2-dioxaborolane (10.5g, 58 mmol, 1.5 equiv), and potassium carbonate (16 g, 115.5 mmol, 3equiv) in a 5 to 1 mixture of 1,4-dioxane and water (185 mL) was spargedwith nitrogen for 15 minutes.(Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(4.16 g, 5.78 mmol, 0.15 equiv) and2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (2.38 g, 5.78 mmol, 0.15equiv) were added and the reaction was refluxed for 36 hours. Aftercooling to room temperature, the reaction was diluted with water (200mL). The layers were separated and the aqueous was extracted with ethylacetate (3×200 mL). The combined organics layers were dried over sodiumsulfate and concentrated under reduced pressure. The crude solid waspurified by column chromatography to give8-methyl-3-(2-methylprop-1-en-1-yl)imidazo[1,2-f]phenanthridine (8.5 g,70% yield, 90% purity) as a light brown solid.

E. Synthesis of4,4,7-Trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A mixture of8-methyl-3-(2-methylprop-1-en-1-yl)imidazo[1,2-f]phenanthridine (1.6 g,5.69 mmol, 1 equiv) and anhydrous aluminum chloride (3.8 g, 28.4 mmol, 5equiv) in dichloromethane (57 mL) were stirred at room temperature for16 hours. The reaction was cooled in an ice bath and water (10 mL) wasadded dropwise. The layers were separated and the aqueous layer wasextracted with dichloromethane (3×50 mL). The combined organic layerswere dried over sodium sulfate and concentrated under reduced pressure.The crude solids purified by column chromatography to give4,4,7-Trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(1.43 g, 88% yield, 98% purity) as a light yellow solid.

F. Synthesis of2-Bromo-4,4,7-trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine:

A mixture of4,4,7-Trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(500 mg, 1.75 mmol, 1 equiv) and N-bromosuccinimide (311 mg, 1.75 mmol,1 equiv) in dichloromethane (11 mL) was stirred at room temperature for2 hours. The reaction was diluted with water (20 mL) and dichloromethane(10 mL). The layers were separated and the aqueous were extracted withdichloromethane (3×20 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography to give2-bromo-4,4,7-trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(575 mg, 90% yield, 97% purity) as a light brown solid.

G. Synthesis of2,4,4,7-Tetramethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A mixture of2-bromo-4,4,7-trimethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(265 mg, 0.73 mmol, 1 equiv), trimethylboroxine (0.6 mL, 4.4 mmol, 6equiv) and potassium carbonate (608 mg, 4.4 mmol, 6 equiv) in a 10 to 1mixture of 1,4-dioxane and water (7 mL) was sparged with nitrogen for 15minutes.(Chloro(2dicyclo-hexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(108 mg, 0.15 mmol, 0.2 equiv) and2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (62 mg, 0.15 mmol, 0.2equiv) were added and the reaction was refluxed for 16 hours. Aftercooling to room temperature, the reaction was diluted with water (10 mL)and ethyl acetate (10 mL). The layers were separated and the aqueouswere extracted with ethyl acetate (3×20 mL). The combined organic layerswere dried over sodium sulfate and concentrated under reduced pressure.The residue was purified by column chromatography to give2,4,4,7-Tetramethyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(100 mg, 46% yield, 95% purity) as a pale yellow solid.

H. Synthesis of Compound 49

Compound 49 was synthesized in an analogous way to Compound 35, yielding13 mg of yellow powder (15%).

Example 8 Synthesis of Compound 50 was Carried Out According to Scheme 8Below

A. Synthesis of 1-chlorophenanthridin-6-amine

A mixture of 3-chloro-2-iodoaniline (8.77 g, 34.6 mmol), CyJohnPhos(0.462 g, 1.319 mmol), and Pd(CH₃CN)₂Cl₂ (0.171 g, 0.659 mmol) wasdissolved in dioxane (80 ml). Triethylamine (13.78 ml, 99 mmol) and4,4,5,5-tetramethyl-1,3,2-dioxaborolane (10.04 ml, 69.2 mmol) were addedto the solution in sequence via syringe. The reaction was reflux for 4h. The reaction was cooled to room temperature and a solid mixture of2-bromobenzonitrile (6 g, 33.0 mmol), S-Phos Pd G2 (0.475 g, 0.659mmol), S-Phos (0.271 g, 0.659 mmol), and potassium carbonate (9.11 g,65.9 mmol) was added to the reaction mixture followed by dioxane (20 ml)and water (20 ml) and the reaction was heated to 85° C. for 16 hours.The crude product was extracted with DCM and vacuumed down to yield anorange oil. This was dissolved in THF (80 mL) and sodium hydride (1.978g, 49.4 mmol) was added at 0° C. and stirred for 20 min. The reactionwas quenched with brine and extracted with DCM. Evaporation of thereaction mixture followed by trituration with ether yielded1-chlorophenanthridin-6-amine as an off-white solid (52% yield).

B. Synthesis of 8-chloroimidazo[1,2-f]phenanthridine

1-chlorophenanthridin-6-amine (864 mg, 3.78 mmol), 2-chloroacetaldehyde(50 wt % in water, 1.02 mL, 7.56 mmol), and sodium bicarbonate (635 mg,7.56 mmol) were combined in iPrOH and refluxed for 1 h. The mixture wascooled to room temperature and poured into water and filtered (99%yield).

C. Synthesis of 8-phenylimidazo[1,2-f]phenanthridine

A mixture of 8-chloroimidazo[1,2-f]phenanthridine (955 mg, 3.78 mmol),phenylboronic acid (829 mg, 6.80 mmol), S-Phos Pd G2 (109 mg, 0.151mmol), S-Phos (62.1 mg, 0.151 mmol), and potassium carbonate (522 mg,3.78 mmol) was vacuumed and back-filled with nitrogen several times.Dioxane (20 ml) and water (4 ml) were added and refluxed for 1 h. Thecrude product was extracted with DCM and brine and purified by columnchromatography to yield product (99% yield).

D. Synthesis of 3-bromo-8-phenylimidazo[1,2-f]phenanthridine

8-phenylimidazo[1,2-f]phenanthridine (1.15 mg, 3.91 mmol) and NBS (0.765g, 4.30 mmol) were combined in DMF and stirred at room temperature for30 minutes, followed by quenching with water. The resultant solid wasfiltered and dried in vacuum, yielding3-bromo-8-phenylimidazo[1,2-f]phenanthridine in 75% yield.

E. Synthesis of 3-(2-methylprop-1-en-1-yl)-8-phenylimidazo[1,2-f]phenanthridine

A mixture of 3-bromo-8-phenylimidazo[1,2-f]phenanthridine (980 mg, 2.63mmol), SPhos Pd G2 (76 mg, 0.105 mmol), SPhos (43.1 mg, 0.105 mmol), andpotassium carbonate (363 mg, 2.63 mmol) was vacuumed and back-filledwith nitrogen several times. Toluene (15 ml), Water (3 ml), and4,4,5,5-tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2-dioxaborolane(1.077 ml, 5.25 mmol) were added and heated at reflux for 16 hours. Theproduct was extracted with DCM and brine and purified by columnchromatography to give3-(2-methylprop-1-en-1-yl)-8-phenylimidazo[1,2-f]phenanthridine in 20%yield.

F. Synthesis of4,4-dimethyl-7-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

3-(2-methylprop-1-en-1-yl)-8-phenylimidazo[1,2-f]phenanthridine (160 mg,0.459 mmol) was dissolved in DCM (10 ml) and aluminum trichloride (184mg, 1.378 mmol) was added. The reaction was stirred for 40 min at roomtemperature. The mixture was quenched with KOH(aq)/brine and extractedseveral times with DCM. The product was purified by columnchromatography to give4,4-dimethyl-7-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizinein 63% yield.

G. Synthesis of Compound 50

(3-phenyl-1H-pyrazole)₂Ir(MeOH)₂(OTf) from Example 4 (0.03 g, 0.043mmol) and4,4-dimethyl-7-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(0.030 g, 0.087 mmol) were combined in 2-ethoxyethanol (0.5 ml),vacuum/backfilled quickly three times with nitrogen, then heated atreflux under nitrogen for 2 h. The product was purified by columnchromatography to give Compound 50 in 56% yield.

Example 9 Synthesis of Compound 108 was Carried Out According to Scheme8 Below

A. Synthesis of tert-Butyl (4-((triisopropylsilyl)oxy)phenyl)carbamate

Triisopropylchlorosilane (32 mL, 0.15 mol, 1.2 equiv) and triethylamine(21 mL, 0.15 mol, 1.2 equiv) were sequentially added to a solution oftert-butyl (4-hydroxyphenyl)carbamate (26.1 g, 0.125 mol, 1 equiv) inTHF (200 mL). The reaction mixture was stirred for 16 hours at roomtemperature. The reaction was filtered and the solids were washed withTHF (2×30 mL). The combined filtrates were concentrated under reducedpressure. The crude product was purified by column chromatography togive tert-Butyl (4-((triisopropylsilyl)oxy)phenyl)carbamate (39.66 g,87% yield) as yellow oil.

B. Synthesis of 4-((Triisopropylsilyl)oxy)aniline

Trifluoroacetic acid (41.51 mL, 0.54 mol, 5 equiv) was added at roomtemperature to a solution of tert-Butyl(4-((triisopropylsilyl)oxy)phenyl)carbamate (39.66 g, 0.1085 mol, 1equiv) in dichloromethane (400 mL). After stirring for 16 hours thesolvent was removed under reduced pressure. The residue was azeotropedwith toluene (3×50 mL). The crude product was purified over silica togive 4-((Triisopropylsilyl)oxy)aniline (25 g, 87% yield).

C. Synthesis of 2,6-Dibromo-4-((triisopropylsilyl)oxy)aniline

Bromine (8.2 mL, 0.16 mol, 2.5 equiv) was added dropwise at 0° C. to asolution of 4-((Triisopropylsilyl)oxy)aniline (17 g, 64.4 mmol, 1 equiv)in a 1:1 mixture of dichloromethane and methanol (60 mL). The reactionmixture was allowed to warm up to room temperature and stirred for 16hours. The reaction mixture was diluted with dichloromethane (200 mL)and washed sequentially with 1M NaOH (2×100 mL) and saturated brine(2×100 mL). The organic layer was dried over sodium sulfate andconcentrated under reduced pressure to give2,6-Dibromo-4-((triisopropylsilyl)oxy)aniline (26.37 g, 97% yield) as abrown oil, which was used subsequently.

D. Synthesis of4-Bromo-8-methoxy-2-((triisopropylsilyl)oxy)phenanthridin-6-amine

A mixture of5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(16.14 g, 62.3 mmol, 1 equiv), 51 (26.37 g, 62.3 mmol, 1 equiv) andpotassium phosphate (43.04 g, 0.187 mol, 3 equiv) in a 4 to 1 mixture oftoluene and water (500 mL) was sparged with nitrogen for 1 hour.trans-Pd(PPh₃)₂Cl₂ (2.8 g, 3.11 mmol, 0.05 equiv) was added and thereaction mixture was refluxed for 20 hours. Additional5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(2.2 g, 8.5 mmol, 0.14 equiv) and trans-Pd(PPh₃)₂Cl₂ (0.3 g, 0.43 mmol,0.0069 equiv) were added and the reaction mixture was refluxed for anadditional 4 hours. The layers were separated and the organic layer waswashed with hot water (2×200 mL). The organic layer was dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography to yield4-bromo-8-methoxy-2-((triisopropylsilyl)oxy)phenanthridin-6-amine in 20%yield.

E. Synthesis of5-Bromo-3-(2-chloroethyl)-11-methoxy-7-((triisopropylsilyl)oxy)imidazo[1,2-f]phenanthridine

A suspension of4-bromo-8-methoxy-2-((triisopropylsilyl)oxy)phenanthridin-6-amine (5.95g, 12.53 mmol, 1 equiv), p-toluenesulfonic acid monohydrate (175 mg) andfresh prepared 2 (6.67 g, 62.63 mmol, 5 equiv) in i-propanol (500 mL)was stirred at the room temperature for 2 hours. Sodium carbonate (3.25g, 37.6 mmol, 3 equiv) and deionized water (12 ml) were added and thereaction mixture was refluxed for 16 hours. After cooling to roomtemperature, the volume of reaction mixture was reduced to ˜60 ml underreduced pressure. The mixture was diluted with ethyl acetate (300 mL)and washed with saturated brine (200 mL). The organic layer was driedover sodium sulfate and concentrated under reduced pressure. The crudeproduct was purified by column chromatography to give5-bromo-3-(2-chloroethyl)-11-methoxy-7-((triisopropylsilyl)oxy)imidazo[1,2-f]phenanthridine(5.53 g, 79% yield).

F. Synthesis of10-Methoxy-6-((triisopropylsilyl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A solution of5-bromo-3-(2-chloroethyl)-11-methoxy-7-((triisopropylsilyl)oxy)imidazo[1,2-f]phenanthridine(5.53 g, 9.84 mmol, 1.0 equiv) in dry THF (300 mL) was sparged withnitrogen for 30 minutes. After cooling to 0° C., 2M isopropylmagnesiumchloride in THF (7.4 mL, 14.76 mmol, 1.5 equiv) was added dropwise viasyringe. The reaction mixture was warmed to the room temperature andstirred for 16 hours. The reaction was quenched with water (10 mL) andthe THF was removed under reduced pressure. The residue was extractedwith dichloromethane (500 mL). The organic layer was washed with water(2×200 mL), dried over sodium sulfate and concentrated under reducedpressure. The crude product was purified by column chromatography togive10-methoxy-6-((triisopropylsilyl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine (3 g, 68% yield).

G. Synthesis of10-Methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-ol

Tetrabutylammonium fluoride trihydrate in THF (30 mL) was added dropwiseto a solution of10-methoxy-6-((triisopropylsilyl)oxy)-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(3 g, 6.72 mmol, 1 equiv) in THF (100 mL). After stirring at roomtemperature for 16 hours, the solvent was removed under reduced pressureand the residue was extracted with dichloromethane. (80 mL). The organiclayer was washed with saturated brine (2×100 mL). Upon washing withsaturated brine, a large precipitate started to form in the organiclayer. The precipitation was filtered and washed with heptanes (2×10 mL)to give pure10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-ol(1.83 g, 94% yield).

H. Synthesis of10-Methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-yltrifluoromethanesulfonate

Trifluoroacetic anhydride (1.14 mL, 6.77 mmol, 1.1 equiv) and pyridine(0.744 mL, 9.24 mmol, 1.5 equiv) were sequentially added at 0° C. to amixture of10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-ol(1.79 g, 6.16 mmol, 1 equiv) in dichloromethane (100 mL). After stirringfor 15 minutes, the reaction was warm to room temperature and stirredfor 6 hours. The reaction mixture was diluted with dichloromethane (200mL) and washed with water (3×100 mL). The organic layer was dried oversodium sulfate and solvent was removed under reduced pressure. Theresidue was triturated with a 10 to 1 mixture of heptanes anddichloromethane (10 mL) to give10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-yltrifluoromethanesulfonate (2.17 g, 83% yield).

I. Synthesis of10-Methoxy-6-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A mixture of10-methoxy-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-6-yltrifluoromethanesulfonate (0.65 g, 1.54 mmol, 1 equiv), phenylboronicacid (0.188 g, 1.54 mmol, 1 equiv) and potassium phosphate (1.06 g, 4.62mmol, 3 equiv) in a 3:1:1 mixture of toluene:1,4-dioxane:water (500 mL)was sparged with nitrogen for 1 hour. Trans-Pd(PPh₃)₂Cl₂ (54 mg, 0.077mmol, 0.05 equiv) was added and the reaction mixture was refluxed for 16hours. The reaction mixture was diluted with dichloromethane (200 mL).The organic layer was washed with warm water (2×100 mL), dried oversodium sulfate and concentrated under reduced pressure to give10-methoxy-6-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(0.527 g, 97% yield).

J. Synthesis of6-Phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-10-ol

1M Boron tribromide in dichloromethane (7.5 mL, 7.5 mmol, 5 equiv) wasadded dropwise at −78° C. to a solution of10-methoxy-6-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizine(0.527 g, 1.5 mmol, 1 equiv) in dichloromethane (100 mL). The reactionwarmed to the room temperature and stirred for 16 hours. The reactionmixture was carefully poured in ice water (150 mL) and the resultingsolid was filtered and washed sequentially with water (30 ml) andheptanes (10 mL) to give6-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-10-ol (0.47g, 93% yield).

K. Synthesis of10-((9-(4-Isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-6-phenyl-3,4-dihydro-dibenzo[b,ij]imidazo[2,1,5-de]quinolizine

A mixture of 2-Bromo-9-(4-isopropylpyridin-2-yl)-9H-carbazole (0.528 g,1.446 mmol, 1 equiv),6-phenyl-3,4-dihydrodibenzo[b,ij]imidazo[2,1,5-de]quinolizin-10-ol(0.486 g, 1.446 mmol, 1 equiv), potassium phosphate (1.67 g, 7.23 mmol,5 equiv), copper (I) iodide (0.138 g, 0.723 mmol, 0.5 equiv), andpicolinic acid (0.445 g, 3.62 mmol, 2.5 equiv) in DMSO (50 mL) washeated at 150° C. for 4.5 hours. After cooling to room temperature, thereaction mixture was poured into water (300 mL) and extracted with ethylacetate (4×100 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure. The crude product waspurified by column chromatography to give10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-6-phenyl-3,4-dihydro-dibenzo[b,ij]imidazo[2,1,5-de]quinolizineas a tan solid (0.55 g, 61% yield).

L. Synthesis of Compound 108

A solution of10-((9-(4-isopropylpyridin-2-yl)-9H-carbazol-2-yl)oxy)-6-phenyl-3,4-dihydro-dibenzo[b,ij]imidazo[2,1,5-de]quinolizine(350 mg, 0.564 mmol, 1 equiv) glacial acetic acid (60 mL) was spargedwith argon for 40 minutes. K₂PtCl₄ (234 mg, 0.564 mmol, 1 equiv) wasadded and the reaction mixture was refluxed for 16 hours. After coolingto room temperature, the yellow-greenish precipitate was filtered andwashed sequentially with water (4×15 mL) and heptanes (2×10 mL) anddried under vacuum at 20° C. for 18 hours. The crude product wasdissolved in dichloromethane (500 mL) and passed through a plug ofsilica gel 10 g) to remove residual K₂PtCl₄. The solvent was removedunder reduced pressure. The residue was triturated with a 1 to 1 mixtureof dichloromethane and heptanes (20 mL), filtered and washed withdichloromethane (2×3 mL) to give Compound 108 (40 mg, yield 8.7% yield,83.2%).

DISCUSSION: The general structure of one embodiment of themetal-coordinated imidazophenanthridine ligand is shown below. The bondsof interest in the computational study are the four carbon-nitrogen(C—N) single bonds. They are labeled as C—N₁, C—N₂, C—N_(ph) for thenitrogen that has three single C—N bonds, and C—N_(m) for the nitrogenthat is coordinated to the metal.

Geometry optimizations of all complexes and ligands were performed inthe Gaussian 09 software package using the hybrid B3LYP functional withthe CEP-31g effective core potential basis set. All results use thismethod unless otherwise stated in the results and discussion.

Bond strengths were calculated by breaking a bond to form a diradicalspecies on the imidazophenanthridine ligand. The bond-broken diradicalspecies was calculated as a triplet state as this is normally lower inenergy than a diradical singlet and therefore the more likely productformed in a bond breaking event. Calculations were performed at theB3LYP/6-31g(d) level and thermodynamics reported for the ground statesinglet→bond broken triplet and a lowest energy triplet (excitedstate)→bond broken triplet.

Calculated TD-DFT values for the lowest triplet excited state (T1) werealso performed at the B3LYP/CEP-31g level of theory but included theCPCM continuum solvent field using THF as the solvent which has beenshown to better match experimental results.

Bond strength calculations were performed on the following compounds:

Calculated bond strengths are shown in Table 1.

TABLE 1 C-N₁ Calc bond C-N_(ph) bond C-N₂ bond C-N_(m) bond Weakest T1strength strength strength strength bond Structure (nm) (kcal/mol)(kcal/mol) (kcal/mol) (kcal/mol) (kcal/mol) Comparative compound 1

468 11.81 74.06 25.92 88.17 n/a 39.80 102.05 11.81 Comparative compound2

474 −1.54 61.26 22.00 84.79 n/a 46.85 109.64 −1.54 Comparative compound3

476 −0.55 60.08 22.34 82.96 n/a 45.18 105.80 −0.55 Comparative compound4

5.31 28.66 n/a 45.57 5.31 Compound 1

468 35.38 90.51 n/a 36.56 35.38 Comparative ligand 1

470 18.73 83.76 34.85 99.87 n/a 45.62 110.64 18.73 Compound (1-3)

472 40.35

Table 1 shows calculated bond strengths for a series of comparativeexamples and invention Compound 1. Where two numbers are seen in thesame cell, the top number represents the thermodynamic differencebetween the excited state triplet→bond broken triplet. The lower numberrepresents the ground state singlet→bond broken triplet. If there isonly one number in the cell, it represents the triplet→triplet bondstrength (T→T). For all comparative compounds 1-4, the C—N₁ bond isshown to be the weakest bond. Bond strengths are found to be weaker inthe excited triplet state compared to the ground state singlet. This isdue to the complex having the energy of the excited state available asthe starting point to the, generally, higher energy bond broken state.In some cases, as shown for comparative compound 2 and 3, the bondbroken state is lower in energy than the starting triplet state.Therefore a bond breaking event may be considered thermodynamicallyfavorable or exothermic. It is found that when aryl substitutions areadded at the C—N₁ bond carbon atom, the bond strength decreases, as seencomparing comparative compound 1 to comparative compounds 2 and 3. Thiseffect may be due to resonance stabilization of the radical species atthe bond breaking site which is stabilized by the aryl substitution.

Stabilization of the weak C—N₁ bond can be achieved by a linkingsubstitution that links the C—N₁ carbon to the carbon on the adjacentfused aryl ring as depicted by “A” in Formula (1a). This linking groupis preferably comprised of elements that provide the proper structuralgeometry to form a bridge across the two carbons of the phenanthridinering system, providing the necessary rigidity to stabilize the C—N₁ bondwhile not lowering the triplet energy of the resulting ligand andcomplex.

The effect of the stabilizing linker is shown in Table 1 for inventionCompound 1. Here the triplet C—N₁ bond strength has greatly improvedfrom 11.81 kcal/mol, for the analogous comparative Compound 1, to 35.38kcal/mol for the invention compound, an increase in theromodynmic bondstrength of >20 kcal/mol. The two carbon linking substituent preventsthe ligand from being able to obtain the appropriate relaxed geometry ofa CN₁ bond broken state. Importantly, the triplet energy is not affectedby this substitution as both invention Compound 1 and ComparativeCompound 1 both have identical triplet energies of 468 nm bycalculation.

The minimized non bond-broken and bond-broken geometries of comparativeexample 1 are shown in FIGS. 3a and 3b . It can be seen that the bondbroken geometry relaxes the ring strain of the fused ring system of theimidazophenanthridine ligand. The tethering substitution, as shown forinvention Compound 1, inhibits the relaxed bond broken geometry, therebyincreasing the thermodynamic bond strength of the C—N₁ bond.

Further experimental evidence of the weakness of the C—N₁ bond is shownby matrix assisted laser desorption ionization mass spectroscopy(MALDI-MS). MALDI-MS can be used to probe weaknesses in bonds in theexcited states of molecules. It is believed that as a measure ofphotochemical stability, MALDI-MS can simulate some of the conditionsfound inside an OLED device, where both charged and excited states arepresent. FIG. 3 shows the MALDI-MS taken in the negative mode forcomparative compound 3. The peak for the parent ion is identified at1529 amu. However the highest intensity peak is found at 1275 amu. Thismass corresponds to a fragment of comparative compound 3 where theimidazole ring has lost the mass of two carbons and the terphenylsubstitution. The structure of proposed fragment is shown in FIG. 3. Theisotopic pattern confirms this fragment contains iridium and isconsistent with the chemical formula of the proposed fragment. Furtherfragments are identified for ligand loss at 1083 amu and imidazole ringdecomposition for two ligands at 1020 amu, as shown in FIG. 4. The datasuggests that the formation of the major fragment requires the ruptureof the C—N₁ bond that is predicted to be a weak bond by calculation.

Photophysical Properties of the Compounds of the Invention

The measured photophysical properties of the invention compounds arereported in the Table 2 below. Complexes were measured at 77K and atroom temperature in 2-methyl tetrahydrofuran solvent at highly diluteconcentrations. Photoluminescent quantum yields (PLQY, Φ_(PL)) weremeasured at 1 wt % in polymethylmethacrylate (PMMA) solid state matrixor 0.4 wt % polystyrene (PS) solid state matrix using a Hamamatsu C9920system equipped with a xenon lamp, integrating sphere and a model C10027photonic multi-channel analyzer. PL transient measurements (τ) werecarried out by time correlated single photon counting method using aHoriba Jobin Yvon Fluorolog-3 integrated with an IBH datastation hubusing a 335 nm nanoLED as the excitation source.

TABLE 2 λ_(max) (nm) τ(μs) λ_(max) (nm) Φ_(PL) Φ_(PL) Compound @ 77 K @77 K @ 298 K PMMA PS

451 5.1 461 0.05 —

440 9.5 448 0.04 —

464 2.9 467 0.62 —

— — — 0.09 —

444 7.5 448 — 0.85

448 6.7 452 — —

— — — 0.68 —

— — — — 0.87

441 18 447 0.14 —

Compound 35 was measured to have deep blue emission, with a highestenergy peak at 77 K of 451 nm, however, the PLQY for the complex is only5%. Compound 49 demonstrates how modifications to the ligand can be usedto improve PLQY. The methyl substitution on the imidazole ring has beenfound to improve the PLQY of non-ethyl bridged phenanthridine imidazoleanalogues. In addition, methyl substitution on the exterior phenyl ringis shown by calculation to affect the ligand bite angle due to thesteric influence of the methyl substituent and the proton on theadjacent aryl ring. This steric effect pushes the phenanthridineimidazole polycyclic ring system geometry closer to the geometry of anon-bridged ligand where the coordinating sites can more closely connectto the metal. This subtle change in the geometry of the ligand allowsfor a stronger interaction between the metal and neutrally coordinatednitrogen, improving the metal-nitrogen bond strength. It is believedthat a stronger metal-nitrogen bond strength can improve the emissivityof a complex by reducing metal-nitrogen bond breaking non-radiativedecay. Therefore both methyl substitutions might be responsible forenhancing the PLQY of Compound 49 compared to Compound 35. Compound 49was measured to have a PLQY of 62% in PMMA matrix, which is very closeto the PLQY value of the non-bridged analog, Comparative Compound 6,which is measured to have a PLQY of 68%. In addition, Compound 49 ismeasured to have a much shorter excited state lifetime at 77 K of 2.9microseconds, compared to an excited state lifetime of 5.1 microsecondsfor Compound 35. This further demonstrates that the methyl substituentsimproved the radiative properties of Compound 49.

Heteroleptic examples with phenylpyrazole ligands (ppz), Compound 48 andCompound 50, are measured to have deep blue emission, but low PLQY.However, the non-bridged reference compound, Comparative Compound 8, isalso measured to have a low PLQY of 14%. It is believed that the lowefficiency may be due to the weak metal-nitrogen bond of the pyrazoleligand. To further support this assumption, tris Ir(ppz)₃ has been shownin the literature to be non-emissive in room temperature solution, buthighly emissive at 77 K. The non emissivity at room temperature isattributed to a weak metal nitrogen bond.

Platinum complexes with bridged phenanthridine imidazole ligands arealso found to be highly emissive with deep blue color. Compound 105 andComparative Compound 7 are both measured to have high PLQY values of 85%and 87%, respectively, in the optically inert polystyrene matrix.Platinum complexes may not require the ligand modifications forimproving PLQY as described for the iridium analogue, Compound 49, dueto a relatively stronger platinum-nitrogen bond strength compared toiridium.

It will be appreciated by those skilled in the art that changes could bemade to the exemplary embodiments shown and described above withoutdeparting from the broad inventive concept thereof. It is understood,therefore, that this invention is not limited to the exemplaryembodiments shown and described, but it is intended to covermodifications within the spirit and scope of the present invention asdefined by the claims. For example, specific features of the exemplaryembodiments may or may not be part of the claimed invention and featuresof the disclosed embodiments may be combined. Unless specifically setforth herein, the terms “a”, “an” and “the” are not limited to oneelement but instead should be read as meaning “at least one”.

It is to be understood that at least some of the figures anddescriptions of the invention have been simplified to focus on elementsthat are relevant for a clear understanding of the invention, whileeliminating, for purposes of clarity, other elements that those ofordinary skill in the art will appreciate may also comprise a portion ofthe invention. However, because such elements are well known in the art,and because they do not necessarily facilitate a better understanding ofthe invention, a description of such elements is not provided herein.

Further, to the extent that any methods of the present invention do notrely on the particular order of steps set forth herein, the particularorder of the steps should not be construed as limitation on the claims.The claims directed to such methods should not be limited to theperformance of their steps in the order written, and one skilled in theart can readily appreciate that the steps may be varied and still remainwithin the spirit and scope of the present invention.

All references, including publications, patent applications, andpatents, cited herein are hereby incorporated by reference to the sameextent as if each reference were individually and specifically indicatedto be incorporated by reference and were set forth in its entiretyherein.

We claim:
 1. A compound having a structure (L_(A))_(n)ML_(m) accordingto Formula 1:

wherein M is a metal having an atomic weight greater than 40, n has avalue of at least 1 and m+n is the maximum number of ligands that may beattached to the metal; wherein A is a linking group selected from thegroup consisting of —CR′R″—CR′R″—, —CR′R′—CR″R″—, and—CR′R′—CR′R′—CR′R′—; wherein each R′ is independently selected from thegroup consisting of H, D, alkyl, cycloalkyl, aryl, heteroaryl, andcombinations thereof, wherein each R″ is independently selected from thegroup consisting of alkyl, cycloalkyl, aryl, heteroaryl, partially orfully deuterated variants thereof, and combinations thereof, wherein R′sand R″s are optionally connected to form a saturated five membered ringor a saturated six membered ring, and combinations thereof, whereinR^(1a) to R^(1g) are each independently selected from the groupconsisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl,and combinations thereof; wherein any one of the ring atoms to whichR^(1b) to R^(1g) are attached may be replaced with a nitrogen atom,wherein when the ring atom is replaced with a nitrogen atom thecorresponding R group is not present; wherein L is a substituted orunsubstituted cyclometallated ligand, wherein L can be joined to R^(1g)through a linking group L²; wherein L² is selected from the groupconsisting of a single bond, NR, O, S, CR¹R², and SiR¹R²; wherein R, R¹,and R² can be same or different, and are independently selected from thegroup consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl,heteroaryl, and combinations thereof; wherein any adjacent R¹ and R² areoptionally connected to form a saturated five membered ring or asaturated six membered ring.
 2. The compound of claim 1, wherein A isselected from the group consisting of —CR′R″—CR′R″— and —CR′R′—CR″R″—.3. The compound of claim 2, wherein each of R′ and R″ is independentlyselected from the group consisting of undeuterated alkyl, partiallydeuterated alkyl, and fully deuterated alkyl.
 4. The compound of claim1, wherein the compound has a peak emissive wavelength less than 500 nm.5. The compound of claim 1, wherein the linking group is selected fromthe group consisting of:


6. The compound of claim 1, wherein at least one of R^(1a) to R^(1g) isselected from the group consisting of alkyl, cycloalkyl, aryl,heteroaryl, partially or fully deuterated variants thereof, andcombinations thereof.
 7. The compound of claim 6, wherein at least oneof R^(1b), R^(1d) and R^(1e) is selected from the group consisting ofalkyl, cycloalkyl, aryl, heteroaryl, partially or fully deuteratedvariants thereof, and combinations thereof.
 8. The compound of claim 6,wherein R^(1d) is selected from the group consisting of alkyl,cycloalkyl, aryl, heteroaryl, partially or fully deuterated variantsthereof, and combinations thereof.
 9. The compound of claim 6, whereinR^(1a) is selected from the group consisting of alkyl, cycloalkyl, aryl,heteroaryl, partially or fully deuterated variants thereof, andcombinations thereof.
 10. The compound of claim 8, wherein R^(1d) isselected from the group consisting of non-deuterated alkyl, partiallydeuterated alkyl, and fully deuterated alkyl.
 11. The compound of claim9, wherein R^(1a) is selected from the group consisting ofnon-deuterated aryl, partially deuterated aryl, and fully deuteratedaryl.
 12. The compound of claim 11, wherein R^(1a) is selected from thegroup consisting of non-deuterated phenyl, partially deuterated phenyl,and fully deuterated phenyl.
 13. The compound of claim 10, whereinR^(1d) is selected from the group consisting of —CH₃, —CD₃, andisopropyl.
 14. The compound of claim 7, wherein R^(1f) is selected fromthe group consisting of —CH₃, —CD₃, and isopropyl.
 15. The compound ofclaim 1, wherein the metal is Ir.
 16. The compound of claim 1, whereinthe ligand L is selected from the group consisting of:

wherein each X¹ to X¹³ are independently selected from the groupconsisting of carbon and nitrogen; wherein each R_(a), R_(b), R_(c), andR_(d) may represent from mono substitution to the possible maximumnumber of substitution, or no substitution; wherein R_(a), R_(b), R_(c),and R_(d) are each independently selected from the group consisting ofhydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl,alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl,alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester,nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, andcombinations thereof; and wherein any two adjacent substituents ofR_(a), R_(b), R_(c), and R_(d) are optionally fused or joined to form aring or form a multidentate ligand.
 17. The compound of claim 16,wherein the ligand L is selected from the group consisting of:


18. The compound of claim 1, wherein ligand L is selected from the groupconsisting of:


19. The compound of claim 16, wherein the compound has a structureselected from the group consisting of (L_(A))₃Ir, (L_(A))Ir(L)₂ or(L_(A))₂Ir(L).
 20. A compound having a structure according to Formula A:

wherein M is Ir; wherein n is 3; wherein A is a linking group selectedfrom the group consisting of —CR′R″—CR′R″— and —CR′R′—CR″R″—; whereineach or R′ and R″ is independently selected from the group consisting ofundeuterated alkyl, partially deuterated alkyl, and fully deuteratedalkyl; wherein R′s and R″s are optionally connected to form a saturatedfive membered ring or a saturated six membered ring, and combinationsthereof, wherein R^(1a) to R^(1g) are each independently selected fromthe group consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl,heteroaryl, and combinations thereof; wherein R^(1a) is selected fromthe group consisting of H, non-deuterated phenyl, partially deuteratedphenyl, and fully deuterated phenyl; wherein R^(1d) is selected from thegroup consisting of H, —CH₃, —CD₃, and isopropyl; and wherein ^(1f) isselected from the group consisting of H, —CH₃, —CD₃, and isopropyl.